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Inflammatory bowel disease (IBD) comprises several chronic inflammatory disorders of 
the gastrointestinal tract with a heterogeneous presentation and potentially severe dis-
ease course. The initial diagnosis of IBD as well as differentiation between different phe-
notypes often represents a challenging clinical issue, as no single diagnostic criterion is 
available. Like many other immune mediated diseases the complex etiopathogenesis of 
IBD is known to be multifactorial based on interactions between genetic and environ-
mental factors, gut microbiota and the immune system, leading to ongoing inflamma-
tion1,2. However neither the single role of these factors nor their supposed interactions 
has yet been completely elucidated. Knowledge of the initial alterations of the immune 
responses in the early phase of IBD, without the influence of immunosuppressive medi-
cation, might, in part, elucidate the first stages of disease development and may there-
fore help to better understand pathogenesis and subsequent clinical heterogeneity and 
clinical disease course.
Clinical aspects in IBD
Historical remarks
In all probability we shall never know who first diagnosed IBD and how the first diag-
nosis was made. Hippocrates (460-377 BC) already wrote about perianal fistula and 
was aware of the fact that diarrhoea was not a single entity, although he could not 
distinguish between an infectious and non-infectious cause3,4. In the first century AD, 
various forms of non-contagious diarrhoea were described freely in the literature by 
physicians such as Aretaeus of Cappadocia (A.D 300). During the nineteenth century, 
non-contagious diarrhoea was commonly reported under different names, such as “the 
flux of Sydenham”5.
The first to refer to the name ulcerative colitis was Sir Samuel Wilks in 1859, when 
he described inflammation in the distal ileum and colon at autopsy of a young woman 
who died after a period of illness with bloody diarrhoea and abdominal pain, in a report 
entitled “The morbid appearance of the intestine of Miss Banks”6. A few years later, in 
1875, Wilks together with Moxon, described the histopathological findings of UC in the 
second edition of the Lectures on Pathological Anatomy7. With today’s knowledge it 
could be argued that Miss Banks was actually suffering from Crohn’s disease instead of 
UC, given the extended inflammation of the ileum.
The first physician to describe Crohn’s disease was, notwithstanding its currently 
coined name, not Burrill Bernard Crohn. The first narrative describing ileal ulcerations 
and enlarged mesenteric lymph nodes in a deceased young man was made by Morgagni 
(1682-1771) in 17618. However Morgagni’s findings may also have fitted the description 
of infectious enteritis, such as tuberculosis or Yersinia infection. Another early report of 
non-infectious enteritis came from the Scottish surgeon Thomas Kennedy Dalziel in his 
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publication of 1913, entitled “chronic interstitial enteritis”9. He described in that paper a 
series of patients suffering from chronic stricturing inflammation of the small and large 
bowel with no evidence of tuberculosis or other active infection. The entity of chronic 
regional enteritis, however, has been attributed to the American gastroenterologist Burrill 
Bernard Crohn who authored, together with his colleagues Leon Ginzburg and Gordon 
D Oppenheimer, the paper “Regional Ileitis: A pathological and clinical entity” in 193210.
Since then, UC and CD have steadily increased in scientific popularity. During the last 
decades numerous studies on the incidence, course and prognosis of the disease have 
been carried out, reporting an increasing incidence of IBD ranging from 0.7 to 14.6/100,000 
for CD, and from 1.5 to 24.5/100,000 for UC, varying greatly between regions11-19. In Eu-
rope, the reported incidence for CD is 3-8/100,000 and 3-14/100,000 for UC20-21.
Clinical diagnosis and disease course
Classification of IBD
A single criterion for diagnosing IBD is not available and therefore a combination of 
clinical, endoscopic, histologic and radiologic criteria is used as a gold standard22. IBD 
comprises different entities currently classified as Crohn’s disease (CD), ulcerative colitis 
(UC), IBD unclassified (IBDU) and indeterminate colitis (IC)23. IBDU should be used in 
cases where differentiation between CD and UC is not possible after endoscopy with 
biopsies and radiologic examinations. The term IC should be preserved for pathologists 
describing a colectomy specimen when definite discrimination between CD and UC can-
not be made24.
Ulcerative colitis
Ulcerative colitis is generally limited to the colon and is classified by the extent of in-
flammation and severity of symptoms23. The symptoms of UC include rectal bleeding, 
diarrhoea and abdominal tenderness. The severity and combination of symptoms de-
pend on the extent of the inflammation. In case of proctitis, rectal bleeding is the main 
symptom, accompanied by rectal urgency, tenesmus and loss of mucopurulent exu-
date. In extensive and left-sided colitis the main symptoms are bloody diarrhoea and 
abdominal pain.
Recent guidelines recommend ileocolonoscopy with biopsies as the most appropri-
ate examination in the primary diagnosis of UC, with the exception of severe colitis 
with large ulcerations when complete colonoscopy may increase the risk of complica-
tions25-27. The endoscopic findings in UC typically start in the rectum and may extend 
more proximally. In mild disease activity, erythema, loss of vascular pattern and granu-
larity of the mucosa are seen, whereas in severe disease ulcerations and spontane-
ous bleeding occur. Correlation between symptoms and disease activity in UC is quite 
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reliable, which can be very helpful in assessing clinical remission and the effectiveness 
of therapy. Radiological techniques have a limited role in the diagnosis of UC. Plain X 
rays of the abdomen or CT scanning may suggest colitis, but endoscopy and histology 
remain the gold standard.
Crohn’s disease
Crohn’s disease presents more heterogeneously than UC, with regard to disease loca-
tion in that it can develop anywhere in the gastrointestinal tract, as well as with regard 
to disease behaviour and perianal manifestations. Symptoms associated with CD vary 
greatly between heavy abdominal pain, bloody diarrhoea and weight loss, to mild ab-
dominal tenderness, while some patients may even be symptom-free.
Different clinical CD phenotypes are currently classified according to the Montreal 
classification23. A clear explanation for the variation in clinical presentation and disease 
phenotype of CD is lacking. Unfortunately, up till now, little attention has been given to 
the potential immunological pathways underlying different CD phenotypes. Interest-
ingly, it has recently been demonstrated that colonic CD is associated with a different 
genetic profile compared with ileal CD and therefore it has been suggested to be a ge-
netic intermediate between ileal CD and UC28.
At present, complete ileocolonoscopy with biopsies is the recommended examina-
tion for diagnosing CD26,29, in combination with upper GI endoscopy and radiological 
imaging of the small bowel in all newly diagnosed patients. Endoscopically, CD is char-
acterized by discontinuous lesions, such as erythema, and ulcerations that can vary 
in size between small aphthous ulcers and large longitudinal ulcerations forming the 
characteristic “cobble stone” appearance, separated by areas of normal tissue30.
The histopathological changes of IBD can be subdivided in two sections: architectural 
changes and inflammatory features. Architectural abnormalities include: crypt distortion 
crypt branching, decreased crypt density and irregular mucosal surface. Inflammatory 
features consist of: increased lamina propria cellularity, large numbers of neutrophils 
especially organized in crypt abscesses and epithelioid granulomas31. Most of these fea-
tures occur in both CD and UC, but have quite different distribution and  localization: 
diffuse and superficial in UC versus discontinuous and transmural in CD32. Furthermore, 
granulomas, when non-IBD aetiology has been excluded, are thought to be an exclusive 
CD characteristic, being present in 21-37% of the endoscopic biopsies31,33.
Imaging in Crohn’s disease
Assessment of the small bowel is possible with different techniques, such as balloon-
assisted enteroscopy, wireless capsule endoscopy (video capsule endoscopy) and radio-
logical imaging. Single or double balloon enteroscopy combines the endoscopic visua-
lisation of the entire small bowel with the possibility of taking biopsies, however, the 
invasive character and length of the procedure limits its clinical use in the primary diag-
14
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nosis of CD. Video capsule endoscopy allows visualisation of the entire small bowel with 
minimal discomfort but without the ability for tissue sampling. Notably, because of the 
risk of capsule retention in a stenotic small bowel segment, capsule endoscopy should 
be preceded by cross-sectional imaging techniques in CD patients. Cross sectional im-
aging techniques, such as abdominal ultrasonography (US), Magnetic Resonance Imag-
ing (MRI) and Computed Tomography (CT) are being recommended in order to stage the 
disease and monitor follow-up. Several guidelines have stated that MR Enterography 
(MRE) might be the most useful imaging modality to assess bowel damage given its 
high contrast resolution, lack of ionizing radiation and ability to cover the whole abdo-
men26,29,34. However MRI is a costly technique requiring elaborated protocols that make 
quantification of active inflammation, by scoring the contrast uptake, rather complex 
and time-consuming. Newer, less expansive options have emerged, such as contrast-
enhanced ultrasound (CEUS), that allow visualization and quantification of bowel wall 
perfusion have emerged35. The diagnostic accuracy of CEUS compared to MRE, and its 
place in the diagnostic work-up of CD patients, still needs to be studied.
Systematic research on the frequency and the clinical impact of findings during up-
per gastrointestinal (GI) endoscopy and small bowel imaging in newly diagnosed adult 
CD patients is lacking. Nevertheless recent European guidelines recommend routine 
upper GI endoscopy and small bowel imaging, such as Magnetic Resonance Enterogra-
phy (MRE) in all newly diagnosed CD patients irrespective of the findings by ileocolonos-
copy29. These recommendations are merely based on expert opinion as no studies have 
addressed the aspects of the diagnostic algorithm in adult IBD patients.
Immunological aspects
Whether different IBD phenotypes are fundamentally different nosological entities or 
part of a mechanistic continuum is still an unanswered question, with both conceptual 
and therapeutic implications. The most important factors involved in the aetiology of 
IBD are the genetic makeup, the environment, gut microbiota and immune respons-
es36-38. Interaction between these components ultimately leads to chronic inflamma-
tion. The study of immune abnormalities in IBD has initially concentrated on the adap-
tive immune system and lately on innate immunity39. Based on available research, it is 
nowadays thought that the recognition of commensal-derived antigens by the adaptive 
immune system and its continuous stimulation by the innate immune system play a key 
role in the immunopathogenesis of IBD36,39. The present knowledge of immunopatho-
genesis originates mostly from research on genetically engineered animal models and 
patients with established, longstanding disease under anti-inflammatory treatment. 
In particular, inducible and adoptive transfer mouse models of intestinal inflammation 
have shown the key role of the effector T lymphocytes for the inflammatory process 
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in the gut38,39. Both T helper 1 (Th1) and Th2 T-cell subsets have been found to cause 
chronic gut inflammation, with CD having a predominantly Th1 cytokine profile (IFN-
gamma, IL12, IL23, TNF-alpha) and UC a predominantly Th2 profile (IL-4, IL-13)40. More 
recently data has also emerged on the effects of other T-cell subsets (regulatory T cells, 
Th17, cytotoxic T cells) as well as endothelial, epithelial and mesenchymal intestinal cells 
in the pathogenesis of IBD41,42.
In order to understand the complex initial interaction between microbiota, the im-
mune system and genetic background, one might start by studying the different im-
mune cell subsets in the gut of newly diagnosed, untreated patients. Information on 
the early immunologic dysregulation and potentially different immunologic pathways 
between patients may deliver new predictive factors for the course of the disease and 
response to therapy.
Early IBD as research model
The complex clinical and pathological nature of IBD, as well as its chronic unpredictable 
course, makes it an extremely interesting research model. The most important ques-
tions arise at the beginning of the disease course and have implications for the whole 
course of the disease. Which diagnostic modalities are needed in an individual patient 
in order to establish a certain diagnosis as well as the severity and extent of the disease? 
Is there an immuno-pathological explanation for differences in clinical phenotypes at 
diagnosis? Could we identify integrated clinical and immuno-pathological phenotypes 
at initial presentation that might predict disease course and response to therapy?
In order to study these questions one must consider early IBD as a research model, 
including the study of early immunological changes without the disadvantage of im-
munosuppression.
In this thesis we wanted to focus on diagnostic aspects in the early phase of IBD, 
integrating both clinical and immuno-pathological characteristics. The heterogeneity of 
the clinical phenotype by presentation requires a different diagnostic work-up for differ-
ent phenotypes and might rely on different immunological mechanisms.
Our hypothesis was that initial diagnostic strategies could be individualized according to 
clinical phenotype at presentation and that integration of clinical and immuno-pathological 
features might identify different immune-based phenotypes with potential value in prognosis 
and guidance for treatment options.
Research questions
In order to test the hypothesis we formulated the following research questions:
1 Which diagnostic modalities have been used over time in the primary diagnosis of 
IBD patients in daily practice and what is the current diagnostic work-up? (Chapter 2)
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2 What is the prevalence of upper GI lesions in adult IBD patients at first presentation 
and are there discriminating features between phenotypes? (Chapter 3)
3 What is the additional value of small bowel imaging in different CD phenotypes at 
first presentation and which modality is most suitable at presentation and during 
follow-up? (Chapter 4,5)
4 Can we identify different immunological phenotypes in the inflamed gut mucosa of 
early IBD? (Chapter 6)
5 How do naive T cells enter the inflamed mucosa of IBD patients? (Chapter 7,8)
Different study models
To answer the first question, we have performed a retrospective cohort analysis of the 
diagnostic modalities used in the IBD population of a secondary care hospital over the 
last four decades.
To answer the second question, a prospective cohort study was performed in a con-
secutive group of newly diagnosed adult IBD patients before initiating immunosuppres-
sive medication. We chose for this approach in order to study the prevalence of upper 
GI involvement without the influence of immunosuppression and to identify possible 
discriminating features between CD and UC at the time of primary diagnosis.
We addressed the third question by performing two studies. First, we examined the 
additional value of small bowel imaging by MRE at the time of primary diagnosis next to 
ileocolonoscopy in a retrospective observational cohort study. Recent European guide-
lines recommend small bowel imaging in all newly diagnosed CD patients independent 
of ileocolonoscopy. By identifying clinical phenotypes at presentation where small bow-
el imaging might add new findings or have no additional value next to ileocolonoscopy, 
we might individualize the diagnostic work-up and increase the adherence to guidelines 
in daily practice.
Secondly, we studied the diagnostic accuracy of CEUS compared to MRE in the as-
sessment of terminal ileitis by performing a prospective cohort study in CD patients, 
using ileocolonoscopy as a reference standard for active inflammation.
In order to answer the fourth question we performed a prospective patient-control 
study of different immunological subsets in the gut mucosa of newly diagnosed IBD 
patients before start of medication and healthy controls. We focused on different lym-
phocyte subsets and T-cell maturation status.
The fifth question was arrived at after observation of high numbers of naïve and 
central memory T cells in a subgroup of the patients. We first performed a review of the 
current literature on the presence and homing process of naïve and memory T cells into 
the gut mucosa. Tertiary lymphoid organs (TLOs) have been suggested to play a role in 
the homing process of naïve T cells in other systemic diseases and malignancies, how-
ever this has not yet been studied in IBD patients.
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We therefore chose to study the presence of TLOs in the biopsy specimens of the newly 
diagnosed IBD patients and their correlation with the presence of naïve and central 
memory T cells.
Outline of the thesis
The heterogeneity and unpredictability of IBD makes clinical decision-making difficult. 
Combining the clinical and immunological characteristics of different phenotypes early 
in the disease course might help target clinical decision-making and facilitate faster and 
more effective medical care. The aim of this thesis is to provide evidence for an indi-
vidualized diagnostic work-up at first presentation and help develop a classification of 
specific disease phenotypes that enable clinicians to apply more focused, personalized 
medicine in this heterogeneous population of IBD patients.
The first part of the thesis focuses on clinical aspects of the primary diagnosis in IBD. 
Chapter 2 provides a historical overview of the changes in endoscopic and radiologic 
examinations for diagnosing IBD.
The prospective study on the endoscopic and histologic alterations during upper GI 
endoscopy in newly diagnosed IBD patients is presented in Chapter 3. In Chapter 4, 
the findings of MRE alongside those of ileocolonoscopy in the primary diagnosis of dif-
ferent subgroups of CD patients, are provided. In Chapter 5, a prospective comparison 
is presented between contrast enhanced abdominal ultrasound (CEUS) and MRE for the 
detection of disease activity in the terminal ileum of CD patients.
The second part of the thesis focuses on immunological characteristics in the gut 
mucosa of newly diagnosed, untreated IBD patients. In Chapter 6 the distribution of 
different T-cell subsets in the mucosa of newly diagnosed IBD patients, including an 
increased number of naïve and central memory T cells in a subgroup of patients, is 
reported. Chapter 7 is a review of the migration pathways of naive T cells and their 
potential role in the inflammatory process in IBD. Finally, Chapter 8 focuses on the 
presence of ectopic lymphoid organs, so called tertiary lymphoid organs, that may play 
a role in the accumulation of naive and central memory T cells in inflamed gut mucosa.
18
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Abstract
background and aim The diagnostic work-up of Inflammatory Bowel Disease (IBD) 
patients has changed in the last decades. We aimed to study historical trends in the 
 usage of diagnostic procedures over the last forty years and evaluate the present clinical 
standards for the primary diagnosis of Crohn’s disease and ulcerative colitis, in a Dutch 
secondary care teaching hospital.
methods Patients from an administrative hospital database, with confirmed Crohn’s 
disease (N=421) or ulcerative colitis (N=391), diagnosed between 1970 and 2007 were 
included. The number of endoscopic and radiological procedures at the time of the pri-
mary diagnosis were collected retrospectively and analysed for time trends.
results In diagnosing CD, between 1970-1980, small bowel enteroclysis (SBE) and 
colonography accounted together for 71% of all diagnostic procedures. In the last period 
of time (2005-2007), the use of SBE and colonography was replaced by MRI enterogra-
phy, and the use of endoscopy increased to 85% of all procedures. In diagnosing UC, 
between 1970-1980, colonography accounted for 33% of all diagnostic procedures. In 
the course of time the use of colonography was totally replaced by endoscopy.
conclusion We describe a considerable change in the use of procedures for the pri-
mary diagnosis of both CD and UC patients, in the last forty years. At present, ileocolo-
noscopy and MRI enterography account for the majority of diagnostic modalities, which 
is in line with recommendations from recent IBD guidelines.
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Introduction
Chronic inflammatory bowel disease (IBD) consists of two major clinical entities known 
as Crohn’s disease (CD) and ulcerative colitis (UC), with a label of IBD “unclassified” 
(IBDU) or indeterminate colitis (IC) when there is difficulty differentiating between CD 
and UC, before or after bowel resection, respectively. Since the first description of the 
disease as “chronic interstitial enteritis” in 1913 by Dalziel et al., and later as “regional 
enteritis” in 1932 by Crohn et al., there has been ongoing research regarding the etiology 
of these chronic entities as well as the appropriate approach to their diagnostic investi-
gation and management1,2.
During the last decades, a relatively large number of population-based studies on 
the incidence, course and prognosis of the disease have been carried out, showing an 
increasing incidence of IBD reaching incidence rates ranging from 0.7 to 14.6/100,000 for 
CD, and from 1.5 to 24.5/100,000 for UC, varying greatly between regions3-12. Only few 
studies have addressed the aspects of the diagnostic algorithm in IBD. An exact diagno-
sis and subclassification is of great importance but remains difficult in up to 10-15% of 
patients, recommending a systematic follow-up with a re-evaluation of the diagnosis in 
this group of patients13,14. A single gold standard for diagnosing IBD is not available and 
therefore the diagnosis is based on a combination of clinical, endoscopic, histologic and 
radiologic criteria15. A systematic description of the diagnostic procedures used in the 
primary diagnosis of IBD is not available and most of the national and international rec-
ommendations and evidence based guidelines, on diagnosing IBD are very recent16-20.
We believe that the choice of the endoscopic and radiologic procedures used for 
diagnosing IBD, have changed in time, depending on the technical innovations made 
in these fields and also on the feasibility and availability of the diagnostic methods in a 
general secondary care hospital. A view of the time trends in the use of the procedures 
in the primary diagnosis of IBD may give us a better understanding of the history of the 
diagnostic process of this disease and help us implementing future diagnostic guide-
lines with new modalities.
The aim of this study is to examine the changes in the usage of diagnostic proce-
dures over the last nearly forty years, the relation between the diagnostic procedures 
used and reclassification of the diagnosis and to evaluate the present clinical standards 
in the primary diagnosis of Crohn’s disease (CD) and ulcerative colitis (UC), in a Dutch 
secondary care teaching hospital.
Materials and methods
Study setting and Patients
Inpatients and outpatients who were diagnosed with Crohn’s disease (CD) or ulcerative 
colitis (UC) in the Rijnstate Hospital (Arnhem, the Netherlands) in the period between 
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1970 and 2007 were identified using the diagnostic codes in the administrative hospital 
database. Chart review of all these patients was undertaken retrospectively. Individual 
information on sex, age, date of diagnosis, smoking habits, initial symptoms and disease 
related characteristics at diagnosis according to the Montreal classification, as well as 
the endoscopic and radiologic procedures used in the primary diagnosis of IBD were re-
corded onto a standard proforma by detailed case-note review. Patients diagnosed with 
incomplete data over the diagnostic procedures at the time of the primary diagnosis 
were excluded Figure 1.
The Montreal classification includes a classification for Crohn’s disease by disease 
location in L1 (ileal), L2 (colonic), L3 (ileocolonic) and +L4 (upper intestinal disease) which 
can be added to any of the other three locations, and by disease behaviour in B1 (non-
stricturing, non-penetrating), B2 (stricturing), B3 (penetrating), with +P as perianal dis-
ease modifier, that can be added to any of the other phenotypes. Based on the distri-
bution of the disease (Montreal classification) ulcerative colitis has been classified in 
proctitis (E1, limited to the rectum), left-sided colitis (E2, limited to the colon distal the 
splenic flexure) and extensive colitis (E3, involvement extending proximal to the splenic 
flexure, including pancolitis)16.
The time of primary diagnosis was defined as the date of the procedure, which re-
vealed objective lesions positive for IBD, for the first time. Furthermore, all examinations 
within one month from the time of primary diagnosis were regarded as procedures at 
diagnosis.
Figure 1  Inclusion diagram
Administratieve  
database  
N=995
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Incomplete data N=147
IBD unclassified N=36
Initial diagnosis 
Crohn’s disease  
N=380
Definitive diagnosis 
Crohn’s disease  
N=421
Definitive diagnosis 
Ulcerative colitis  
N=391
N=41
Initial diagnosis 
Ulcerative colitis  
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The diagnosis of CD was based on the presence of two or more of the following criteria: 
(I) history of abdominal pain, diarrhoea and weight loss; (II) macroscopic appearance 
at endoscopy (or operation) showing segmental, discontinuous lesions with or without 
rectal involvement, aphtous ulceration, fissuring and penetrating ulceration, cobble-
stones or strictures; (III) radiological evidence of stenosis or mucosal inflammation in 
the small bowel, segmental colitis, or fistulae; (IV) microscopic evidence compatible 
with CD including epithelial granulomas and transmural inflammation.
The diagnosis of UC was based on the presence of three or more of the following 
criteria: a history of diarrhoea and/or bloody stools; macroscopic appearance on endo-
scopy of continuous mucosal inflammation affecting the rectum extending to some of 
all of the colon; microscopic features on biopsy compatible with UC; and no suspicion of 
CD on biopsy, ileocolonoscopy and small bowel imaging.
Diagnostic procedures
The endoscopic procedures were done using standard flexible video endoscopy. An 
 ileocolonoscopy is defined as the endoscopic procedure with intubation of the colon 
and terminal ileum, while during a colonoscopy and sigmoidoscopy the colon intubation 
reaches the coecum or the descending colon, respectively.
The small bowel radiologic examination with barium sulfate suspension was done 
using the enteroclysis technique (nasal intubation with a small-bore enteric tube, di-
rected by fluoroscopic guidance into distal duodenum or jejunum). The colonography 
was performed using the double-contrast method obtained by combined use of barium 
suspension and air.
The magnetic resonance of the small bowel was performed using the per-oral meth-
od, which was done after a period of 5h fasting and ingestion of 1 liter of a 6% man-
nitol solution in the last hour before the MRI. The MRI protocol consisted of multiple 
pre- and post-contrast sequences, with fat saturation after intravenous administration 
of gadolinium DTPA (Dotarem; Guerbet Nederland B.V.). In our hospital, computed to-
mography enterography (CTE) is only used in patients with absolute contraindications 
for MR enterography.
Statistical analysis
All data were entered in a structured database, and were extracted for analysis with SPSS 
statistical software, version 15.0. Frequency tables were provided for demographics and 
clinical characterization (including Montreal classification) at the time of diagnosis, and 
presented for either Crohn’s disease or ulcerative colitis over five different time cohorts: 
1970-1979, 1980-1989, 1990-1999, 2000-2004 and 2005-2007. The period between 
2000-2007 was divided in two because of the introduction of the MR enterography in 
2005. The median number and type of diagnostic procedures were assessed over the 
same time cohorts and plotted over time for both Crohn’s disease and ulcerative colitis.
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Finally, we analyzed all patients that were reclassified from ulcerative colitis to Crohn’s 
disease, or vice versa, during the course of disease. For characterization of all reclassi-
fied patients we described demographics, clinical characterization and diagnostic pro-
cedure used at time of diagnosis, followed by the procedures used for reclassification.
Results
We identified a total of 995 patients diagnosed with IBD during the study period. A 
number of 147 patients were excluded because of incomplete data and 36 (3%) patients 
received the diagnosis IBD unclassified (IBDU) Figure 1. The definitive diagnosis of CD 
was made in 421 patients (52%), and UC in 391 (48%) patients. In the course of time we 
observed an increase in the number of newly diagnosed patients, as well as a higher age 
at the time of diagnosis, in both Crohn’s disease and ulcerative colitis Table 1.
Findings in patients diagnosed with Crohn’s disease
The mean age at diagnosis of the 421 patients with CD was 34 years (SD 14) of whom 
63% were female. Regarding disease location, we found an increase in the number of 
patients with disease location in the upper digestive tract Table 1.
In the seventies, the radiological procedures such as small bowel enteroclysis and 
colonography were mostly used in diagnosing CD Figure 2a. Sigmoidoscopy was used in 
53% of the patients, being the only available endoscopic procedure at that time Table 2. 
In the eighties, the complete colonoscopy was performed in 13% of the patients, fol-
lowed by a decrease in the use of small bowel enteroclysis and colonography, in favour 
of the endoscopic methods, in the nineties Table 2. In the last period, small bowel 
Figure 2a    Time trends in the use of radiological procedures in diagnosing Crohn’s disease
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enteroclysis was replaced by MR Enterography Figure 2a. Regarding the endoscopic 
procedures, we observed an obvious growth in the number of patients undergoing an 
(ileo)colonoscopy (83% between 2005-2007), as well as an increase in the use of upper 
endoscopy (20% between 2005-2007) Table 2, Figure 2b.
Table 1  Demographic and clinical characteristics of patients diagnosed with IBD during the study period
1970-1979 1980-1989 1990-1999 2000-2004 2005-2007
CD UC CD UC CD UC CD UC CD UC
n=15 n=12 n=40 n=44 n=123 n=119 n=133 n=129 n=110 n=87
F/M 11/4 10/2 27/13 23/21 84/39 55/64 77/56 69/60 66/44 40/47
Age at diagnosis (%)
A1 (<16) 1 (7) 1 (8) 3 (8) 1 (3) 6 (5) 3 (2) 2 (2) 8 (6) 1 (1) 0
A2 (17-40) 14 (93) 9 (75) 29 (73) 27 (61) 81 (66) 58 (49) 88 (66) 59 (46) 64 (58) 39 (45)
A3 (>40) 0 2 (17) 8 (20) 16 (36) 36 (29) 58 (49) 43 (32) 62 (48) 45 (41) 48 (55)
Extend of CD at diagnosis (%)
L1 4 (25) 24 (60) 49 (40) 35 (26) 31 (28)
L2  8 (53) 8 (20) 58 (47) 58 (44) 49 (45)
L3 4 (25) 7 (18) 16 (13) 38 (29) 30 (27)
+L4 0 1 (3) 5 (4) 18 (14) 10 (9)
+P 2 (13) 5 (13) 22 (18) 13 (10) 11 (10)
Disease behavior of CD at diagnosis (%)
B1 8 (53) 19(48) 75 (61) 79 (59) 79 (72)
B2 6 (40) 14 (35) 24 (19) 40 (30) 18 (16)
B3 0 3 (8) 18 (15) 9 (7) 11 (10)
B4 1 (7) 3 (8) 7 (6) 3 (2) 3 (3)
Location of UC at diagnosis (%)
E1 9 (75) 17 (39) 37 (31) 41 (32) 32 (37)
E2 1 (8) 23 (52) 59 (50) 62 (48) 36 (41)
E3 1 (8) 4 (9) 23 (19) 26 (20) 19 (22)
Smoker (%) 10(67) 5 (42) 17(43) 7 (16) 51 (41) 9 (8) 45 (34) 12 (9) 40 (36) 8 (9)
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Table 2  Diagnostic procedures per number of patients, during the study period
1970-1979 1980-1989 1990-1999 2000-2004 2005-2007
Total number  
of patients
CD
N=15
UC
N=12
CD
N=40
UC
N =44
CD
N=123
UC
N 119
CD
N=133 
UC
N=129
CD
N=110
UC
N =87
Sigmoidoscopy 
(%)
8 (53) 10 (83) 16 (40) 38 (86) 49 (40) 89 (75) 37 (28) 95 (74) 18 (16) 59 (68)
Colonoscopy (%) 0 0 5 (13) 7 (16) 32 (26) 18 (16) 42 (32) 18 (14) 20 (18) 15 (17)
Ileocolonoscopy 
(%)
0 0 0 0 16 (13) 3 (3) 43 (32) 13 (11) 72 (65) 13 (15)
Upper endoscopy 
(%)
0 0 1 (2) 0 13 (11) 0 23 (17) 0 22 (20) 0
SBE (%) 9 (60) 0 30 (75) 0 55 (45) 0 67 (50) 0 7 (6) 0
Colonography (%) 11 (73) 5 (42) 15 (37) 18 (41) 30 (24) 20 (17) 14 (10) 14 (11) 0 2 (2)
MR enterography 
(%)
0 0 0 0 0 0 1 (1%) 0 18 (16) 0
Median number 
of procedures/
patient (Range)
2 (2) 1,5 (2) 2 (2) 1 (2) 2 (3) 1 (2) 2 (3) 1(1) 2 (2) 1 (1)
Figure 2b    Time trends in the use of endoscopic procedures in diagnosing Crohn’s disease
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Findings in patients diagnosed with ulcerative colitis
The mean age at diagnosis of the 391 patients with UC was 41 years (SD 16), of whom 
50% were female. In the course of time, we noticed a growing number of patients with 
an extensive UC at the time of diagnosis Table 1. The number of patients diagnosed by 
colonography decreased from 42% in the seventies, to 2% in the most recent period of 
time. Between 2005-2007, 32% of the patients were diagnosed by a (ileo)colonoscopy 
and 68% by a sigmoidoscopy Table 2, Figure 3.
Findings in patients diagnosed with IBD unclassified
The mean age at diagnosis of the patients diagnosed with IBDU was 39 (SD 11) of whom 
12 were female. IBDU was diagnosed between 2005-2007. A number of 20 patients were 
diagnosed by ileocolonoscopy, 4 patients by colonoscopy and 2 patients by sigmoido-
scopy. In 2 patients a MRE was performed, and other 2 patients underwent a gastro-
scopy. None of the patients diagnosed with IBDU has been reclassified during follow-up.
Reclassification of the diagnosis during follow-up
A total of 41 patients were reclassified from the diagnosis ulcerative colitis into Crohn’s 
disease. Most of these patients were diagnosed in the nineties (51%) and the median 
value of the period between the primary diagnosis and reclassification was 5 years with 
a range 1-32 years. A total of 33 patients (80%) were diagnosed at first by sigmoidoscopy 
alone, or in combination with colonography or small bowel enteroclysis. Most patients 
(n=26, 63%) were reclassified by use of ileocolonoscopy Table 3.
Figure 3  Time trends in the use of radiologic and endoscopic procedures in diagnosing ulcerous colitis
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Discussion
In this retrospective study, over a period of almost forty years we reported a clinical 
significant change in the use of diagnostic modalities for the primary diagnosis of IBD. 
According to our results, forty years ago CD was mostly diagnosed using radiologic 
procedures, such as small bowel enteroclysis and colonography, while combining colo-
nography with sigmoidoscopy made the diagnosis of UC. In the last twenty-five years 
technical innovations have led to an expansion in the use of flexible video-endoscopy. 
Starting in the nineties there is an unmistakable increase in the use of (ileo)colono-
scopy, although in a minority of patients the primary diagnosis of colonic CD is still 
made by sigmoidoscopy. Furthermore we observed a growing use of upper endoscopy 
Table 3  Reclassification of the diagnosis from UC into CD
Number (%)
Female/male ratio 25/16
Age at diagnosis (mean) 35 years (SD 15)
Date of primary diagnosis
1970-1979
1980-1989
1990-1999
2000-2004
2005-2007
2 (5)
5 (12)
21 (51)
8 (20)
5 (12)
Period of time till reclassification (median) 5 years (Range 1-32)
Diagnostic procedures at primary diagnosis
Sigmoidoscopy
Sigmoidoscopy + colonography
Sigmoidoscopy+ SBE
Colonoscopy
Colonoscopy +colonography
Colonography
21 (51)
9 (22)
3 (7)
3 (7)
2 (5)
3 (7)
Diagnostic procedures at reclassification
Ileocolonoscopy
Upper endoscopy
Sigmoidoscopy 
SBE 
MRE
Surgery
26 (63)
2 (5)
4 (10)
3 (7)
2 (5)
4 (10)
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at the time of primary diagnosis of CD, which could form an explanation for the higher 
number of patients diagnosed with an additional location in the upper digestive tract.
Regarding UC, in the last period the use of (ileo)colonoscopy has completely replaced 
the colonography, while a relative high number of patients (68%) were still being diag-
nosed by sigmoidoscopy alone. Recent American guidelines recommend sigmoidoscopy 
as well as colonoscopy in the primary diagnosis of UC17. In our study 10% of the UC 
patients were later reclassified as having Crohn’s disease. 80% of these patients were 
initially diagnosed by using sigmoidoscopy alone or in combination with SBE or colo-
nography. In the majority of these patients the findings by ileocolonoscopy decided the 
definitive classification. These data support the recommendation in the most recent 
European guidelines that ileocolonoscopy is needed in the work-up of all patients sus-
pected of IBD18-22. Sigmoidoscopy alone or in combination with radiological procedures, 
represents an incomplete diagnostic work-up in the primary diagnosis of IBD.
The group of patients with endoscopic and histopathological findings that cannot 
differentiate between CD and UC should be diagnosed as IBD unclassified (IBDU), ac-
cording to the Montreal classification. In our population the group of IBDU patients 
turned out to be small, as the diagnosis was only made after 2004. The clinical relevance 
of an accurate classification lies also in the fact that a number of patients with IBDU 
could later turn out to have a different type of colitis due to infections of drugs23-24. At 
present, endoscopic examination has become the gold standard in the diagnosis of IBD 
as it provides direct macroscopic and histologic information for evaluating the colon, the 
terminal ileum and upper digestive tract. According to most recent Dutch recommen-
dations, initial diagnostic colonoscopy should intubate the terminal ileum and include 
systematic biopsies from each anatomic segment of the bowel (rectum, sigmoid, left, 
transverse and right colon, and ileum) while upper endoscopy is still not recommended 
in all patients but is reserved for symptomatic patients. However some authors, in-
cluding recent European guidelines regard upper-gastrointestinal Crohn’s disease as a 
challenging and underestimated diagnostic problem, and claim that all newly diagnosed 
patients with Crohn’s disease should undergo upper endoscopy25. Furthermore, recent 
European guidelines recommend small bowel imaging in all newly diagnosed CD pa-
tients irrespective of ileocolonoscopy for assessment of disease extent and eventual 
complications. Such general, extensive diagnostic work-up is based on merely expert 
opinion and has not yet been proven to be clinical relevant or cost-effective in the daily 
practice26,27.
The role of newer techniques for examination of the small bowel, such as video 
capsule examination and balloon-assisted enteroscopy in the primary diagnosis of CD, 
is quite limited at the moment. The true benefit of the video capsule examination is 
not yet clear, as there are presently no standardized criteria for the diagnosis of CD 
by using this investigation28. Balloon-assisted enteroscopy allows visualization of the 
small bowel with the possibility of obtaining biopsy samples and eventual endoscopic 
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therapy (e.g. dilatation of stricture, cauterization of a bleeding site). In a recent paper 
complete enteroscopy rates of 66% and 22% for double-balloon and single-balloon 
enteroscopy were reported, respectively29. Therefore double-balloon enteroscopy has 
been recommended as the non-surgical gold standard procedure for deep small-bowel 
endoscopy29,30. However balloon-assisted enteroscopy is still not generally available and 
regarded as an invasive endoscopic procedure.
The diagnosis of small intestinal CD complications relies mostly on radiologic im-
aging modalities. Small bowel enteroclysis is widely available and historically the most 
used technique for detection of small bowel lesions when CD is suspected30. However 
small bowel enteroclysis has major disadvantages, as it is invasive, burdensome and ac-
companied by a relatively high dose of radiation exposure. Furthermore the detection of 
the small bowel wall alterations is indirect, without providing any information about the 
extra-intestinal abdomen (visceral fat, the lymph nodes and the vascular structures) or 
possible complications.
In our cohort, MR enterography has replaced small bowel enteroclysis, in the last 
3 years. The high tissue contrast obtained using the MRI, combined with the absence 
of ionizing radiation, makes it suitable for repetitive imaging in patients with Crohn’s 
disease.
At present the work-up in the primary diagnosis of an IBD patient includes an ileo-
colonoscopy and in patients suspected of small bowel CD an additional cross-sectional 
imaging modality such as CT enterography or MR enterography. Both radiological meth-
ods are very accurate for the detection of IBD of the small bowel, but the use of the CT is 
limited by the ionizing radiation needed, especially in the follow-up of young patients31. 
Recently CT enterography was demonstrated to be a cost-effective alternative for small 
bowel follow-through in diagnosing small bowel Crohn’s disease. Although they did not 
study MR enterography, a fundamental finding was that the accuracy and not the direct 
costs of a procedure, is the primary driver of the cost-effectiveness of a diagnostic test 
for Crohn’s disease32.
Careful evaluation of disease characteristics at baseline is essential for differential 
diagnosis and assessment of disease severity and behaviour, requiring a combination of 
endoscopic and cross-sectional modalities33. However the heterogeneity of the clinical 
presentation of IBD patients suggests that diagnostic work-up might be individualized 
according to clinical phenotype34.
In conclusion, this study demonstrated strong time trends in the primary diagnostic 
process of IBD, in the period before publication of the most national and international 
guidelines. Recent guidelines generally recommend a complete assessment at baseline, 
endoscopic and radiologic, however without robust evidence of clinical benefit or cost-
effectiveness. Unanswered questions over the role of upper GI endoscopy or radiologic 
imaging in the early phase of IBD still need to be studied, in order to improve the diag-
nostic process and facilitate guidelines implementation in the daily practice.
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Abstract
background The prevalence of upper gastrointestinal (GI) involvement in adult in-
flammatory bowel disease (IBD) has mostly been studied in patients with long-standing 
disease. The aim of this study was to prospectively evaluate the prevalence of upper 
GI involvement in a consecutive series of newly diagnosed, treatment-naive adult IBD 
patients, irrespective of upper GI tract symptoms.
methods Consecutive patients with suspected IBD underwent combined ileocolonos-
copy and upper endoscopy with biopsies. Patients diagnosed with either Crohn’s disease 
(CD) of ulcerative colitis (UC), denying use of NSAID were included in the study. Helico-
bacter pylori infection was diagnosed histologically and positive patients were excluded 
from the analysis. Endoscopic and histologic lesions in the stomach and duodenum 
were recorded. Upper GI location (+L4) was defined as a combination of endoscopic and 
histological lesions.
results A total of 152 patients, (108 CD and 44 UC) were analyzed. Endoscopic lesions 
were only seen in CD patients (60/108, 55%). Histological lesions were present in both 
CD and UC patients: focally enhanced gastritis in 58 CD (54%) and 10 UC (23%), granu-
lomas in 30 CD (28%). Upper GI disease location was diagnosed in 44 CD (41%) and no 
UC patients. Upper GI tract symptoms were reported in 14/44 (32%) patients with upper 
GI location.
conclusion A high prevalence of upper GI involvement was observed in newly dia-
gnosed CD patients, with a majority of the patients being asymptomatic. Focally en-
hanced gastritis was common in both CD and UC patients, while granulomatous inflam-
mation was restricted to CD.
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Introduction
The clinical work up of newly diagnosed adult patients with Crohn’s disease (CD) has not 
yet been studied prospectively. Ileocolonoscopy with biopsies is the golden standard 
for establishing the diagnosis1-4. Whether upper endoscopy should be added to ileoco-
lonoscopy in all patients, in order to examine the disease extent at primary diagnosis is 
still unclear.
Recent European and American guidelines recommend further examination of the 
upper gastrointestinal (GI) tract in all newly diagnosed patients, irrespective of the find-
ings at ileocolonoscopy in order to determine the location and extent of any CD le-
sions1-3. However, evidence of frequency, type of lesions and clinical impact of these 
findings in newly diagnosed adult patients is missing. Recently it has been stated that 
nearly half of the IBD guideline recommendations are solely based on expert opinion5.
CD is classically defined as an inflammatory bowel disease with fissural, granuloma-
tous ulceration affecting any part of the digestive tract, while in ulcerative colitis (UC) 
more superficial inflammation is by definition limited to the colon-rectum4,6-8. The dif-
ference in distribution throughout the intestinal tract is one of the major discriminators 
between CD and UC6,9-12.
The paradigm regarding location and extent of these two different types of inflam-
mation in Inflammatory Bowel Disease (IBD) is at present being challenged by recent 
reports of gastroduodenal lesions in adult patients with ulcerative colitis (UC)13. The 
so-called ulcerative gastroduodenal lesions (UGDL) or gastroduodenitis associated with 
UC (GDUC) appear incompatible with the original disease concept of UC being confined 
to the large intestine. On the other hand, these clinical entities seem exclusively to be 
associated with postcolectomy status and pouchitis13-15.
In adult patients with Crohn’s disease (CD), the prevalence of upper gastrointestinal le-
sions irrespective of gastrointestinal (GI) symptoms, has been reported to be up to 16%16.
The Montreal classification facilitates the classification of the upper GI involvement 
in CD, yet a clear definition and consensus on the macroscopic and microscopic lesions 
confirming the diagnosis is lacking17. In approximately 10-15% of patients with the prima-
ry diagnosis of idiopathic chronic colitis, it is difficult to distinguish between CD and UC, 
reflected by the diagnostic category IBD-unclassified (IBDU)12,17-18. It has been suggested 
that a routinely performed upper GI endoscopy at the time of primary diagnosis, may 
be useful in differentiating between CD and UC. This requires data on the prevalence, 
endoscopic and histologic nature of upper GI findings in both CD and UC adult patients, 
at the time of primary diagnosis. Up till now, gastroduodenal endoscopic and histological 
lesions in treatment naïve newly diagnosed, adult IBD patients have not yet been sys-
tematically studied. Available data in adult patients originate primarily from retrospective 
studies or case series performed in patients already using IBD- related anti-inflammatory 
medication such as 5-ASA compounds, corticosteroids and thiopurines19-24.
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The aim of the present study was to prospectively evaluate the prevalence of upper GI 
involvement in a consecutive series of newly diagnosed, treatment-naive adult IBD pa-
tients irrespective of upper GI tract symptoms.
Materials and Methods
Patients
Consecutive, adult patients with symptoms of chronic diarrhea, rectal blood loss, ab-
dominal pain or weight loss, underwent combined ileocolonoscopy and upper endos-
copy. From this group, newly diagnosed CD and UC patients were included in the study. 
Use of non-steroidal anti-inflammatory drugs (NSAID) or proton pump inhibitors (PPI) 
during the preceding 4 weeks and diagnosis of IBD unclassified (IBDU) were considered 
exclusion criteria (Figure 1). The diagnosis of CD and UC was established and certified 
by clinical, endoscopic and histological standard criteria1,3,6. During ileocolonoscopy the 
type and distribution of the lesions were recorded and multiple biopsies were taken from 
ileum and colon in order to establish the diagnosis. Microscopic features such as diffuse 
versus focal chronic inflammation and crypt disruption, superficial versus transmural, 
absence or presence of granuloma (not related to crypt injury) and presence of paneth 
cell metaplasia and crypt abscesses were used to differentiate between UC and CD.
Patients with inflammatory disease limited to the colon and no histologic criteria or 
other evidence to favor either CD or UC were diagnosed as IBDU.
Data concerning age, sex, upper GI symptoms and smoking status were recorded.
Figure 1  Inclusion diagram of the patients
Suspected IBD
N=235
Excluded
N=39 No informed consent
N=16 No IBD diagnosis
N=11 NSAIDs or PPI use
N=6 IBDU diagnosis
Included IBD
(CD or UC)
N=163
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Upper GI endoscopy and histology
The endoscopic examinations were performed under conscious sedation using a fore-
head-view instrument (Olympus, type CF 180). During upper GI endoscopy, the pres-
ence of mucosal lesions in the esophagus, stomach and duodenum including granular, 
erythematous mucosa, erosions, ulcers, nodular lesions and strictures was assessed. 
Mucosal biopsy specimens were sampled before any anti-inflammatory (IBD) treatment. 
During upper endoscopy, four mucosal biopsies of normal gastric corpus and antrum 
and two biopsies of normal duodenal mucosa were taken for histopathological exami-
nation. Additional biopsies were taken from specific macroscopic lesions if observed. 
The tissue was fixed in 10% buffered formalin, routinely processed and stained with he-
matoxylin and eosin. Presence of Helicobacter pylori (H. pylori) was identified on biopsy 
samples by Giemsa stain. Histological features analyzed were: acute or chronic inflam-
matory infiltrate, focal crypt destruction, ulceration, ‘focally enhanced gastritis’ (FEG) 
defined by the presence of a peri-foveolar or peri-glandular cellular infiltrate containing 
mononuclear cells and granulocytes, and epithelioid granulomas.
An epithelioid cell granuloma was defined as a focal granulomatous inflammation, 
consisting of aggregation of macrophages that are transformed in epithelial-like cells. 
These epithelioid cells can occasionally fuse to form multinucleated giant cells and can 
be surrounded by a collar of lymphocytes. One pathologist who was blinded to the fi-
nal diagnosis, highly experienced in histopathological evaluation of the gastrointestinal 
tract, examined each biopsy specimen.
Definitions
Upper GI disease location of CD, +L4 according to the Montreal classification, was de-
fined based upon both macroscopic and microscopic criteria. Macroscopic criteria were 
erosions, aphthous lesions, ulcerations and strictures. Aspecific findings such as erythe-
ma and oedema were also recorded but were not seen as an independent criterion for 
the diagnosis of IBD. The diagnosis of upper GI CD was confirmed when the macro scopic 
findings were accompanied by microscopic features such as focal enhanced gastritis, 
focal crypt irregularity/crypt distortion, fissural ulceration and/or granuloma’s in the 
absence of H. pylori infection.
Statistical analysis
Descriptive statistics of continuous data are reported as means or medians with stan-
dard deviations (SD) or interquartile ranges [IQR], respectively. Categorical data are re-
ported as absolute numbers and percentages. All analyses were performed using SPSS 
Statistics [version 21 Chicago, IL USA].
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Ethical considerations
Regional medical ethics committee approval was obtained prior to the study, and all 
patients provided written informed consent. The study was performed according to the 
principles of the Declaration of Helsinki.
Results
A total of 115 CD and 48 UC patients were included in the study. H. pylori infection was 
present in 7 (6%) CD and 4 (8%) UC patients and these patients were excluded from 
Table 1 Baseline characteristics and Montreal classification of patients at presentation
Patient characteristics Crohn’s disease Ulcerative colitis 
Number of patients 108 44
Gender (male/female) 46/62 16/28
Age at diagnosis
 • A2 (between 17-40 years old)
 • A3 (above 40 years old)
67
41
20
24
Disease location (N(%))
 • L1 (small bowel only)
 • L2 (large bowel only)
 • L3 (small and large bowel)
 • +L4 (upper GI)
 • +P (perianal disease)
 • E1 (proctitis)
 • E2 (left sided colitis)
 • E3 (pancolitis) 
34 (32%)
23 (21%)
51 (47%)
44 (41%)
13 (12%)
8 (18%)
8 (18%)
28 (64%)
Disease behaviour (N(%))
 • B1 (non-stricturing non-penetrating)
 • B2 (stricturing)
 • B3 (penetrating)
 • S1 (mild UC)
 • S2 (moderate UC)
 • S3 (severe UC)
81 (75%)
16 (15%)
11 (10%)
10 (23%)
23 (52%)
11 (25%)
Upper GI symptoms
L4 with upper GI symptoms
L4 without upper GI symptoms 
23 (21%)
14
9
3 (7%)
Smoking status
 • Active smoking
 • Ex smoking
 • No smoking
49 (45%)
9 (8%)
50 (47%)
8 (18%)
7 (16%)
29 (66%)
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further analysis. Baseline clinical characteristics according to Montreal classification at 
initial presentation and demographics of all included patients are presented in Table 1. 
In all patients, endoscopic and histologic inflammatory disease activity in the ileum, 
colon or both was observed. A minority of patients, 23/108 CD (21%) and 3/44 (7%) UC 
patients reported upper GI tract symptoms, such as pain localized in epigastrium ac-
companied by nausea and/or vomiting. Upper GI disease location (+L4) was present in 
14/23 (61%) of the symptomatic CD patients.
Endoscopic findings
Macroscopic findings were detected at upper GI endoscopy in 60/108 (55%) CD patients. 
Endoscopic lesions, such as erythema, aphthae, ulcers and nodules were restricted to 
the stomach in 19 patients and to the duodenum in 15 patients (Figure 2). In 26 patients 
both gastric and duodenal lesions were observed. The distribution of the endoscopic 
Figure 2  Endoscopic findings of Crohn’s disease- related upper gastrointestinal lesions
A Nodular antrum gastritis. 
B Ulceration and erythematous thickening of the inflamed mucosa in the antrum. 
C Aphthous ulcerations on top op thickened mucosal folds in the antrum. 
D Aphthous ulcerations in the second part of the duodenum.
A
C
B
D
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findings in the stomach and duodenum and the corresponding histologic lesion for each 
location are described in the cross Table 2.
Furthermore 4/60 (7%) patients had aphthous ulcerations located in the esophagus.
Defined upper GI location of CD (+L4), based on combined macroscopic and micro-
scopic criteria, was established in 44/108 (41%) patients. Upper GI disease (+L4) was ac-
companied by ileum location (L1) in 13/44 (29%) patients, by colon location (L2) in 6/44 
(14%) and by ileo-colonic location (L3) in 25/44 (57%) patients. Upper GI symptoms were 
present in 14/44 (32%) patients with upper GI disease location.
Table 2 Histologic Findings Presented According to the Presence  
and Location of Endoscopic Lesions
Gastric endoscopic findings Duodenal endoscopic findings
Er
yt
he
m
a
A
ph
th
ae
U
lc
er
s
N
od
ul
es
St
ri
ct
ur
es
N
F
Er
yt
he
m
a
A
ph
th
ae
U
lc
er
s
St
ri
ct
ur
es
N
F
Crohn’s disease N9 N24 N6 N5 N1 N64 N10 N22 N9 N0 N67
Histological findings
Chronic inflammation N3 N4 N8 N4 N13 N3 N7
Erosions  N1 N2 N3 N2
Ulcerations N2 N2
FEG N2  N18 N6 N5 N1 N27
Granuloma N1  N12 N5 N5 N1 N9 N2 N2
Normal findings N4  N2 N27 N6 N4 N60
Ulcerative Colitis N3  N41 N44
Histological findings
Chronic inflammation N1 N9
Erosions
Ulcerations
FEG  N10
Granuloma
Normal findings  N2 N23 N44
N: numbers referring to frequency of observed changes; NF: normal findings; FEG: focally enhanced gastritis.
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In UC patients, no macroscopic lesions were identified, except atypical gastric erythema 
in 3/44 (7%) patients. The three symptomatic UC patients had no lesions on upper GI 
endoscopy.
Histological findings
Histological abnormalities were detected in 77/108 (71%) CD patients and are summarized 
in Table 2. FEG was found in 58/108 (54%) CD patients (Figure 3A). Granulomas in stom-
ach and/or duodenum biopsies were found in 34/108 (31%) CD patients (Figure 3B).
Histological inflammation without endoscopic lesions included granuloma forma-
tion in 9 patients, FEG in 27 patients, chronic idiopathic gastritis in 8 patients and chron-
ic idiopathic duodenitis in 7 patients.
In UC, histological findings included chronic idiopathic inflammation and FEG, which 
were identified in 19 out of 44 patients (43%). FEG was found in 10 out of 44 UC patients 
(23%) (Table 2).
Discussion
The prevalence of upper GI endoscopic lesions was 55% in treatment-naive, newly 
diagnosed adult CD patients, irrespective of upper GI symptoms. The most common 
macroscopic findings in H. pylori-negative CD patients were (aphthous) ulcerations in 
the duodenum or stomach. In 41% of all CD patients, macroscopic lesions were accom-
panied by histological findings, thus qualifying for the diagnosis of upper GI CD (+L4). 
Figure 3   Histological findings of IBD- related upper gastrointestinal lesions
A Focally enhanced gastritis characterized by collections of lymphocytes, neutrophils and 
macrophages surrounding a small group of pits and/or glands (haematoxylin and eosin stain, 
original magnification × 100).
B Granulomatous inflammation (haematoxylin and eosin stain, original magnification × 200)
A B
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In newly diagnosed UC patients, no macroscopic aphthous lesions or ulcerations were 
observed in H. pylori-negative patients, but microscopic inflammation was observed in 
43% of UC patients. Granulomatous inflammation in stomach or duodenum biopsies 
was exclusively observed in CD patients, irrespective of endoscopic findings. Focally 
enhanced gastritis was present in both CD and UC patients, either in combination with 
granulomas in CD or as an isolated finding, regardless of the presence of mucosal le-
sions during upper endoscopy.
Most of the histological findings reported in gastroduodenal biopsies of CD and UC 
are not specific for one of the main two phenotypes of IBD. Initially, FEG was thought 
to be a diagnostic hallmark of CD inflammation in the gastric mucosa25. However, in 
several studies, it has been shown that even if FEG is more common in CD, it may also 
be a feature in some UC patients26-28. The currently presented findings confirmed these 
data as we identified FEG in 23% of UC patients.
For upper GI lesions associated with UC, a new entity called Ulcerative Gastroduo-
denal Lesions (UGDL) has been proposed13,14. The authors defined UGDL as diffusely 
inflamed, friable or granular mucosa with multiple erosions, similar to the characteristic 
colorectal inflammation of UC. The prevalence of UGDL in two different studies was 
4,7% (15/322) and 7,6% (19/250); remarkably, all patients with upper GI lesions had a 
pancolitis or postcolectomy status13. Furthermore, UGDL was associated with pouchitis 
in up to 61,5% of patients14,15. Although we found a high count (43%) of microscopic in-
flammation in our UC patients, we encountered no such lesions in our population. This 
may be explained by the cohort size, the early phase of the disease course, or exclusion 
of IBD-related drug therapy in the current UC patient group.
In a recent prospective study the occurrence of upper GI involvement was analyzed 
in a heterogeneous group of asymptomatic CD patients (45 newly diagnosed and 74 
previously diagnosed CD patients). The reported overall prevalence for upper GI CD in-
volvement was 16% (19/119), of which 68% (13/19) were newly diagnosed CD patients16. 
Others observed upper GI findings in known CD and UC patients, reporting minute en-
doscopic lesions in 78% (18/23) CD and 53% (10/19) UC patients whilst using IBD-related 
anti-inflammatory medication21. In a retrospective study on known CD patients with 
long-standing disease, the reported prevalence of CD related upper GI endoscopic le-
sions reached 48%, most of the lesions being found in the stomach22. Furthermore, in 
recent reports on endoscopic gastroduodenal findings in known IBD patients, bamboo 
joint-like appearance of the gastric mucosa has been described as a typical, although 
not exclusive lesion of CD, as it has been described in some UC patients too23,24. In the 
present series no such lesion has been observed possible because no standard dye-
spraying technique was used or, more likely due to a lower incidence of bamboo joint-
like appearance in untreated patients with early stage of IBD.
Up till now the presence of granulomatous inflammation in gastroduodenal biop-
sies appeared to be the only histological finding in IBD patients restricted to CD. The 
reported prevalence of granuloma formation in upper GI biopsies of adult CD patients 
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lies between 4-11 %16,20-22. However these results originate from studies in patients with 
long-standing CD on immunosuppressive treatment.
In children at first presentation of IBD, granulomas in upper tract mucosal biopsies 
were described in 26% to 40% of the cases29-32. The prevalence of upper GI lesions at 
primary diagnosis in pediatric IBD patients is high, such as mild macroscopic inflamma-
tion in up to 64% of the patients, both in CD as well as in UC29-31. Granulomatous in-
flammation, assuming that other causes are being excluded, was the only differentiating 
feature consistent with the exclusive diagnosis of CD29-33. Therefore upper GI endoscopy 
at primary diagnosis was proposed as a standard procedure in the diagnostic work-up of 
pediatric IBD patients, allowing for diagnostic differentiation using microscopic granulo-
matous inflammation as a guide34.
In the present study a high prevalence of upper GI endoscopic lesions in newly di-
agnosed, treatment-naive CD patients has been observed. It comprised mostly mild 
aphthous gastritis and duodenitis, but the majority of these patients (68%) reported no 
upper GI related symptoms. In our experience, the clinical relevance of upper GI findings 
in asymptomatic, adult CD patients at the time of primary diagnosis is therefore limited, 
restricting the use of routine upper endoscopy in newly diagnosed, adult CD patients.
Whether upper GI disease location of CD at the time of primary diagnosis may predict 
a complicated disease course has not yet been properly prospectively studied. There-
fore, at this moment the use of upper endoscopy should be limited to symptomatic 
patients and patients with IBD Unclassified in order to discriminate between CD and UC, 
specifically in case of granulomatous inflammation at histopathological examination.
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Abstract
background The value of Magnetic Resonance Enterography (MRE) in determining 
the extent and severity of Crohn’s disease (CD) in addition to a complete ileocolonosco-
py at the time of the primary diagnosis has been advocated in recent guidelines though 
not yet been studied. The aim of this study was to assess the additional value of MRE 
following initial diagnostic ileocolonoscopy of CD.
methods Patients who underwent MRE within 3 months of primary ileocolonoscopy 
were retrospectively included in the analysis. Additional findings on MRE next to ileo-
colonoscopy were assessed including strictures, entero-enteral fistula, abscesses and 
extended small bowel disease activity. MRE findings were subsequently analyzed in dif-
ferent CD phenotypes.
results A total of 163 newly diagnosed CD patients were included in the analysis. MRE 
revealed additional findings in 28% (45/163) of all patients. Prevalence of additional MRE 
findings was 67% (21/32) in those cases in which ileum could not been intubated, com-
pared to 18% (24/131) in patients with a complete ileocolonoscopy. In patients without 
ileitis at ileocolonoscopy no additional lesions were seen on MRE. Strictures, entero-
enteral fistula and abscesses were mostly observed during MRE examination in patients 
with severely active ileitis at endoscopy.
conclusions Prevalence of MRE findings next to ileocolonoscopy in newly diagnosed 
CD patients is high in endoscopically assessed stricturing disease and severe disease 
activity of the terminal ileum, corroborating the use of standard diagnostic MRE in these 
clinical circumstances.
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Introduction
Crohn’s disease (CD) is a chronic transmural inflammatory disease of the gastro-intes-
tinal tract, which widely varies in presentation, extent and location. A single gold stan-
dard for the diagnosis of CD is not available but is confirmed by clinical evaluation and 
a combination of endoscopic, histological, radiological, biochemical investigations and 
occasionally surgery. For diagnostically assumed CD, ileocolonoscopy with biopsies is 
a well-established first line procedure to confirm the diagnosis1. Disease localization 
at primary diagnosis is reported in 33% of patients to be limited to the terminal ileum, 
in 47% of the patients limited to the colon and in 20% ileocolonic lesions have been 
reported2.
Current diagnostic guidelines recommend additional routine small bowel imaging in 
all newly diagnosed CD patients, irrespective of the findings at ileocolonoscopy. How-
ever, this recommendation is solely based on the expert opinion of a panel, as studies 
on this matter are lacking3.
Magnetic Resonance Enterography (MRE) is the recommended radiological tech-
nique for determining the extent and complications of CD, considering its diagnostic ac-
curacy, lack of ionizing radiation and patient acceptance compared to Ultrasound, Com-
puted Tomography Enterography and Magnetic Resonance Enteroclysis3-16. MRE has a 
high sensitivity in the assessment of terminal ileum disease activity, fistulas, strictures, 
and abscesses as well as the extent of small bowel activity17-18.
However, the complementary value of MRE in addition to ileocolonoscopy in newly 
diagnosed CD patients remains yet unclear, as it has not yet been studied. In patients 
with a non-complicated CD in the colon and/or terminal ileum, small bowel imaging is 
suspected to provide little extra information compared to ileocolonoscopy alone, espe-
cially in isolated colonic disease19. On the other hand an additional MRE could provide 
vital information in more elaborate and penetrating forms of small bowel CD, such as 
the detection of strictures, extended small bowel activity, fistulas or abscesses.
Therefore, the aim of this study was to assess the value of MRE regarding new clini-
cal relevant findings in addition to ileocolonoscopy at primary diagnosis of CD. More-
over, we wanted to identify CD patients that would benefit the most from an additional 
MRE at the time of primary diagnosis.
Methods
Study population and period
All patients labeled with the diagnosis treatment combination (DTC) code for CD at a 
large regional hospital in Arnhem, The Netherlands (Rijnstate Hospital) between 2009 
and 2015 were retrospectively reviewed Figure 1. The CD diagnosis was established and 
57
mr  enterography  at  primary  diagnosis  of  cd
registered by the treating physician and was based on a combination of endoscopic, his-
tological, radiological and/or biochemical investigations according to the Lennard-Jones 
criteria. Patients of 16 years and older, who underwent a MRE within 3 months of ileoco-
lonoscopy at primary diagnosis were included. Patients primarily diagnosed before 2009 
were not included due to possible changes in MRE protocol. Patients with a diagnosis of 
ulcerative colitis (UC), inflammatory bowel disease unclassified (IBD-U) or an otherwise 
doubtful CD diagnosis and in case of inadequate MRE quality, were excluded from the 
analysis.
From the medical records of the included patients the following data were retrieved: 
patient age, gender, date and findings of ileocolonoscopy at the time of primary dia-
gnosis, date and findings of MRE, time to follow-up, disease location and behavior at the 
time of primary diagnosis according to the Montreal classification.
Subgroups were made based on Montreal classifications, intubation of terminal il-
eum during endoscopy (yes or no) and severity of the ileitis (mild or severe). The cause 
for not intubating the ileum was identified and these patients were analyzed separately.
The Montreal classification was used to classify CD location [ileal (L1), colonic (L2), 
ileocolonic (L3)] and disease behavior [non-stricturing, non-penetrating (B1), stricturing 
(B2), and penetrating (B3)] based on primary ileocolonoscopy20,21. Gastroesophageal in-
Figure 1  Inclusion diagram of the patients
CD patients identified by DTC
(N=545)
Did not meet inclusion criteria
(N= 380):
• Age <16 years (N=15)
• No primary CD diagnosis (N=326)
• No MRE within 3 months (N=39)
Excluded (N=2)
• Insufficient MRE quality
Included in the analysis  
(N=163)
Inclusion criteria (N=165):
• Established CD
• Age >16 years
• MRE within 3 months
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volvement was not considered in this study as not all patients underwent upper endos-
copy. Subjects with both stricturing and penetrating disease were classified as having 
penetrating disease (B3). Perianal fistulizing disease was recorded as a separate modifier 
(+P) and this localization did not constitute penetrating disease (B3) on its own.
Ileocolonoscopy
Patients underwent endoscopy under conscious sedation. The ileocolonoscopy was 
performed after standard bowel preparation with 4 liter of polyethylene glycol electro-
lyte solution.
The ileocolonoscopy was scored for presence of ileitis and/or colitis, severity of in-
flammation in the terminal ileum, stenosis and fistulas based on the report made by 
the performing endoscopist. Severity of inflammation in the terminal ileum was either 
classified as mild or severe, while colitis was only noted as present or absent. The ileitis 
was scored as mild in the presence of small aphthous ulcers (estimated diameter 0.1-0.5 
centimeters) separated by normal mucosa and as severe when large ulcers (estimated 
diameter >0.5 centimeters) and/or diffuse inflamed mucosa was seen.
Stenosis was defined, as a localized narrowing of the intestinal lumen reported by 
the endoscopist, either passable or not passable with the scope.
Magnetic Resonance Enterography
MRE was performed according to the standard local protocol. Patients fasted for at least 
4 hours and were asked to drink 1.0 liter of a water-based oral preparation fluid contain-
ing 2,5% mannitol and 0,5% locust bean gum, in a time span of 45 minutes before the 
MRI, without any particular preparation of the colon. MRI scans were performed with 
the patient in prone position, using a body coil on a 1.5T MRI unit (Intera 1.5 T, Philips 
medical systems, Best, Holland). Patients were given butylscopolamine 20 mg intra-
venously, as intestinal motility inhibitor immediately before the examination to avoid 
bowel peristalsis artifacts. Patients were scanned in the prone position to avoid wall 
movement of the abdomen.
The scanning protocol included a coronal breath-hold T2-weighted single-shot (SSh) 
turbo spin-echo and a coronal T2 breath-hold balanced fast field echo (FFE). The field of 
view of these T2 weighted studies was the whole abdomen, from the xyphoid process 
to the pubic bone. Slice thickness was 5 mm consecutive, which resulted in an average 
of 30 images in the coronal plane. After 60 seconds of manual administration of the in-
travenous contrast medium (Gadoteric acid, Dotarem) (0.5 mmol/ml) 0.2 ml per kg body 
weight), T1 weighted sequences were applied in the transverse and coronal plane with a 
fat saturation spectrally attenuated inversion recovery (SPAIR).
The MRE report was scored for the presence of findings such as terminal ileitis (ter-
minal ileum affected adjacent to the ileocecal valve), preterminal ileitis (more than 10 
cm normal ileum between the ileocecal valve and the affected ileum), extended ileitis 
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(more than 40cm of small bowel affected), stenosis, fistulas and abscesses. Stenosis 
was defined as a narrowing of a thickened bowel segment with a proximal area of dila-
tion. Fistulae were defined as tubular tracts with or without high signal intensity, be-
tween two small bowel loops. Abscesses were described as a fluid collection, with or 
without associated air and a well-defined wall.
Mural contrast enhancement was considered present if there was a clear visual en-
hancement of a small bowel segment compared to adjacent loops of the terminal ileum, 
at visual assessment. All these scans were re-examined by an experienced abdominal 
radiologist who was blinded to the patient data.
Outcome measures
Primary outcome measures were the percentage of patients with additional small bowel 
findings on MRE and the descriptive characteristics of these findings. The findings of 
ileocolonoscopy and MRE were analyzed and compared between different subgroups: 
intubation of the terminal ileum during endoscopy (yes or no), different Montreal clas-
sification after primary ileocolonoscopy and endoscopic severity of the ileitis (mild or 
severe).
Statistical analysis
Statistical analysis of the data was performed using IBM SPSS statistics (SPSS 21.0). Cat-
egorical variables were described using frequencies and percentages. Continuous vari-
ables were summarized using medians and range. The Pearson’s chi-squared or Fisher-
Exact test was used to determine statistical significance between proportions. P values 
less than 0.05 were considered to indicate statistical significance.
Ethical considerations
Approval of the local ethics and feasibility committee for medical research from the 
Rijnstate hospital Arnhem, in The Netherlands was obtained in August 2015. The study 
was performed according to the principles of the Declaration of Helsinki. Furthermore, 
there was no conflict of interest or sponsoring involved.
Results
The study population consisted of 163 patients with CD who underwent MRE within 3 
months of primary diagnosis by ileocolonoscopy. The main baseline characteristics and 
endoscopic findings of our patients are summarized in Table 1 and Table 2. Two CD pa-
tients were excluded because the MRE quality was insufficient to examine the terminal 
ileum due to lack of sufficient distension of the ileum.
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A number of 39 newly diagnosed CD patients did not undergo MRE within 3 months 
of initial ileocolonoscopy and were therefore excluded from the analysis Figure 1. Out 
of these patients, 10 (26%) had colonic CD with normal ileum on ileocolonoscopy, 16 
(41%) had mild ileitis on ileocolonoscopy, 12 (30%) had severe ileitis and 1 patient had 
an incomplete ileocolonoscopy because of stricture. The patient with incomplete colo-
noscopy and two other patients with severe disease underwent an CT of the abdomen 
next to ileocolonoscopy.
Endoscopic findings
A total of 131/163 (80%) patients had successful endoscopic intubation of the terminal 
ileum during endoscopy. In 32/163 (20%) patients the terminal ileum was not intubated 
due to stenosis (16.5%) or technical limitations (3.1%) The findings of ileocolonoscopy, 
including disease location and endoscopic severity are described in Table 2. From the 
20 patients with no endoscopic signs of active ileal inflammation, 17 patients had isolat-
ed colonic CD with a normal endoscopic and histologic aspect of the terminal ileum. In 
three patients ileal disease was present in the form of fibrotic scars, post-inflammatory 
polyps and stricturing of the terminal ileum without signs of active inflammation at the 
time of the primary ileocolonoscopy.
Magnetic Resonance Enterography findings
The Magnetic Resonance Enterography findings in addition to ileocolonoscopy findings 
are summarized in Table 3. In 28% of all patients additional small bowel lesions were 
found on MRE after ileocolonoscopy. Additional findings on MRE were present in 18% 
of the patients following complete ileocolonoscopy compared to 66% of the patients 
without ileum intubation (p<0.05) Table 3.
Table 1  Baseline characteristics of patients at presentation
Baseline characteristics Number of patients Median (spread)/Percentage
Age at diagnosis
A2 (16-39 years)
A3 (>40 years)
Male
Female
Perianal disease (+p)
163
116
47
61
102
23
28 years [16-72]
71.2%
28.8%
37.4%
62.6%
14.1%
Days between MRE and ileocolonoscopy
< 1 week
1 week - 1 month
1 month - 3 months
163
64
70
29
11 days [0-92]
39.3%
42.9%
17.8%
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No statistically significant difference was found between patients with isolated ileum 
(L1) and ileocolonic (L3) endoscopic disease. Patients with isolated colonic disease dur-
ing ileocolonoscopy (L2) showed no additional small bowel findings on MRE, precluding 
Chi-square testing in this group.
Patients with endoscopic stricturing disease (B2) had more new lesions on MRE 
compared to non-stricturing/non-penetrating disease (B1) (p<0.05). In the patients with 
signs of entero-enteral fistula on primary endoscopy (B3), the MRE confirmed the pres-
ence of fistula and revealed new lesions such as stenosis or abscess Table 3. The ad-
ditional MRE findings in mildly active endoscopic ileitis were restricted to five cases 
showing ileitis in the proximal ileum (skip lesions) without small bowel complications 
and one case of extended ileitis (>40 cm).
Table 2  Findings at ileocolonoscopy in all patients
Ileocolonoscopy characteristics Number of patients (%)
Procedure (N=163)
Ileum intubated
Ileum not intubated
→ due to technical limitations
→ due to stenosis
Location of stenosis
→ colon
→ ileocecal valve
131(80.4%)
32 (19.6%)
5 (3.1%)
27 (16.5%)
7 (4.3%)
20 (12.3%)
Ileum inflammation severity (N=131)
→ no active inflammation
→ mild
→ severe
20 (15.3%)
48 (36.6%)
63 (48.1%)
Localization at endoscopy (N=131)
→ isolated ileum activity (L1)
→ isolated colonic activity (L2)
→ ileocolonic activity (L3)
66 (50.4%)
17 (13.0%)
48 (36.6%)
Behavior at endoscopy (N=131)
Non-stricturing/Non-penetrating (B1)
Stricturing (B2)
→ passable with scope
 colon
 ileocecal valve
 ileum
→ impassable with scope
 ileum
Entero-enteral fistulas (B3)
100 (76.3%)
29 (22.1%)
15 (11.5%)
1 (0.8%)
5 (3.8%)
9 (6.9%)
14 (10.7%)
2 (1.5%)
62
chapter  4
Discussion
In the present study, additional findings on MRE following primary ileocolonoscopy were 
observed in 28% of newly diagnosed CD patients. The highest percentage of additional 
MRE small bowel lesions was found in patients with incomplete ileocolonoscopy (67%) 
and in patients with stricturing endoscopic disease (35%). In isolated colon CD at ileoco-
lonoscopy no additional findings were seen on the MRE. Patients with mild endoscopic 
ileitis had no small bowel complications on MRE.
Current guidelines recommend additional imaging of the small bowel in all newly 
diagnosed CD patients, irrespective of the findings at ileocolonoscopy. The underlying 
reason for this recommendation may be that sensitivity of ileocolonoscopy in determin-
ing the location and extent of disease activity, especially in penetrating and stricturing 
forms of small bowel CD is limited3. However a majority of the patients experience no 
CD complications at time of first presentation. Previous studies have shown that MRE 
has a high sensitivity for both assessing the terminal ileum disease activity, fistulas, 
strictures, and abscesses as well as the extent of small bowel activity of Crohn’s dis-
ease17,18. In most studies the accuracy of MRE has been compared with ileocolonoscopy 
but the complementary diagnostic value of MRE was disregarded22,23. It has recently 
been stated that nearly half of the Inflammatory Bowel Disease guideline recommen-
dations are based on expert opinion or lack any solid scientific evidence necessitating 
corroborating (or denying) investigations24.
Table 3  Additional findings at MRE next to ileocolonoscopy
Magnetic Resonance Enterography findings Additional 
findings (%)
New terminal 
ileitis (%)
Preterminal 
ileum activity 
(%)
Length >40cm 
(%)
New stenosis  
(%)
New entero-
enteral  
fistula (%)
Abscesses  
(%)
Change in Montreal  
classification  
(Behavior/Location)
All patients (N=163)
Ileum intubated (n= 131)
Ileum not intubated (n=32)
45 (27.6%)
24 (18.3%)*
21 (65.6%)*
21 (12.9%)
1 (0.8%)
20 (62.5%)
16 (9.8%)
12 (9.2%)
4 (12.5%)
6 (3.7%)
5 (3.8%)
1 (3.1%)
3 (1.8%)
3 (2.3%)
0 (0%)
9 (5.5%)
7 (5.3%)
2 (6.3%)
6 (3.7%)
5 (3.8%)
1 (3.1%)
11 (6.7%)/14 (8.5%)
8 (6.1%)/0 (0.0%)
3 (9.4%)/13 (40.6%)
Clinical phenotype after ileocolonoscopy (N=131)
Ileal (L1) (n=66)
Colonic (L2) (n=17)
Ileocolonic (L3) (n=48)
Non-stricturing/non-penetrating (B1) (n=100)
Stricturing (B2) (n=29)
Penetrating (B3) (n=2)
14 (21.2%)**
0 (0%)
10 (20.8%) **
12 (12.0%)*
10 (34.5%)*
2 (100%)
0 (0.0%)
0 (0.0%)
1 (2.1%)
0 (0.0%)
0 (0.0%)
1 (50.0%)
6 (9.1%)
0 (0.0%)
6 (12.5%)
8 (8 %)
3 (10.3%)
1 (50.0%)
3 (4.5%)
0 (0.0%)
2 (4.2%)
3 (3.0%)
1 (3.4%)
1(50.0%)
2 (3.0%)
0 (0.0%)
1 (2.1)
0 (0.0%)
2 (6.9%)
1 (50.0%)
5 (7.6%)
0 (0.0%)
2 (4.2%)
1 (1.0%)
4 (13.8%)
2 (100%)
2 (3.0%)
0 (0.0%)
3 (6.3%)
2 (2.0%)
2 (6.9%)
1 (50.0%)
5 (7.5%)/0 (0.0%)
0 (0.0%)/0 (0.0%)
3 (6.3%)/0 (0.0%)
2 (2.0%)/0 (0.0%)
6 (20.7%)/0 (0.0%)
0 (0%)/0 (0.0%)
Ileum inflammation severity (N= 114)
Fibrotic lesions and stenosis without active inflammation (N=3)
Mild (N=48)
Severe (N=63)
3 (100%)
6 (12.5%)
15 (23.8%)
1 (33.3%)
0 (0.0%)
0 (0.0%)
1 (33.3%)
5 (10.4%)
6 (9.5%)
2 (66.6%)
1 (2.1%)
2 (3.2%)
3 (100%)
0 (0.0%)
0 (0.0%)
1 (33.3%)
0 (0.0%)
6 (9.5%)
1 (33.3%)
0 (0.0%)
4 (6.3%)
2 (66.6%)/0 (0.0%)
0 (0.0%)/0 (0.0%)
8 (12.7%)/0 (0.0%)
* p <0.05
** p=0.11
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In a previous subgroup analysis of the value of MRE next to primary ileocolonoscopy 
in 49 patients was stated that small bowel imaging provides little extra information 
in non-complicated CD19. Moreover, it was suggested that in isolated colon CD dur-
ing complete ileocolonoscopy, small bowel imaging adds no information to endoscopy. 
An important role for MRE was mentioned in case of incomplete ileocolonoscopy or 
suspicion of complicated disease. However predictive factors of complicated disease 
were not addressed19. Predictive factors for complicated CD might include extensive 
small bowel disease, young age at diagnosis, perianal disease activity, early stricturing/
penetrating disease and smoking but the clinical value of these factors has not yet been 
prospectively studied in a large patient cohort25,26.
One of the strengths of the present study lies in refining the indication for additional 
small bowel imaging based on macroscopically findings of the primary ileocolonoscopy. 
Furthermore, the period between the primary ileocolonoscopy and MRE was short, as 
82.2% underwent MRE within a month, with an overall a median period of 11 days. 
Moreover, the number of patients included was sufficiently high to draw robust conclu-
sions. The main limitation of this study was the retrospective design. The prognostic 
value and clinical impact of the additional MRE findings at the time of the primary diag-
nosis could not be reliably determined in this study. Furthermore, the inclusion criteria 
might have induced a selection bias, because only patients who underwent MRE were 
included. The isolated colonic disease group could therefore be underrepresented in 
our study.
Table 3  Additional findings at MRE next to ileocolonoscopy
Magnetic Resonance Enterography findings Additional 
findings (%)
New terminal 
ileitis (%)
Preterminal 
ileum activity 
(%)
Length >40cm 
(%)
New stenosis  
(%)
New entero-
enteral  
fistula (%)
Abscesses  
(%)
Change in Montreal  
classification  
(Behavior/Location)
All patients (N=163)
Ileum intubated (n= 131)
Ileum not intubated (n=32)
45 (27.6%)
24 (18.3%)*
21 (65.6%)*
21 (12.9%)
1 (0.8%)
20 (62.5%)
16 (9.8%)
12 (9.2%)
4 (12.5%)
6 (3.7%)
5 (3.8%)
1 (3.1%)
3 (1.8%)
3 (2.3%)
0 (0%)
9 (5.5%)
7 (5.3%)
2 (6.3%)
6 (3.7%)
5 (3.8%)
1 (3.1%)
11 (6.7%)/14 (8.5%)
8 (6.1%)/0 (0.0%)
3 (9.4%)/13 (40.6%)
Clinical phenotype after ileocolonoscopy (N=131)
Ileal (L1) (n=66)
Colonic (L2) (n=17)
Ileocolonic (L3) (n=48)
Non-stricturing/non-penetrating (B1) (n=100)
Stricturing (B2) (n=29)
Penetrating (B3) (n=2)
14 (21.2%)**
0 (0%)
10 (20.8%) **
12 (12.0%)*
10 (34.5%)*
2 (100%)
0 (0.0%)
0 (0.0%)
1 (2.1%)
0 (0.0%)
0 (0.0%)
1 (50.0%)
6 (9.1%)
0 (0.0%)
6 (12.5%)
8 (8 %)
3 (10.3%)
1 (50.0%)
3 (4.5%)
0 (0.0%)
2 (4.2%)
3 (3.0%)
1 (3.4%)
1(50.0%)
2 (3.0%)
0 (0.0%)
1 (2.1)
0 (0.0%)
2 (6.9%)
1 (50.0%)
5 (7.6%)
0 (0.0%)
2 (4.2%)
1 (1.0%)
4 (13.8%)
2 (100%)
2 (3.0%)
0 (0.0%)
3 (6.3%)
2 (2.0%)
2 (6.9%)
1 (50.0%)
5 (7.5%)/0 (0.0%)
0 (0.0%)/0 (0.0%)
3 (6.3%)/0 (0.0%)
2 (2.0%)/0 (0.0%)
6 (20.7%)/0 (0.0%)
0 (0%)/0 (0.0%)
Ileum inflammation severity (N= 114)
Fibrotic lesions and stenosis without active inflammation (N=3)
Mild (N=48)
Severe (N=63)
3 (100%)
6 (12.5%)
15 (23.8%)
1 (33.3%)
0 (0.0%)
0 (0.0%)
1 (33.3%)
5 (10.4%)
6 (9.5%)
2 (66.6%)
1 (2.1%)
2 (3.2%)
3 (100%)
0 (0.0%)
0 (0.0%)
1 (33.3%)
0 (0.0%)
6 (9.5%)
1 (33.3%)
0 (0.0%)
4 (6.3%)
2 (66.6%)/0 (0.0%)
0 (0.0%)/0 (0.0%)
8 (12.7%)/0 (0.0%)
* p <0.05
** p=0.11
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Assessment of disease extension and activity in patients with CD is required in or-
der to determine the therapeutic strategy, and may have major prognostic implica-
tions27. The extent of the prognostic impact of small bowel imagining after initial 
ileocolonoscopy is unclear as a combined disease severity index capturing different 
prognostic factors, such as clinical phenotype, mucosal lesions and bowel damage, is 
missing25,28. However, imaging of the small bowel by using MRE is a costly procedure 
and the indication for imaging should be appropriately argued based on the disease 
characteristics. Our results confirmed that in case of an incomplete primary ileocolo-
noscopy, MRE might reveal important new findings regarding small bowel extent and 
complications of CD. High prevalence of additional findings was also present in case 
of stricturing of the terminal ileum during a complete ileocolonoscopy. MRE findings 
in case of mildly active endoscopic ileitis were of limited clinical value and no small 
bowel complications were seen in this group of patients.
In conclusion, MRE is a valuable addition to ileocolonoscopy in determining the 
location and extent of CD, in some well-defined groups of newly diagnosed patients. 
Additional MRE is indicated in all cases of incomplete endoscopy, stricturing and se-
verely active ileitis at primary endoscopy. Furthermore MRE should also be performed 
in all cases of endoscopic suspicion of entero-enteral fistula in order to assess the 
extent of the lesions and presence of concomitant complications such as stenosis 
and abscesses. In cases of mildly active endoscopic ileitis the additional value of MRE 
following complete primary ileocolonoscopy was limited and therefore MRE is not 
routinely indicated in these patients. Moreover, when the disease activity is isolated 
to the colon during a complete ileocolonoscopy, MRE could be omitted from the di-
agnostic work-up.
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Abstract
background and aims To prospectively examine the feasibility and accuracy of Con-
trast Enhanced Ultrasound (CEUS) in the assessment of Crohn’s disease (CD) activity in 
the terminal ileum in comparison to Magnetic Resonance Enterography (MRE), using 
endoscopy as a reference standard.
methods 105 consecutive patients with alleged clinically active CD were assessed by 
MRE and CEUS. CEUS of the terminal ileum was performed using an intravenous micro-
bubble contrast enhancer. Accuracy values of CEUS and MRE for the presence of active 
terminal ileitis were evaluated using the Receiver Operating Characteristic method, us-
ing endoscopic findings as a reference standard. Sensitivity and specificity values of 
MRE and CEUS were compared by the McNemar test.
results CEUS was feasible in 98% of patients, MRE in all. Optimal diagnostic accuracy 
in CEUS was obtained at a peak intensity value of 10%, showing 100% sensitivity, 92% 
specificity and an accuracy of 99% in demonstrating ileal mucosal inflammation. For 
MRE, overall sensitivity, specificity and accuracy were, 87%, 100%, and 88%, respec-
tively. CEUS and MRE were highly correlated in assessing length and wall thickness of 
the terminal ileum. CEUS identified 11 of 16 MRE-detected strictures, but no fistulae.
conclusion The accuracy of CEUS is comparable to that of MRE in the assessment of 
active, uncomplicated terminal ileal CD and therefore a valuable bedside alternative to 
MRE in the follow-up of these patients.
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Introduction
Crohn’s disease (CD) is a chronic transmural inflammatory disease of the gastrointes-
tinal tract characterized by a widespread variation in severity and relapsing episodes 
of disease activity. Exclusive ileum disease is observed in approximately 30% of pa-
tients, whereas the ileocecal segment is involved in more than 50% of all CD patients1. 
Assessment of the severity of CD-associated inflammatory activity is used to monitor 
therapeutic results and plan further medical or surgical therapy. Clinical markers and 
laboratory tests are suboptimal indicators of disease activity2,3. Additional methods 
to reliably estimate disease activity include endoscopy and radiological imaging tech-
niques. Ileocolonoscopy is considered the gold standard for CD disease activity in the 
colon and terminal ileum, allowing tissue sampling. This however is an invasive and, 
from patients’ perspective, burdensome method4. Complete visualization of the small 
bowel and of extramural disease manifestations may be performed by CT Enterography 
and MR Enterography (CTE and MRE)5-7. These two techniques have a similar diagnostic 
accuracy for CD disease extension and activity, as reported by Panes et al8. MRE is not 
widely available as it is a rather costly technique, whilst repeated CTE induces cumula-
tive ionizing radiation exposure, particularly important in this group of relatively young 
patients9-11. The sensitivity of grey scale ultrasound (US) for the detection of CD disease 
activity of the terminal ileum ranges from 63% to 100%, with a specificity in the range 
of 77-100%8,12-15. Contrast enhanced ultrasound (CEUS) with new intravenous contrast 
agents allows visualisation of bowel wall perfusion. Quantitative evaluation of enhance-
ment during CEUS improves the accuracy of ultrasound for the presence and severity of 
active inflammation in ileal CD16-22. Ultrasound is less suitable in the assessment of CD 
activity located in the large bowel, because of the limited ability to accurately localise 
the affected bowel segments.
The diagnostic value of bowel wall enhancement with CEUS in the evaluation of CD 
disease activity, in comparison to MRE, was assessed in two studies23-24. Both of these 
used clinical disease activity scores as a reference, showing no correlation with either 
contrast enhancement by CEUS or by MRE. Therefore, these studies did not provide a clear 
assessment of the diagnostic value of CEUS as compared to MRE in daily clinical practice.
The aim of this study was to assess the feasibility and accuracy of CEUS in the de-
tection of CD activity in the terminal ileum, as compared to MRE, using endoscopy as a 
reference standard for active inflammation.
Materials and Methods
Study population
From October 2009 to December 2012 a total of 107 consecutive adult patients with 
established active CD, who attended the Department of Gastroenterology of a large 
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regional hospital (Rijnstate Hospital, Arnhem, NL), were prospectively enrolled in the 
study. The initial diagnosis of CD located in the terminal ileum, colon or both was con-
firmed in all patients according to the usual clinical, endoscopic and histological cri-
teria25. The inclusion criteria were: age over 18 years and a clinical indication for an 
ileocolonoscopy, to assess localization, extent and severity of the presumptive activity 
of CD (primary diagnosis, clinical relapse or recurrence). Patients who did not agree 
to participate in the study were excluded from the study, as were pregnant women. 
Further exclusion criteria were: contraindications for MRE such as claustrophobia, MR-
unsafe devices and implants, renal insufficiency and conditions potentially related to 
the toxicity of Sonovue® (Bracco, Italy); also a history of ischemic coronary disease and 
cardiac failure.
The clinical disease activity at inclusion was scored using the Harvey Bradshaw In-
dex26 and blood samples were taken for the measurement of C-reactive protein (CRP).
The study was performed according to the principles of the Declaration of Helsinki. 
Approval of the regional ethics committee for medical research from Arnhem-Nijme-
gen, in The Netherlands (CMO Arnhem-Nijmegen) was obtained on September 2009 
and all patients provided written informed consent.
Endoscopy
All patients underwent endoscopy under conscious sedation. The ileocolonoscopy was 
performed after standard bowel preparation with 4 liter of polyethylene glycol elec-
trolyte solution. The disease activity was scored using the Simple Endoscopy Score for 
CD (SES-CD)27, adjusted to score ileal disease activity. The SES-CD score was originally 
designed by Daperno et al. to score the mucosal disease activity in Crohn’s disease, 
through the whole colon and the terminal ileum for the length that has been examined 
by endoscopy. The four variables selected were: the size of ulcers, proportion of ulcer-
ated surface, the surface with any other lesions and the presence of stenosis. Each vari-
able was scored from 0 to 3 in each of the 5 segments (ileum, right colon, transverse 
colon, left colon, rectum) with a maximal total score for the SES-CD of 48. When these 
variables are only scored for the terminal ileum the maximal score is 12. A score of 0 
equals no endoscopic lesions and a score of 1 implies the presence of erythematous 
mucosa over less than 50% of the surface without any aphthous lesions or ulcerations. 
Before the start of the study, we defined a score of 0-1 in the terminal ileum, as no ac-
tive inflammation and a score of 2 or higher as active inflammation.
Magnetic Resonance Enterography
Within a period of maximally two weeks from the reference ileocolonoscopy and before 
any therapeutic changes, the patients underwent MRE followed by CEUS on the same day.
The MRE studies were performed according to a standardized protocol. Patients 
fasted for at least 6 hours and were asked to drink 1.0 liter of a water-based oral prepa-
ration fluid containing 2,5 % mannitol and 0,5% locust bean gum, in a time span of 45 
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minutes before the MRI, without any particular preparation of the colon. MRI scans 
were performed with the patient in prone position, using a body coil on a 1.5T MRI unit 
(Intera 1.5 T, Philips medical systems, Best, Holland). All patients were given butylsco-
polamine 20 mg intravenously, as intestinal motility inhibitor immediately before the 
examination to avoid bowel peristalsis artifacts. Patients were scanned in the prone 
position to avoid wall movement of the abdomen.
The scanning protocol included a coronal breath-hold T2-weighted single-shot (SSh) 
turbo spin-echo and a coronal T2 breath-hold balanced fast field echo (FFE). The field of 
view of these T2 weighted studies was the whole abdomen, from the xyphoid process to 
the pubic bone. Slice thickness was 5 mm consecutive, which resulted in an average of 
30 images in the coronal plane. After 60 seconds of manual administration of the intra-
venous contrast medium (Gadoteric acid, Dotarem®) (0.5 mmol/ml) 0.2 ml per kg body 
weight), T1 weighted sequences were applied in the transverse and coronal plane with a 
fat saturation spectrally attenuated inversion recovery (SPAIR). The terminal ileum was 
the center of the field of view of these last three sequences.
The MRE images were analysed by two experienced abdominal radiologists. They 
were aware of the diagnosis of CD and blinded for clinical, endoscopic and CEUS data. 
Parameters scored included the length of affected bowel, wall thickness measured at 
the point of maximum diameter of the affected small bowel wall, stratified wall appear-
ance and perivisceral fibrofatty proliferaton, stenosis, fistulae, abscesses and enhance-
ment after administration of gadolinium (Table 1). Stenosis was defined as a narrowing 
of a thickened bowel segment with a proximal area of dilation (>3.0 cm). Fistulae were 
defined as tubular tracts with high signal intensity, between two small bowel loops. 
Abscesses were described as a fluid collection, with or without associated air and a 
well-defined wall.
Mural contrast enhancement was considered present if there was a clear visual 
enhancement of a small bowel segment compared to adjacent loops of the terminal 
ileum, at visual assessment.
Grey scale Ultrasound and Contrast enhanced Ultrasound
Ultrasound was performed with a Philips US device (Philips IU22®), using a convex 3-5 
MHz probe. All studies started with a grey scale US examination to find the terminal 
ileum and assess wall thickness, induration of surrounding fatty tissue and enlarged 
lymphnodes. Stenosis and length of the pathologic bowel wall was estimated, as well 
as complications such as abscess formation and fistulae. The thickest segment of the 
terminal ileum was identified and used to perform analysis of contrast enhancement. 
We injected the second generation, ultrasonic contrast agent (SonoVue®, Bracco, Milan, 
Italy) as a bolus of 2.5 ml through a three-way 20-gauge catheter in an antecubital vein, 
followed by a bolus of 10 ml saline solution (0.9% NaCl)28. CEUS was performed with a 
7.5MHz linear probe and contrast-tuned technology, based on a low mechanical index 
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and a real-time scan to ensure the preservation of the contrast agent. A low acoustic 
power setting was used, expressing a low mechanical index (MI), 0.09-0.14, of a 7.5 MHz 
linear probe.
Disease parameters analyzed during the grey scale US included identification of 
the terminal ileum, wall thickness measurement at the maximal diameter of the af-
fected terminal ileum (pathological mural thickening defined as a wall thickness above 
3 mm), evaluation of the affected bowel length, stratified wall appearance, perivisceral 
findings such as creeping fat and stenosis, fistula or abscess (Table 1). Stenosis was 
described as narrowing of a thickened, rigid bowel lumen with a proximal area of dila-
tion (>3.0 cm). Fistulae were defined as tubular hypoechoic tracts between two small 
bowel loops. Abscesses were described as a fluid collection, with or without associated 
air and a well-defined wall19.
CEUS images were assessed directly after injection of the contrast agent, by re-
cording a videoclip at the level of the most affected terminal ileum loop. After primary 
imaging, quantification software Qontrast® (Bracco, Italy) was applied to obtain con-
trast-enhanced sonographic perfusion maps, allowing immediate evaluation of the 
peak intensity (PI), time to peak (TTP), and the regional blood volume (RBV), being pro-
portional to the area under the curve (Figure 1). These parameters, measured within 
the region of interest (ROI) selected by the operator, have formerly been described as 
indicators for disease activity16-19. Qontrast software is able to quantify the contrast 
enhancement from a sequence of the perfusion frames and to generate a chromatic 
map that allows immediate evaluation of the perfusion properties of the selected region 
(region of interest, ROI). The quantification procedure is being performed for each pixel 
encompassed by the ROI on the frame sequence. The ultrasound video intensity of the 
Table 1  Radiological parameters assessed by MR Eenterography (MRE), Grey scale Ultrasound (US)  
and Contrast enhanced Ultrasound (CEUS)
Radiologic parameters MRE Grey scale US
Wall thickness
Length
Stratified wall appearance
Perivisceral fibrofatty proliferation
Stenosis
Fistulae
Abscesses
+
+
+
+
+
+
+
+
+
+
+
+
+
+
 MRE  CEUS
Maximum Enhancement
Time to peak
Regional Blood Volume
+
−
−
+
+
+
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pixels comprised in each ROI is being measured in gray-scale levels, from 0 (black pixels) 
to 255 (white pixels), and expressed in mean ± SD through histogram analysis. Further-
more a virtual color image of the bowel can be obtained, composed of a primary color 
scale varying from red (maximum signal intensity) to blue (minimum signal intensity) 
and correlating with the numeric value of the signal intensity expressed in percentages 
(maximum intensity =100%). In each patient two different regions of the color map with 
the highest echo-signal intensity after contrast injection, were analyzed and the mean 
value was used for the statistical analysis.
Within the brightest zone of the intestinal wall, which represents the highest degree 
of vascularization, we made two measurements per injection. The kinetic parameters 
(PI, TTP, RBV) calculated for both ROI were then averaged for each patient18. The radiolo-
Figure 1  Perfusion map obtained by Qontrast® software.
Left side: contrast uptake based on increased microvascularization of the terminal ileum in a patient with severe 
endoscopic disease activity. 
Right side: contrast uptake of the terminal ileum in a patient with normal endoscopic appearance.
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gist performing the ultrasonography (grey scale and CEUS) was aware of the diagnosis of 
Crohn’s disease, but blinded to the patient’s present clinical, endoscopic and MRE data.
Statistical Analysis
Categorical variables were described using frequencies and percentages. Continuous 
variables were summarized using medians and range.
A Receiver Operating Characteristic (ROC) analysis was performed to determine the 
optimal cut-off value for different CEUS variables in order to differentiate active from 
inactive endoscopic disease. The value of contrast enhancement at MRE and CEUS in di-
agnosing active luminal CD was assessed by calculating the sensitivity, specificity, posi-
tive and negative predictive values and accuracy with 95% confidence intervals (95% CI), 
using endoscopic disease activity as reference standard. The sensitivity and specificity 
of the two modalities were compared by the McNemar test. The correlations between 
different radiological parameters assessed by MRE and ultrasound were determined by 
Spearman’s nonparametric correlation coefficient. We additionally applied the plot of 
the difference between the values measured by the two techniques against the mean 
of the measurements. This method described, by Bland and Altman, allows the visual-
ization of the concordance between two tests for different measured values, in order 
to examine the actual agreement more closely. The smaller the difference between the 
values measured by the two tests, the better the correlation29.
P values less than 0.05 were considered to indicate statistical significance. Statistical 
analysis of the data was performed using the Statistical Package for the Social Sciences 
(SPSS 21.0).
Results
Study population
Over a 37-month period, 107 consecutive patients were included. The main demograph-
ic and clinical data are shown in Table 2. Two CD patients (2%) were not included in 
the analysis because their terminal ileum could not be visualized by B mode US and 
therefore no contrast assessment was done. Both patients had no active ileal disease 
on endoscopy.
The endoscopically determined location and disease behavior of all patients is de-
scribed in Table 2 according to the Montreal classification. Intubation of the terminal 
ileum was attempted in all patients. However, 11 (10%) of the 105 patients had a stenosis 
(colon or ileocecal valve) disallowing endoscopic intubation of the terminal ileum. An 
incomplete stricture of the terminal ileum that could be passed by the endoscope was 
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present in 19 (18%) patients. Twelve patients (11%) had a normal appearance of the ter-
minal ileum next to an inflamed colon and these were classified as L2 according to the 
Montreal classification30. Endoscopic disease activity at the site of the terminal ileum 
was present in 82 (79%) of the patients.
Table 2  Baseline demographic and clinical characteristics of the CD patients (n=105)
Variables Absolute frequency (%)
Male
Female
Age [median (range)]
46 (44 %)
59 (56%)
33 (18-65)
Disease location 
Ileal
Colonic
Ileocolonic
56 (53%)
12 (12%)
37 (35%)
Disease behavior 
Non-stricturing/non-penetrating
Stricturing
Penetrating
Postoperative status (ileocecal resection)
Serum CRP > 5 mg/l
Clinical remission (HBI <4)
65 (62%)
34 (32%)
6 (6%)
16 (15%)
63 (60%)
15 (14%)
Table 3  Statistical values for MR Enterography (MRE) and Contrast enhanced Ultrasound (CEUS) in 
detection of active endoscopic inflammation in the terminal ileum.
Contrast enhancement  
at MRE (95% CI)
Contrast enhancement  
at CEUS (peak>10%) (95% CI)
Positive true
False positive
Negative true
False negative
Sensitivity *
Specificity #
PPV
NPV
Accuracy
71 
0
12
11
87% (77%-93%) 
100% (73%-100%) 
100% (95%-100%) 
52% (31%-73%) 
88% (80%-94%)
82
1
11
0
100% (96%-100%) 
92% (62%-99%) 
99% (93%-100%) 
100% (71%-100%) 
99% (94%-100%)
* P value for pairwise McNemar test was 0,01 for MRE versus CEUS.
# P value for pairwise McNemar test was 1.0 for CEUS versus MRE.
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MR Enterography
No adverse events from MRE, performed as per protocol in all patients, were reported.
The signal intensity after administration of gadolinium was scored as normal in 27 
patients (26%) and increased in 78 (74%) of the patients.
Overall sensitivity of gadolinium enhancement in detecting the presence of any ac-
tive inflammation of the terminal ileum was 87%, with a specificity of 100% and an 
accuracy of 94% (Table 3).
The median length of the affected terminal ileum was 7 cm (range 3-50 cm). The 
median measured wall thickness was 5.5 mm (range 3-13 mm). MRE detected a total of 
five enteroenteral fistulae (Figure 2) and sixteen cases of ileal stenosis with prestenotic 
dilation (Figure 3).
Grey scale US and Contrast enhanced US
A large majority of patients (98%) were suitable for grey scale US and CEUS and no 
adverse effects were reported. The median value of the peak intensity (PI) was 33.5% 
(4-62%) and the median value of the regional blood volume (RBV) was 646.1 cm³ (18-
1769,2 cm³). PI was registered after a median time to peak (TTP) of 20,5 seconds (2-42,8 
seconds).
Figure 2  Forty- two-year-old male patient with Crohn’s disease and enteroenteral fistula of the terminal 
ileum
A Coronal MR Enterography images (T2-weighted single-shot turbo spin-echo, on the left image; T1-weighted fat 
saturated, spectrally attenuated inversion recovery after Gadoteric acid administration, on the right image) of a 
patient with enteroenteral fistula and increased enhancement after contrast administration (white arrow). 
B Longitudinal Contrast enhanced ultrasound of the affected ileum of the same patient (Gray scale ultrasound image 
on the right side; Contrast enhanced ultrasound image on the left side), showing severe wall thickening on the Gray 
scale ultrasound (white arrow) and strong enhancement after Sonovue® administration on the Contrast enhanced 
ultrasound (white arrow), but no fistula. 
C Endoscopic image of the same patient, with a fistula opening in the terminal ileum.
A
B
C
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Figure 3  Thirty-one-year-old female patient with Crohn’s disease and stenosis of the ileocolic anastomosis 
after ileocecal resection
A Coronal MR Enterography images (T2-weighted single-shot turbo spin-echo on the left image; T1-weighted fat 
saturated, spectrally attenuated inversion recovery after Gadoteric acid administration, on the right image) of a 
patient with stenosis (white arrow) and increased enhancement of the ileocolic anastomosis (white arrow). 
B Longitudinal Contrast enhanced ultrasound (Gray scale ultrasound image, on the right side; Contrast enhanced 
ultrasound image, on the left side), of the same patient with a short stenosis of the ileocolic anastomosis (white 
arrow) and increased enhancement after Sonovue® administration (white arrow). 
C Endoscopic image of the same patient showing an ulcerative stenosis of the neoterminal ileum.
A
B
C
Figure 4 Receiver Operating Characteristic curve for performance of Contrast enhanced Ultrasound for 
the diagnosis of active ileitis at endoscopy. Peak intensity (solid line) and Regional Blood Volume 
(dotted line).
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The cut-off value for PI that best depicted the presence of active endoscopic disease, 
indicated by the area under the ROC curve, was 10% (Figure 4). This value provided a 
sensitivity of 100% in detecting the presence of active inflammation at the site of the 
terminal ileum, with a specificity of 92% and an accuracy of 99% (Table 3).
The cut-off value for RBV that best detected active endoscopic disease was 200 cm³, 
achieving a sensitivity of 93%, specificity of 83% and accuracy of 88%. The area under 
the curve for PI was 0.96 (95%CI 0.89-1.00) and for RBV 0.93 (95% CI 0.82-1.00).
The median length of the affected bowel was 6 cm (range 3-20 cm). The median 
measured wall thickness was 5.5 mm (range 3-13 mm) and a stratified wall appearance 
was detected in 53 patients (50%) (Figure 5). Furthermore, grey scale US detected ste-
nosis of the terminal ileum with prestenotic dilation, in 11 patients.
Correlation between MRE and US findings
The length of the lesion measured by MRE correlated with the measured length of the 
pathologic bowel wall by US (r=0.92, P<0.001). In order to more closely examine the 
agreement of measurement between the two imaging techniques, we constructed a 
Bland and Altman plot. There was a high agreement for diseased segments below 10 
cm, but a rather poor agreement for diseased segments above 15 cm (Figure 6).
Figure 5  Twenty-five-year-old male patient with Crohn’s disease of the terminal ileum
A Coronal MR Enterography images (T2-weighted single-shot turbo spin-echo on the left image; T1-weighted fat 
saturated, spectrally attenuated inversion recovery after Gadoteric acid administration, on the right image ) of a 
patient with ileitis terminalis demonstrating marked wall thickening of the terminal ileum (white arrow) and mild 
enhancement after contrast administration (white arrow). 
B Longitudinal Contrast enhanced ultrasound (Gray scale ultrasound image, on the right side; Contrast enhanced 
ultrasound image, on the left side), of the same patient showing wall thickening on Gray scale ultrasound (white 
arrow) and strong enhancement after Sonovue® administration on Contrast enhanced ultrasound (white arrow). 
C Endoscopic image of the same patient with an ulcerative ileitis terminalis.
A
B
C
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There was also a high correlation between the wall thickness of the affected terminal 
ileum, between MRE and US (r=0.97, P<0.001). When looking at the Bland and Altman 
plot, the agreement between the two techniques was least in patients with a wall thick-
ness between 6 and 10 mm (Figure 7). In assessing the wall stratification and perivis-
ceral findings, the two methods agreed in 89 and 90 out of the 105 patients, respectively.
In diagnosing stenosis, grey scale US showed a sensitivity of 63% compared to MRE 
(11 out of the 16 strictures similarly diagnosed). None of the five enteroenteral fistulae 
on MRE could be identified by US.
Discussion
This study has demonstrated a high accuracy of CEUS combined with grey scale US for 
detecting mucosal disease activity in ileal CD. Grey scale US identified the (neo)terminal 
ileum in 105 out of 107 CD patients.
Figure 6 The relation between the mean length and the difference in length of the affected small bowel 
measured by MR Enterography and Contrast Enhanced Ultrasound.
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When compared to endoscopic disease activity, enhancement by means of SonoVue® 
administration during CEUS had a high sensitivity in diagnosing active inflammation 
located in the terminal ileum. For assessing active intestinal inflammation, a higher 
accuracy for the peak intensity (PI) value than for the regional blood volume (RBV) was 
confirmed by CEUS-generated time-intensity curves. Regarding morphology, the US and 
MRE showed a high correlation for a diseased segment under 10 cm and for a wall thick-
ness under 6 mm or above 10 mm, with slightly less accuracy for thicknesses between 
these two measurements. US seemed less accurate in identifying affected bowel seg-
ments longer than 10 cm. Furthermore, grey scale US identified 63% of the stenosis but 
none of the five enteroenteral fistulae.
In a former study, semi-quantitative findings from CEUS were found to correlate with 
dynamic contrast-enhanced MRE (r=0,623, P=0,003). CEUS and MRI findings, however, 
did not correlate with clinical and laboratory parameters measuring disease activity 
(CDAI and CRP). Therefore, the authors concluded that CEUS and MRE were not able to 
evaluate disease activity23. In a more recent study, CEUS was compared with MRE in the 
assessment of small bowel CD, again using clinical parameters as reference standard. In 
Figure 7 The relation between the mean wall thickness and the difference in wall thickness measured by 
MR Enterography and Contrast Enhanced Ultrasound.
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about one third of the 30 patients included, CEUS or MRE were able to detect active dis-
ease. Additionally MRE and CEUS were weakly correlated with clinically assessed disease 
activity (CDAI), with a Spearman’s coefficient r=0.39824. Comparison of our results with 
findings in the literature is difficult. Study protocols and definitions of disease activity 
vary considerably and standardized semi-quantitative measurements to compare out-
come are lacking. In the present study, cut-off values for PI and RBV values of contrast 
enhancement at CEUS were calculated using ROC analysis and therefore could differ 
from other studies.
Increased wall microvascularization and proliferation of microvessels in the severely 
affected bowel of CD patients has been reported in several histopathological stud-
ies31-33. Furthermore, a strong relation between changes in the vascularization of the 
diseased bowel loop and inflammatory activity has been suggested31,34. Color and power 
Doppler ultrasonography have also been used to assess the wall hypervascularization 
of inflamed loops31,34,35. Findings detected by Doppler US are related to large arteries of 
the bowel wall and therefore this method is probably less accurate in predicting mild 
parietal inflammation35. Nonetheless, parietal contrast enhancement after intravenous 
gadolinium administration during MRE has been used to indicate transmural inflamma-
tion and was shown to be helpful in differentiating active from inactive CD7,36-38.
At present, MRE is recommended as the preferred imaging technique in CD because 
of its safety and its accurate, reproducible visualization of the entire small bowel tract39. 
In this study, quantitative assessment of the terminal ileum enhancement by CEUS was 
more sensitive in detecting active endoscopic inflammation than the qualitative as-
sessment of enhancement after gadolinium administration during MRE. This difference 
may be explained by differences in the assessment technique and by the different phar-
macodynamics of both contrast agents. Gadolinium chelates migrate and accumulate 
in the interstitium, including the fibrous tissue of chronic lesions. US contrast agents 
(gas microbubbles) remain in the microcirculation and degrade quickly in the vascular 
system. These blood-pool contrast agents theoretically lead to enhancement restricted 
to structures with an increased microvascularization and are not retained in the fibrous 
tissue19. This could explain a higher sensitivity of CEUS in distinguishing between active 
and inactive intestinal lesions.
A limitation of the diagnostic performance of US in this study was the lack of ac-
curate detection of fistulae and abscesses that may be due to underrepresentation in 
this series of patients. Recently, a retrospective analysis demonstrated good accuracy of 
CEUS with grey scale US in diagnosing abscesses and phlegmons in CD40. Another limi-
tation was that contrast enhancement at MRE was not quantitatively scored. However, 
quantitative scoring of contrast-uptake during MRE is not standard procedure in daily 
practice, being rather complex and time-consuming. Besides, several recent papers 
have described the value of qualitative assessment of contrast enhancement during 
MRE compared to endoscopic disease activity41,42.
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One of the strengths of the present series was the size of the study population, which 
enabled a reliable statement with respect to feasibility and sensitivity. However, the 
specificity may be less reliable due to the limited number of patients with a normal ter-
minal ileum during endoscopy. Furthermore, the use of endoscopically assessed disease 
activity authorized an objective grading of active inflammation and therefore a reliable 
reference standard.
Among the cross sectional imaging techniques available for the assessment of 
patients with ileal CD during follow-up, the addition of CEUS to a standard grey scale 
US study may constitute an attractive, practical imaging modality: there is a lack of 
radiation exposure, it is readily available and it comes at low cost. Furthermore, three 
different recent studies in CD patients argue the value of CEUS in predicting outcome 
after treatment with immunomodulators and/or TNF blockers43-45 and diagnosing post-
operative recurrence46. Therefore, we believe, although not replacing MRE as an imag-
ing technique in all patients, CEUS may well be used as an additional technique in the 
follow-up of patients with known ileal CD.
In conclusion, CEUS is feasible and accurate in detecting the presence and activity 
of CD in the terminal ileum. The performance of this imaging modality is comparable to 
MRE in uncomplicated ileitis, defined as a short affected terminal ileum not complicated 
by fistulae or abscesses. CEUS represents a valuable, easily applicable bedside tool in the 
follow-up of terminal ileum involvement in CD.
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Abstract
background The phenotype of the T-cell subpopulations and their related cytokine 
networks in the gastrointestinal mucosa of IBD patients can potentially be used as a 
predictive value for clinical course and response to therapy. Here, we analyzed T-cell 
subpopulations in newly diagnosed, untreated, adult patients and correlated them with 
clinical presentation.
methods Mucosal biopsies from duodenum, ileum and colon mucosa of patients with 
Crohn’s disease (CD), Ulcerative Colitis (UC) and controls were obtained. The Simple En-
doscopy Score in CD and the full Mayo score in UC were used to score disease activity. 
Mucosa-infiltrating T cells were characterized by flowcytometric immunophenotyping 
and stimulated to assess cytokine secretion.
results Based on the expression of the maturation and activation markers CD45RA and 
CD27, we identified four different profiles. Profile A contained mainly CD45RA+CD27+ 
naïve T cells; profile B: mainly CD45RA-CD27+ central memory T cells; profile C: mainly 
CD45RA-CD27- effector memory T cells, and profile D consisted of similar percentages 
of these afore mentioned subpopulations. Profile A was only observed in ileum/colon 
of IBD patients, associated with upper gastrointestinal location and perianal disease 
in CD and expressed more TNFα and less IFNg. In contrast, profile D was restricted to 
controls. There was no correlation between the different T-cell profiles and endoscopic 
disease activity.
conclusions Newly diagnosed IBD patients display different T-cell maturation profiles 
in the gut mucosa, corresponding to distinct cytokine responses. Follow-up studies are 
needed to determine whether the profiles associate with clinical course and response 
to therapy.
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Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are complex, multifactorial disorders, 
which result from aberrant immune responses to gut luminal antigens in genetically 
susceptible hosts1,2. From the clinical point of view, inflammatory bowel disease (IBD) 
represents a heterogeneous group of conditions regarding disease location, disease be-
havior and clinical course.
In an attempt to explain this diversity, clinical parameters such as young age at di-
agnosis, early need for steroid treatment and perianal involvement in CD, or various 
blood-derived biomarkers proved to be disappointing in predicting disease behavior3-5. 
Similarly, several international collaborative genetic studies have so far identified 163 
IBD-associated susceptibility loci6. This knowledge underlined the immunological phe-
nomena related to IBD but did not elucidated its pathogenesis and cannot be used as 
predictor in treating individual patients3,6,7.
Next to the genetic background of the patient, alterations in T-cell subsets within 
the gut mucosa appear to play an important role in the pathogenesis of IBD8. Bone 
marrow-derived lymphoid progenitor T cells undergo positive and negative selection in 
the thymus, resulting in the release of immunocompetent naïve T cells in the circula-
tion9. These naïve T cells have previously been thought to circulate exclusively between 
secondary lymphoid organs, such as peripheral and mesenteric lymph nodes9. However, 
several reports suggest that naïve T cells also enter non-lymphoid organs such as the 
intestinal mucosa, especially at sites of inflammation10-12.
Besides an increased amount of naïve CD45RA+ T cells, which has been described in 
both CD and UC13, differentiated T-cell subpopulations seem to differ between these two 
clinical entities. In CD, the major cytokines interferon y (IFNy) and IL17 are derived from 
T-helper (Th) 1 and Th17 cell differentiation, respectively14. Whereas UC has been shown 
to be predominantly driven by a Th2-like differentiation process, leading to the expan-
sion of natural killer T (NKT) cells and production of the cytokines IL4 and IL131,2. Fur-
thermore, other cytokine profiles have been associated with both forms of IBD, such as 
the pro-inflammatory cytokines TNFα and IL6, and regulatory cytokines such as IL108,14.
Notably, these immunological typologies were mainly based on experimental stud-
ies in murine models15,16, whereas studies on T cells in the intestinal mucosa of humans 
have typically been performed in IBD patients that were under treatment with immune 
modulating therapies17-19.
Here, we have determined the distribution of different T-cell subpopulations and 
their related cytokine profiles in the gastrointestinal mucosa of newly diagnosed, un-
treated, adult IBD patients. We show that variations in T-cell subpopulations in the gut 
mucosa, early in the course of disease, were associated with different clinical subtypes 
of IBD and may in future help to stratify patients that are likely to respond to a certain 
therapy.
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Materials and methods
Patients and controls
Patients with symptoms of chronic diarrhoea, rectal blood loss, abdominal pain or 
weight loss, underwent combined ileocolonoscopy and upper endoscopy. From this 
group, fifty-one newly diagnosed CD patients and fourteen newly diagnosed UC patients 
were included in the study. The diagnosis of IBD was established and certified by clini-
cal, endoscopic and histological standard criteria20.
Endoscopic severity of disease activity was assessed using the Simple Endoscopy 
Score for CD (SES-CD) and the full MAYO score for UC21. Following the standardized 
diagnostic procedures, comprising laboratory tests, endoscopy and if needed additional 
imaging techniques, all IBD patients were classified according to the clinical phenotype 
at diagnosis using the Montreal classification, although this usual is confidently estab-
lished after 5 years follow-up22.
Controls were recruited from a patient population who underwent endoscopy for 
other reasons. Control biopsies were taken from 14 individuals who underwent ileocolo-
noscopy for polyp/cancer screening and 10 individuals who underwent upper endoscopy 
because of functional dyspepsia, showing no signs of gastrointestinal pathology during 
endoscopic and histological examination.
Baseline clinical characteristics according to Montreal classification at initial pre-
sentation and demographics data of all included patients and controls are presented in 
Table 1.
Tissue samples and cell preparation
Mucosal biopsy specimens were sampled before any anti-inflammatory (IBD-)treat-
ment. During colonoscopy, biopsies were harvested from the macroscopically most in-
flamed region of the colon and ileum. In addition to biopsies taken for histopathological 
examination, four biopsies from the terminal ileum and four biopsies from the colon 
were taken for immunological determination. During upper endoscopy, four mucosal 
biopsies of normal gastric corpus and antrum and two biopsies of normal duodenal 
mucosa were taken for histopathological examination and two additional biopsies for 
immunological examination. When endoscopic lesions were observed, biopsies for im-
munologic examination were specifically harvested from macroscopic lesions such as 
erosions or ulcerations.
All biopsy specimens from apparently healthy individuals were sampled from mac-
roscopically normal mucosa.
Biopsy samples were kept in phosphate-buffered saline solution (PBS) at 2-8 oC and 
processed within 8 hours. All samples were finely minced in Hanks/1% BSA using a 
70mm gaze and spatula followed by Ficoll density gradient centrifugation. After wash-
ing, the homogenate was resuspended in 0,5 ml Hanks/1% BSA and the cell number was 
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estimated by microscopic counting using a Kova cell chamber. From the total cell sus-
pension, 200ml was used for flowcytometric analysis disregarding absolute cell num-
ber. When total cell number was more than 1 × 106/ml, the remaining cell suspension 
was incubated over night at 37oC in the presence of 1 µg/ml phorbol myristate acetate 
(PMA)/1µM ionomycin to assess cytokine secretion.
Flow cytometry and cytokine assays
Flow cytometric immunophenotyping encompassed three six-color analyses: Mix 1: 
CD19-FITC, CD7-PE, CD45-PerCP/CY5.5, CD56-PE/CY7, CD3-APC and HLA-DR-APC-H7/
CY7. Mix 2: CD103-FITC, CD45RA-PE, CD27-PerCP/CY5.5, CD4-PE/CY7, CD3-APC and 
CD8-APC-H7/CY7. Mix 3: TCRγ∂-FITC, FoxP3-PE, CD45-PerCP/CY5.5, CD4-PE/CY7, CD25-
APC, CD3-APC-H7/CY7 (all from Becton Dickinson, USA) using a FACS Canto (BD Biosci-
ences, USA). Within the lymphocyte population (CD45+SSClow), B cells (CD19+), NK cells 
(CD56+CD3-), T cells (CD3+CD7+) and T-cell subpopulations like Tregs (CD25highFoxP3+), 
Table 1 Baseline characteristics and Montreal classification of patients and controls at presentation
Patient characteristics CD UC C
N of patients 51 14 14
Age at diagnosis 33(±13) 35(±14) 45(±16)
Gender (male/female) 19/32 5/9 4/10
Disease location (N(%))
 • L1 (small bowel only)
 • L2 (large bowel only)
 • L3 (small and large bowel)
 • +L4 (upper GI)
 • +P (perianal disease)
 • E1 (proctitis)
 • E3 (pancolitis) 
20 (39%)
12 (24%)
19 (37%)
19 (37%)
4 (8%)
1 (7%)
13 (93%)
Disease behavior (N(%))
 • B1 (non-stricturing, non-penetrating)
 • B2 (structuring)
 • B3 (penetrating)
39 (76%)
9 (18%)
3 (6%)
Simple Endoscopy Score – CD (N(%))
 • Mild (4-10)
 • Moderate (11-19)
 • High (≥20)
 • MAYO Score – UC (N(%))
 • 1 (mild)
 • 2 (moderate)
 • 3 (severe
21 (41%)
17 (33%)
13 (26%)
2 (14%)
7 (50%
5 (36%)
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mucosal T cells (CD103+) and CD4+ or CD8+ T cells were expressed as percentage of the 
whole lymphocyte population.
Naïve and memory T-cell profiles were studied in colon/ileum biopsies by analyzing 
the combination of CD45RA and CD27 expression23. The CD45RA+CD27+ population 
was defined as the naïve T-cell subset, the CD45RA-CD27+ as the central memory T-cell 
subset and the CD45RA-CD27- as the effector memory T-cell subset23.
Additionally to the phenotypic identification, mucosal T cells were functionally char-
acterized, by stimulating the cell suspensions from biopsies with PMA/ionomycin. After 
overnight stimulation, the supernatants were frozen for flowcytometric cytokine analy-
sis using BDTM Cytometric Bead Array (CBA, BD Biosciences; USA). Levels of IL2, IL4, IL6, 
IL10, TNFα, IFNy en IL17 were reflected to standard concentrations of the respective pro-
teins and initially expressed in pg/ml. However, as cytokine levels measured in the su-
pernatant of overnight incubated cell suspensions were dependent of the cell number in 
the culture and the relative T-cell number, the individual cytokine levels were expressed 
as a percentage of the total excreted cytokine level instead of pg/ml.
Statistical analysis
Data are shown as mean ± standard deviation (SD), as median in case of non-Gaussian 
distribution, or as values for individual specimens in the figures. The Mann-Whitney 
non-parametric test was used for determination of statistical significance. Values of 
P  ≤0.05 were considered to be significant.
Ethical considerations
Regional medical ethics committee approval was obtained prior to the study, and all 
patients provided written informed consent. The study was performed according to the 
principles of the Declaration of Helsinki.
Results
Distribution of lymphocytes in mucosa of duodenum and ileum/colon
To assess the distribution of lymphocyte subsets in duodenum and ileum/colon, we 
determined their numbers in IBD patients and healthy controls.
In the lymphocyte population of the duodenum of IBD patients, T cells were pre-
dominant: 74% in CD and 75% in UC, with low frequencies of B cells: 4% in CD and 9% in 
UC. The median CD4/CD8 ratio in duodenum was 0,3 in CD and 0,2 in UC patients. The 
majority of the duodenal T cells were of mucosal origin, (CD103+): 81% in CD and 84% in 
UC (Figure 1 and Table 2). Furthermore, B cells were more numerous in the ileum and 
colon of IBD patients than in duodenum, with a median of 34% and 38% of the lym-
phocyte population in CD and UC, respectively. In both CD and UC, T cells represented 
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56% of the lymphocytes, of which a minority was of mucosal origin (CD103+): 15% in CD 
and 11% in UC. The mean CD4/CD8 ratio in ileum/colon was 2,3 in CD and 3,2 in UC. 
The frequencies of CD25highFoxP3+ Tregs in ileum/colon were 14% in CD and 13% in UC 
(Figure 1 and Table 2).
In healthy control samples, the distribution of B and T-cell numbers in duodenum and 
ileum/colon was comparable to that of IBD patients. However, the numbers of Tregs (CD-
25highFoxP3+), non-mucosal (CD103-) T cells and the CD4/CD8 ratio in the ileum/colon were 
significantly higher in IBD patients compared to controls (Figure 1 and Table 2).
Figure 1 Distribution of lymphocyte subsets in mucosa of duodenum and ileum/colon of IBD patients 
and controls. Representative flow cytometry dot plots show the distribution of (A) CD19+ B cells 
and CD3+ T cells, (B) mucosal CD103+ within the CD3+ T cells, (C) CD4 and CD8 T cells and (D) 
CD25highFoxP3+ regulatory T cells.
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Naïve and memory T-cell profiles in ileum/colon mucosa of IBD patients  
and controls
Within the CD3+ T-cell population present in ileum/colon, naïve and memory T-cell pro-
files were studied by analyzing expression of CD45RA and CD27 (23). The CD45RA+CD27+ 
population was defined as the naïve (TN), the CD45RA-CD27+ as the central memory (TCM) 
and the CD45RA-CD27- as the effector memory (TEM) T-cell subset.
IBD patients showed a higher frequency of TN cells compared to controls (31% in CD 
and 28% in UC vs 19% in controls). Additionally, IBD patients also showed an increased 
number of TCM cells (37% in CD and 42% in UC vs 25% in controls). In contrast, the num-
ber of the TEM cells was lower in IBD patients compared to controls (20% in CD and 19% 
in UC vs 33% in controls).
Within the ileum/colon mucosa of IBD patients, we observed a remarkable variability 
in the frequencies of naïve and memory T cells. We identified four different profiles (pro-
file A-D), which consisted mainly (>40%) of either CD45RA+CD27+ naïve T cells (profile 
A), CD45RA-CD27+ central memory T cells (profile B), CD45RA-CD27- effector memo-
ry T cells (profile C), or an equal (each ~30%) distribution of these before mentioned 
Table 2 The median values of gut-derived lymphocytes (CD19+ B cells, CD3+ T cells, CD4/CD8 ratio, 
CD103+ mucosal T cells and CD25highFoxP3+ Tregs) in the duodenum and ileum/colon mucosa 
of controls, CD and UC patients. Numbers (with exception of CD4/CD8 ratio) are percentages 
of lymphocyte population, characterized by light scatter characteristics and CD45 expression. 
Representative FACS plots for each staining are shown in Figure 1.
 CD  UC C p value
Duodenum
B cells (CD19+) 4 (1-34) 9 (1-36) 6 (1-20) Ns
T cells (CD3+) 74 (12-95) 75 (55-88) 78 (35-97) Ns
Mucosal T cells (CD103+CD3+) 81 (13-97) 84 (34-96) 83 (17-96) Ns
CD4/CD8 ratio 0,3 (0,03-2,8) 0,2 (0,06-0,75) 0,2 (0,04-2,8) Ns
Tregs (CD25highFoxP3+) 2 (0-17) 3 (0-14) 2 (0-8) Ns
Ileum/colon
B cells (CD19+) 34 (1-66) 38 (14-56) 26 (5-49) Ns
T cells (CD3+) 56 (11-80) 56 (41-84) 64 (28-84) Ns
Mucosal T cells (CD103+CD3+) 15 (2-65) 11 (3-62) 30 (4-78) 0,02
CD4/CD8 ratio 2,3 (0,38-7,5) 3,18(0,47-8) 1,2 (0,4-4,59) Ns
Tregs (CD25highFoxP3+) 14 (6-28) 13 (5-20) 5 (3-14) 0,002
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subpopulations (profile D, Figure 2A). The TN and TCM cells were mostly non-mucosal 
(CD103-) CD4+ T cells, whereas the TEM cells were mostly CD8+ T cells of mucosal origin 
(CD103+) (Figure 3).
Notably, the mainly naïve T-cell profile A was only observed in IBD patients, while 
the mixed T-cell profile D was only present in controls. In IBD patients, the T-cell profile 
Figure 2 Naïve and memory T-cell profiles in ileum/colon mucosa of IBD patients and controls. (A) 
Representative flow cytometry dot plots of the four different maturation T-cell profiles: Profile A: 
>40% TN cells, CD45RA+CD27+, profile B: >40% TCM cells, CD45RA-CD27+; profile C: >40% TEM 
cells CD45RA-CD27- and profile D: an equal distribution of TN, TCM and TEM cells. (B) Percentage 
of IBD patients and controls displaying the various T-cell maturation profiles.
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B with mostly central memory T cells, was the most predominant. However, we did not 
observe significant different profiles between CD and UC patients (Figure 2B).
Cytokine levels in different maturation T-cell profiles of patients and controls
In addition to the phenotypic identification, cytokine production by mucosal T cells 
from ileum/colon was characterized by stimulating biopsy-derived cell suspensions for 
24h with PMA/ionomycin (Figure 4). The number of lymphocytes in duodenum was too 
low to perform stimulation assays.
Figure 4 Cytokine levels in different maturation T-cell profiles of patients and controls. Cells derived from 
colon/ileum biopsies of IBD patients and controls were stimulated overnight with PMA/Ionomycin 
to assess cytokine production. The levels of TNFa, IFNg, IL17 and IL10 are indicated for the 
different T-cell maturation profiles.
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Supernatants from ileum/colon biopsies containing high numbers of naïve T cells (pro-
file A and B) produced more TNFα compared to the supernatants of biopsies containing 
predominantly TEM cells (profile C). TNFα levels as percentage of total measured cyto-
kines from biopsies with T-cell profiles A and B were 30% and 26%, respectively vs. 17 % 
from biopsies with T-cell profile C (P=0,004) in CD; A 32%, B 20% vs. C 19%; P=0,12 in UC 
(Figure 4A). In addition, these cells produced lower amounts of IFNγ (A and B 47% vs. 
C 66%, P=0,003 in CD; A 47%, B 37% vs. C 63% P=0,34 in UC) (Figure 4B). In contrast, 
IBD patients with mainly TEM cells (profile C) produced more IL17 and less IL10 compared 
to the more naïve A and B profiles (Figure 4CD).
T-cell maturation profile in CD patients is associated with the clinical phenotype 
at presentation
In order to determine the clinical value of immunophenotypic T-cell profiling in mucosa 
of IBD patients, we correlated the observed profiles to the clinical phenotype. We found 
that in CD patients profile A was associated with upper gastrointestinal tract involve-
ment (65%) and perianal disease at presentation (75%). However, there was no associa-
tion between the immunologic profiles and the disease extension in patients with UC 
or with the endoscopic disease activity scored by SES-CD and endoscopic MAYO score.
In summary we describe three immunologic subgroups in early stage, untreated, adult 
IBD patients characterized by different numbers of naïve and memory T-cell subsets in 
the gut mucosa. Remarkably, cytokine levels differ significantly between these profiles 
and we observed an association with clinical phenotype at presentation
Discussion
In this study, we have analyzed T-cell subsets in the gut mucosa of a large cohort of 
newly diagnosed, untreated, adult IBD patients. CD19+ B cells were particularly located 
in ileum/colon, while CD3+ T cells were the major lymphocytic cell population in duo-
denum. The T-cell compartment in the ileum/colon samples of the IBD patients was 
dominated by T cells of non-mucosal origin (CD103-), corroborating the concept of in-
creased recruitment of systemic activated T cells to the inflamed mucosa. Furthermore, 
high frequencies of CD45RA+CD27+ naïve T cells were identified in the intestinal mucosa 
of colon/ileum of a subgroup of CD as well as UC patients.
The subgroup of patients with a high frequency of TN cells (profile A, CD45RA+CD27+) 
in ileum/colon, showed higher levels of TNFa and lower levels of IFNγ, compared to the 
subgroup with predominant TEM cells (profile C, CD45RA-CD27-).
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Cells derived from IBD patients with mainly TEM cell phenotype (profile C), secreted in-
creased levels of IFNγ and IL17 compared to the other profiles, reflecting a predominant 
Th1/Th17 response in this subgroup of IBD patients. Furthermore, higher frequencies 
of naïve T cells in CD patients correlated with more extended and penetrating disease, 
reflecting a more aggressive presentation.
In healthy controls, lower frequencies of TN cells (CD45RA+CD27+) and relative higher 
number of T cells from mucosal origin (CD 103+) were found. These findings, as well as 
higher frequencies of B cells in colon versus duodenum, are in line with a recent study 
of human T and B cell compartmentalization in healthy subjects10. Although the para-
digm is that only activated and memory T cells have access to non-lymphoid tissues, 
such as the gut mucosa, it has been shown that naïve T cells are also able to access 
parenchymal tissues24.
Previously, it has been demonstrated that transfer of naïve T cells (CD4+CD45RB+) in 
T cell-deficient mice can cause an IBD-like syndrome15,16. In humans, there have been a 
limited number of studies investigating the recruitment of naïve T cells to the gut muco-
sa of IBD patients, which were all under immunosuppressive treatment. A relative high 
number of naïve T cells (CD4+CD45RBhigh CD45RA+), producing a high amount of TNFα 
and a low amount of IFNγ, has been described in the intestinal mucosa of both CD and 
UC13. This has been confirmed by demonstrating the presence of CD45RA+ T cells in the 
inflamed mucosa of five UC patients25. Increased levels of truly naïve T cells, which have 
not encountered cognate antigen for their specific T-cell receptor (also known as recent 
thymic emigrants (RTE)) have also been described in the mucosa of treated UC patients, 
irrespective of disease activity26. In contrast, these RTE’s were not found in CD patients.
Furthermore, it was recently reported that in IBD patients frequencies of muco-
sal CD4+CD45RA+ T cells were decreased during treatment with corticosteroids or 
biologicals, whereas frequencies of early activated (CD4+CD69+) and memory T cells 
(CD4+CD45RO+) remained unchanged17. This effect of immunosuppressive therapy may 
explain the discrepancy with the findings of an increased frequency of CD45RA+ cells in 
our cohort of newly diagnosed, untreated, IBD patients.
Irrespective of disease phenotype and T-cell maturation profiles, we have detected 
a higher number of regulatory T cells (Tregs, CD25highFoxP3+) in colon/ileum of IBD pa-
tients compared to controls. In other studies, similar frequencies have been observed 
in IBD patients during immunosuppressive therapy27,28, suggesting that the frequency 
of Tregs is not influenced by such treatment. In mouse models it has been shown that 
Tregs are capable to regulate Th1- and Th17-derived colitis by producing high levels of 
IL10, which is not yet confirmed in humans29-31. Additionally to IL-10 secreting Tregs, a 
distinct population of regulatory T cells (FoxP3+) producing IL17 and IFNγ was described 
in inflamed colon mucosa of CD patients32. Recent data suggest that Th17 and FoxP3+ 
T cells could be related to or arise from the same precursor, dependent on a distinct 
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cytokine environment33-37. Therefore, the exact role of Tregs in the pathogenesis of IBD 
remains to be resolved.
In our cohort, cells derived from ileum/colon biopsies with a more naïve T-cell pro-
file produced higher levels of TNFα compared to biopsies with a more effector memory 
T-cell profile. This finding corroborates the role of TNFα in the initiation of the immune 
response, T-cell proliferation and differentiation described by others38,39. Different num-
bers of naïve and memory T cells in the gut mucosa of IBD patients could reflect differ-
ent stages of the inflammatory process or on different T-cell migration and maturation 
pathways characterizing different IBD phenotypes.
The effect of neutralizing TNFα during priming of naïve CD4+ T cells was recently 
studied in vitro. It was shown that anti-TNFα treatment inhibited T-cell activation and 
polarized naïve T cells towards higher IL-10 and lower IFNγ production40. These findings 
raise the question if early anti-TNFa therapy in patients with a predominant naïve T-cell 
maturation profile could beneficially influence the course of the disease.
Our data suggest that there are differences in influx of naïve T cells in the gut mu-
cosa associated with different levels of pro-inflammatory cytokines during the early 
phase of untreated IBD. Further studies will elucidate if the described T-cell maturation 
profiles reflect different disease phenotypes and provide a rationale for the heterogenic 
clinical presentation of IBD. The long-term follow-up of this patient cohort may reveal 
the alleged clinical value of these mucosal T-cell profiles, both with respect to disease 
progression as well as response to immunosuppressive therapy.
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Abstract
Little is known about different phases of T-cell maturation in gut mucosa. Based on cur-
rent knowledge about the migratory pathways of naïve and memory T cells, it is believed 
that access to peripheral, non-lymphoid tissues is restricted to memory T cells. Surpris-
ingly, there is increasing evidence of high numbers of naïve T cells in the chronically 
inflamed gut tissue of patients with inflammatory bowel disease. This could partially be 
explained by new formation of ectopic lymphoid organs. Ongoing recruitment of naïve 
T cells at inflammatory sites might play a role in the immunopathogenesis of inflamma-
tory bowel disease.
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Introduction
Inflammatory bowel diseases (IBD) are believed to result from aberrant inflammatory 
responses to the intestinal bacterial antigens in a genetically susceptible individual. 
Available evidence argues an important role for the adaptive immune system in IBD. 
Most research has focused on increased migration and proliferation of activated or 
memory T cells (Th1, Th2, Th17 and regulatory T cells) in the inflamed gut mucosa1,2. As 
naïve T cells (TN) are normally thought to be excluded from inflamed tissue, the matura-
tion process at extra-lymphoid effector sites like the inflamed gut mucosa in IBD, has 
received less attention. However, TN are the initiators of the inflammatory cascade of 
activated T-cell expansion and differentiation, and may therefore play a central role in 
inflammatory processes.
Lymphoid progenitors originating from bone marrow stem cells undergo maturation 
and selection in the thymus to become functional CD4+CD8- or CD4-CD8+ (single posi-
tive) T lymphocytes. In this thymic selection process, T cells that can recognize peptide 
in the context of self-major histocompatibility complex (MHC) molecules are positively 
selected whereas auto-reactive T cells are deleted in the thymus3. Of all T cells enter-
ing the thymus, the stringent thymic selection leaves only 3%4. The TN cells leaving 
the thymus still have to experience antigen driven post-thymic maturation before they 
proliferate and differentiate into memory T cells5. The classical view states that TN cells 
exclusively recirculate between secondary lymphoid organs (SLOs, e.g. lymph nodes, 
Peyer’s patches (PPs) and the spleen) through lymph and blood, whereas only memory T 
cells are able to enter non-lymphoid organs6. However, recent evidence has shown that 
TN cells routinely traffic through non-lymphoid organs and might be activated outside 
the confined lymphoid complex7-16. These findings shed new light on the role of TN cells 
in autoimmune disease.
This review summarizes the current knowledge of the involvement of TN cells in IBD. 
We focus on the migration and activation of these cells in the non-lymphoid, healthy 
and inflamed gut.
T-cell subsets: maturation and activation
Human T cells can be subdivided into different sets, either according to their immu-
nophenotype (expression of leukocyte differentiation markers) or to their functional-
ity (production of chemokines). Considering phenotypic characterization, the two main 
categories are TN cells, which have not yet encountered any (foreign) antigen, and mem-
ory T cells, which are antigen-experienced. The phenotypic changes during the antigen 
driven maturation and activation process are depicted in Table 1 and Figure 1.
TN cells can be subdivided in two subsets: recent thymic emigrants (RTEs), also called 
‘truly naïve’ and mature naïve T cells (TMN)4. RTEs have not yet met the antigen for their 
specific T-cell receptor (TCR) and have no proliferation history. TMN cells are also ‘antigen 
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-inexperienced’ but underwent proliferation in response to homeostatic survival sig-
nals17. RTEs can be identified by the expression of CD45RA, CD31, CD27, CD28, CCR7, 
CD62L18 and are enriched with TCR excision circles (TRECs)4. TRECs are non-replicative 
circular excision DNA products of TCR gene rearrangement17,19. Post-thymic prolifera-
tion of RTEs causes diminishing of TRECs, downregulation of a set of surface markers 
(CD31, PTK7) generating ‘proliferative-experienced’ TMN cells4.
Table 1 Different maturation stages of human T cells are distinguished by various cell surface markers.
Surface markers RTE TMN TCM TEM TEMRA
CD31 + − − − −
CD45RA + + − − +
CCR7 + + + − ±
CD62L + + + − −
CD27 + + + ± −
CD28 + + + ± −
CD45RO − − + + −
Immunophenotypical subsets of T cells: RTE, recent thymic emigrant; TMN, mature naïve T cells; TCM, central memory T 
cells; TEM, effector memory T cells; TEMRA, effector memory T cells re-expressing CD45RA. Surface markers: CD = cluster 
of differentiation; CCR7, chemokine receptor 7, CD62L, L-selectin. Normal expression (+), moderate expression (±), no 
expression (-).
Figure 1 Human T-cell maturation subsets.
RTE TMN TCM TEM TEMRA
CD45RA
CD45RO
CCR7
CD27
CD28
CD31
L-selectin
˙4˚7
Lymphoid homing Peripheral tissue homing
Immunophenotypical subsets of T cells by expression of several cell surface markers. Intensity of color of markers 
indicates level of expression. RTE, recent thymic emigrant; TMN. mature naïve T cells; TCM, central memory T cells; TEM, 
effector memory T cells; TEMRA effector memory T cells re-expressing CD45RA; CCR7, chemokine receptor 7; CD62L, 
L-selectin.
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T cells that have encountered antigen, can immunophenotypically be subdivided 
into central memory T cells (TCM), effector memory T cells (TEM) and effector memory 
T cells re-expressing CD45RA (TEMRA). During maturation, TCM express CD45RO instead of 
CD45RA, but retain CCR7 and CD62L, which are important homing markers for lymphoid 
tissue. During further maturation, TEM cells downregulate both CCR7 and CD62L and 
acquire new adhesion markers such as the gut-homing markers α4β7 and CCR920-22. A 
subset of effector memory T cells, known as TEMRA cells (re)express CD45RA and occa-
sionally also CCR7, but remain distinguishable from TN cells by their lack of CD27, CD28 
and CD62L. When defining TN cell subsets by immunophenotype, the use of at least 
two markers is recommended18. Different combinations have been suggested: CD45RA 
and CD27/CD2818, or CCR7 and CD2723. Unfortunately, this is not yet common practice 
and T cells are often defined as naïve or memory solely by the expression of CD45RA/
RO. This makes the distinction between TN cells and TEMRA cells practically impossible. 
Contamination of the TN cell subset with TEMRA cells may lead to inaccurate conclusions 
and hamper comparability between studies.
Migration of naïve T lymphocytes during homeostasis
Migration of immune cells is a process referred to as homing. The general belief be-
fore 1964 was that lymphocytes randomly circulate through the body. The first signs 
hinting otherwise were found in rats and mice24,25, showing that certain lymphocytes 
only homed to the lymph node or the spleen. Thirty years later, these findings were 
confirmed in sheep. Additionally distinct migratory routes for naïve and memory T cells 
were suggested6. Most of our further understanding on T-cell migration and prolifera-
tion is still based on research in animal models although it is obvious that these models 
(with a lifespan of several months up to a few years, in pathogen-free conditions) can-
not reflect the human exposure to multiple pathogens over decades26. Human studies 
are still limited, as only peripheral blood or tissues from surgical resection material are 
easily accessible.
The formerly accepted migration model with distinct routes for naïve and memory 
T cells turns out not to be as segregated as suggested before. TN cells do not only cir-
culate through blood and lymph between SLOs but also enter non-lymphoid organs, 
which were first thought to be exclusively confined to memory T cells. TN cells have 
recently been identified in non-lymphoid tissue of healthy individuals, representing ap-
proximately 10% of the T cells at the intestinal sites (jejunum, ileum and colon)14. Ad-
ditionally, up to 50% of the T cells in non-lymphoid organs of the gut in steady-state 
mice were shown to express CCR7 (TN, TCM, and TEMRA)10. An immune-surveillance or 
tolerance-induction role of TN cells entering the non-lymphoid tissues has been advo-
cated11. Although central tolerance during thymic selection eliminates most of the auto-
reactive T cells, some of them might escape and migrate to the periphery. In this way, 
naïve auto-reactive T cells (RTEs and TMN) could enter healthy tissues; become activated 
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and initiate chronic inflammation. On the other hand, influx of TN cells in non-lymphoid 
tissue possibly induces tolerance to organ-specific antigens within the tissue itself17.
Antigen-presentation to TN cells takes place primarily in the SLOs. Following antigen 
recognition, further maturation of TN cells evolves towards memory T cells, which ex-
press tissue-specific surface receptors. TCM cells express the same lymph node homing 
molecules as TN cells, namely L-selectin (CD62L) and chemokine receptor 7 (CCR7, also 
known as CD197), and therefore also have the potential to home to SLOs27. TEM cells are 
CCR7-CD62L- and express tissue homing molecules like α4β7 which binds to mucosal 
adressin-cell adhesion molecule-1 (MAdCAM-1), and CCR9 which interacts with chemo-
kine (C-C motif) ligand 25 (CCL25) in the gut endothelium12.
TN cells usually do not express tissue-specific homing receptors on their surface, 
with exception of moderate levels of α4β7. They enter the lymph node and PPs across 
specialized post-capillary venules called high endothelial venules (HEV). HEV endothelial 
cells are cuboidal and are surrounded by multiple layers of fibroblastic reticular cells that 
produce various extracellular matrix components forming a thick basal lamina. Micro-
Figure 2 Migration of mature naïve (TMN) and central memory (TCM) T cells during homeostasis
TMN
TCM
L-selectin
CCR7
LFA-1
PNAd CCL21 ICAM-1
a. High Endothelial Venule in lymph node 
TMN
TCM
L-selectin
CCR7
LFA-1
MAdCAM-1 CCL21 ICAM-1
b. High Endothelial Venule in Peyer’s patch 
˙4˚7
˙4˚7
1a
3 2 3
1b
1
2
a TMN and TCM cells migrate into a lymph node by interaction with surface receptors on high endothelial venules (HEV). 
(1) CD62L binds with peripheral lymph node adressin (PNAd); (2) chemokine receptor 7 (CCR7) binds with chemokine 
(c-c motif) ligand 21 (CCL21) and (3) lymphocyte function-associated antigen 1 (LFA-1) binds with intercellular adhe-
sion molecule 1 (ICAM-1).
b TMN and TCM cells migrate into Peyer’s patches by interaction with surface receptors on HEV. Tethering and rolling is 
mediated by interaction of mucosal adressin-cell adhesion molecule 1 (MAdCAM-1) and CD62L (1a) and αβ7 integrin 
(1b). Further adhesion and migration occurs through CCR7 with CCL21 (2) and LFA-1 with ICAM-1 (3).
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scopically they can easily be distinguished from normal venules, which have flat endo-
thelium and a thin basal lamina28. HEV endothelium expresses molecules that function 
in lymphocyte trafficking. This occurs through interaction between surface molecules 
on the lymphocytes with their HEV-expressing ligand counterparts: CD62L on the T cells 
with peripheral lymph node addressin (PNAd) and MAdCAM-1; CCR7 on the T cells with 
CCL21; and lymphocyte function-associated antigen 1 (LFA-1, also known as CD11aCD18) 
on the T cells with intercellular adhesion molecule 1 (ICAM-1 also known as CD54) Fig-
ure 2a12,29. In contrast to HEV in peripheral lymph nodes, HEV in PPs do not express 
PNAd. In PPs, the tethering/rolling step is mediated by the interaction of CD62L and 
α4β7 with MAdCAM, while further adhesion and migration of T cells happens through 
LFA-1 and ICAM-1 Figure 2b30. The binding of CD62L to MAdCAM-1 is dependent on the 
presence of specific carbohydrate ligands on the MAdCAM-131,32. Evidence supporting 
this interaction is demonstrated in mice studies, but is still missing for human.
Migration of naïve T lymphocytes in IBD
Tertiary Lymphoid Organs
There is increasing evidence for primary T-cell responses independent of SLOs. Chronic 
inflammation and solid tumors have been found to induce formation of HEV-like ves-
sels in non-lymphoid inflamed tissue and tumor tissue, organizing around so called 
tertiary lymphoid organs (TLOs)33-37. These TLOs are ectopic accumulations of lymphoid 
cells, arising at a non-lymphoid location, through a process called lymphoid neogenesis. 
Contrarily, primary and secondary lymphoid organs are found at specific, predefined, 
sites that seem to be genetically fixed and develop before birth38. TLOs morphologically 
resemble SLOs, since they also have T and B cell compartments, lymphoid chemokines, 
antigen presenting cells (like dendritic cells) and HEV-like vessels and are therefore also 
able to recruit TN cells.
How and why TLO formation occurs is unclear. HEV-like vessels presumably facilitate 
lymphocyte influx into TLOs, but it is also possible that TN cells gain initial access to 
non-lymphoid tissues via regular blood vessels and that HEVs are formed later in the 
process8. Lymphotoxin α1β2 (LTα1β2, TNF family member) may have a prominent role 
in regulating the formation of (secondary and tertiary) lymphoid organs and is crucial 
for HEV development and maintenance39,40. After priming, TN CD4+ cells induce LTα1β2 
expression on their surface41,42. The presence of ectopic CCL21 on blood vessels dur-
ing inflammation may trigger the influx of CCR7+ T cells (TN and TCM). This provides a 
source of LTα1β2, perpetuating CCL21 expression and facilitating the formation of HEV-
like vessels and TLOs. Notably, blocking the Lymphotoxin (LT) pathway in colitis mouse 
models reduced the severity of inflammation and was equally efficacious as anti-TNFα 
therapy43,44.
113
on  naivety  of  t  cells  in  inflammatory  bowel  disease: a  review 
Clinical significance of TLOs has already been described in other diseases like colorectal 
cancer and rheumatoid arthritis. In early-stage colorectal cancer, TLOs are associated 
with a better prognosis45 and are suggested as a possible marker for prognosis46. In 
patients with rheumatoid arthritis TLOs were present in 49% of synovial tissue and its 
presence coincided with longer disease duration and lower response to therapy (more 
refractory disease)47. Reversal of TLOs was a good marker of response to therapy.
Tertiary lymphoid organs in IBD
Recent studies have shown that TLOs might play a role in chronic inflammation of the gut 
in IBD. Ectopic CCL21 on blood vessels and PNAd-expressing HEV-like vessels has been 
detected in inflamed gut tissue of patients with ulcerative colitis (UC). A positive correla-
tion between CCL21 expression and influx of TN cells was observed8. CCL21 production 
was demonstrated in inflamed tissue of patients with Crohn’s disease (CD) and UC, and 
lymphoid aggregates were found in 50% of their intestinal biopsy samples35. HEV-like 
vessels in the active phase of UC and CD were identified only in inflamed gut tissue, com-
pared to a scarce presence of these vessels in non-inflamed colon or during remission 
of IBD48,49. Furthermore, the formation of ectopic lymphoid follicles or TLOs was found 
in diseased ileal segments of CD patients50. In contrast to the chronically inflamed IBD 
tissue, acute inflammation was not accompanied by the induction of lymphoid aggre-
gates and HEV-like vessels48. MAdCAM-1+ intestinal lamina propria venules are increased 
in UC, both in active disease and remission, compared to normal controls51. There was 
great co-expression of PNAd among MAdCAM-1+ vessels in patients with active disease 
(66.5%) when compared to patients in remission (7.62%) and PNAd was not detected in 
the colonic mucosa of normal controls. In a recent study in mice with chronic ileitis, the 
induction of ectopic lymphoid tissue has been demonstrated in the inflamed intestine, 
with a statistically significant increase of CCL21 expression and accumulation of TN cells, 
TEM and TCM cells in the terminal ileum, compared to healthy wild type mice15.
Thus far, it remains difficult to distinguish gut-associated lymphoid tissue (GALT) 
from TLOs and an unambiguous definition is lacking33. Nonetheless, chronically in-
flamed gut induces organized structures that cannot be observed in the gut of healthy 
controls. These structures, referred to as TLOs, are present in the deeper layers of the 
epithelium and contain PNAd-expressing HEV-like vessels, that distinguishes them from 
the submucosal PPs48,50,51.
Naïve T cells in IBD
Mice: the T-cell transfer model
Immunodeficient mice (CB17 severely combined immunodeficient/recombinase acti-
vating gene-1-/-) develop chronic, severe intestinal inflammation, after transfer of na-
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ïve (CD4+CD45RBhigh) donor T cells into their peritoneal cavity52. Co-transferring memory 
(CD4+CD45RBlow) T cells inhibits the development of intestinal inflammation53 and single 
transfer of the memory subset does not cause inflammation54. One could expect that 
the transferred TN cells are primed within GALT and mesenteric lymph nodes (MLNs) 
before inducing colitis. However, the induction of colitis by transfer of TN cells was also 
demonstrated in mice deficient of SLOs (GALT, MLN and spleen)55. This study underlines 
that SLOs are not required for priming TN cells into colitogenic effector T cells to initiate 
colitis, leaving the site of priming in these models to be defined. As the pattern of exacer-
bation and remission of human IBD has not been perfectly phenocopied in these mouse 
models, the presence and the role of TN cells in the gut of IBD remains to be elucidated56.
The potential role of naïve T cells in human IBD
The first suggestions indicating a potential role of (maturation of) TN cells in the patho-
genesis of IBD came from a few (case-)reports showing the effectiveness of thymecto-
my in adult patients with IBD57-60. Thymectomy has been performed in UC patients with 
thymic hyperplasia and was successful for maintaining remission in patients refractory 
to conventional therapy58,60. Additionally, thymectomy was also performed in a CD pa-
tient developing myasthenia gravis, leading to remission of her CD activity59. No further 
publications have arisen on the potential of thymectomy in IBD.
Already in 1995 it was revealed that chronic inflammation in CD induced migration 
of TN cells to inflamed sites. The study involved ileal samples of CD patients and bowel 
samples of controls with colon carcinoma. In the intestines of controls, blood vessels 
were only found in the lamina propria and beneath the muscularis mucosa, and they 
exhibited the characteristics of normal (flat) venules. The inflamed intestines of CD pa-
tients showed numerous dilated and highly activated small vessels with HEV character-
istics, extending from the superficial mucosa layers throughout the deep submucosa. 
These vessels and the perivascular and mucosal infiltrates all harbored mainly mac-
rophages and T cells. The majority of T cells within the (sub)mucosal infiltrates were 
TN (CD45RA+CD31+CD62L+CD27+) and TCM (CD45RO+CD31-CD62L+CD27+) cells. The normal 
intestinal mucosa of controls was predominantly populated by TEM cells (CD45RO+ CD31-
CD62L- CD27-)7.
The expression of maturation markers on CD4+ T cells was analyzed in the intestinal 
mucosa of both CD and UC patients with active disease. Almost all patients were using 
corticosteroid medication and were included at the time they underwent partial resec-
tion of the intestine. Non-involved bowel segments of patients undergoing bowel resec-
tion for cancer treatment were used as control. The numbers of CD45RA+ T cells were 
increased in the intestine of IBD patients (49.0% in UC and 27.7% in CD) as compared 
to controls (4.5%). The CD45RA+ cells found in IBD patients were mainly located in ‘fol-
licular structures’9.
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Another study aimed to characterize T cells present in the intestine of IBD patients 
before and after therapy. Sigmoid-derived biopsy specimens of IBD patients (CD as well 
as UC) with distal active colitis were evaluated. Patients that were in remission with 
mucosal healing showed a reduction of >50% of CD4+CD45RA+ T cells, compared to 
inflamed mucosa of patients with active disease. There was no difference in the amount 
of memory T cells in the inflamed mucosa when compared to non-inflamed mucosa16.
Regarding RTEs in IBD patients, increased TREC levels in mucosal but not peripheral 
blood lymphocytes were found in UC patients, indicating direct recruitment of RTEs into 
the inflamed mucosa13. However these results have not yet been duplicated.
We recently studied the maturation of T cells in the gut mucosa in a large group 
of newly diagnosed, untreated IBD patients. Remarkably high frequencies of TN were 
identified in a subgroup of CD as well as UC patients (naïve profile). This group of pa-
tients expressed different pro-inflammatory cytokine levels (higher TNF-alpha and low-
er interferon-gamma) compared to the group of patients with high frequencies of TEM. 
Furthermore, there was an association between the naïve profile and extended disease 
location in CD61. We elaborated on the possible correlation between differences in the 
maturation status of the T-cell subsets early in disease course and disease heterogene-
ity. An extended follow-up of this cohort may elucidate the prognostic value of different 
maturation profiles at primary diagnosis.
Conclusions
Contrarily to previous ideas, there is increased evidence that TN cells migrate to non-
lymphoid organs in homeostasis and even more in chronic inflammation. During chron-
ic inflammation, migration of TN cells could be facilitated by TLOs. Formation of these 
TLOs appears dependent on LTα1β2; however the signals triggering these mechanisms 
are waiting to be characterized. Presence of TLOs implies an ongoing recruitment of TN 
and TCM cells to the gut mucosa, maintaining a continuous inflammatory process. The 
relevance of targeted therapy against this phenomenon has not yet been studied. It 
is conceivable that a process involving dissolution of TLOs could restore immunologic 
homeostasis.
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Abstract
background Naive and central memory T lymphocytes (TN and TCM) can infiltrate the 
inflamed gut mucosa in Inflammatory Bowel Disease (IBD) patients. The homing of 
these subsets to the gut might be explained by ectopic formation of tertiary lymphoid 
organs (TLOs), containing high endothelial venules (HEVs). We aimed to evaluate the 
presence of HEVs and TLOs in inflamed intestinal mucosa of newly diagnosed, untreat-
ed, IBD patients in relation to the presence of TN and TCM lymphocytes.
methods IBD patients (n=39) and healthy controls (n=8) were prospectively included. 
Biopsy samples of respectively inflamed and normal intestine were analyzed by im-
munohistochemistry for lymphocytes (CD3/CD20), blood vessels (CD31) and PNAd ex-
pression (MECA-79). TN and TCM lymphocyte subsets were identified by flowcytometric 
immunophenotyping.
results A higher number of HEVs was found in the inflamed colon of patients with 
ulcerative colitis (median density 3.05 HEV/mm2; (IQR) 0-6.39) and ileum of Crohn’s dis-
ease patients (1.40 HEV/mm2; IQR 0-4.34) compared to healthy controls (both 0 HEV /
mm2; P=0.033). A high density of colonic HEVs (HEVhigh) was associated with increased 
numbers of TN and TCM in the inflamed gut (median 87%; IQR 82-93% of T-cell popula-
tion), compared to HEVlow patients (58%; IQR 38-81%; P=0.003). The number of colonic 
follicles was higher in HEVhigh patients (median 0.54/mm2; IQR 0.28-0.84) compared to 
HEVlow patients (median 0.25/mm2; IQR 0.08-0.45; P=0.031) and controls (0.31/mm2; IQR 
0.23-0.45; P=0.043).
conclusion The presence of extra-follicular HEVs and TLOs was strongly associated 
with TN and TCM cell mucosal infiltration in a subgroup of newly diagnosed IBD patients.
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Introduction
Lymphocyte activation and homing of lymphocytes to target organs are key phenom-
ena in chronic inflammation, including Inflammatory Bowel Diseases (IBD). Lymphocyte 
activation is triggered by interaction of antigen receptors with cognate antigens. The 
initial priming of naive T lymphocytes (TN) occurs in secondary lymphoid organs (SLOs; 
spleen, lymph nodes, gut associated lymphoid tissue (GALT; Peyer’s patches, isolated 
lymphoid follicles and appendix)). SLOs are genetically encoded specialized environ-
ments for optimal antigen presentation and lymphocyte activation. Upon antigen prim-
ing in the SLO, activated T lymphocytes migrate to non-lymphoid tissue sites, where 
they may exercise effector (pro-inflammatory or regulatory) functions upon renewed 
antigen encounter. It is well known that activated effector memory T lymphocytes (TEM) 
travel to the gut mucosa following α4β7/MAdCAM-1 and CCR9/CCL25 interaction at the 
level of post-capillary venules1,2.
In physiological conditions, TN and central memory T lymphocytes (TCM) are thought 
to migrate exclusively to SLOs1,3. Specialized vessels, so-called high endothelial venules 
(HEVs), direct tissue migration of circulating TN and TCM into SLOs. This process is guided 
by different vascular addressins, such as MAdCAM-1 and peripheral lymph node ad-
dressin (PNAd). PNAd on endothelial cells is the ligand of L-selectin, which is expressed 
on TN and TCM lymphocytes, while practically absent on the majority of TEM or effector 
memory T cells re-expressing CD45RA (TEMRA). PNAd can be identified by the monoclo-
nal antibody MECA-794,5. Distribution of these addressins differs between peripheral 
lymph node, mesenteric lymph node and Peyer’s patches. MAdCAM-1 is constitutively 
displayed on HEVs in Peyer’s patches and mesenteric lymph node and on flattened ven-
ular endothelial cells in the intestinal lamina propria6. PNAd is predominantly present 
on HEVs in peripheral lymph node, mesenteric lymph node and at very low levels on the 
abluminal side of HEVs in Peyer’s patches4.
Previously we have demonstrated the presence of TN and TCM lymphocytes in non-
lymphoid gut tissue7-11. In our previous work we identified three subgroups of newly 
diagnosed IBD patients with either increased percentage of mucosal TN, TCM or TEM7. It 
is still unclear how homing of these TN and TCM lymphocytes to non-lymphoid tissue is 
established.
Processes occurring during chronic inflammation and formation of solid tumors 
were shown to induce ectopic formation of HEV-like vessels in non-lymphoid inflamed 
and tumor tissue, constituting the so-called tertiary lymphoid organs (TLOs)12-15. Little 
is known about HEVs in IBD pathogenesis (reviewed in16), since published data is lim-
ited to patients with long-standing disease who are commonly using anti-inflammatory 
treatment5,17.
We aimed to investigate the presence of HEVs and their relation to lymph follicles 
in the inflamed intestinal mucosa of newly diagnosed, untreated IBD patients. Since 
TN and TCM lymphocytes are known to express L-selectin7,18,19, we aimed to determine 
123
hevs  associated  with  t-cell  subsets  in  ibd
whether the infiltration of these cells in the inflamed intestinal mucosa of newly diag-
nosed, untreated, IBD patients is correlated with the presence of HEVs and TLOs.
Material and methods
Patients and samples
At the department of Gastroenterology and Hepatology of the Rijnstate Hospital, Arn-
hem, The Netherlands, 39 newly diagnosed adult IBD patients and eight healthy con-
trols were prospectively included in the study. The diagnosis of IBD was based on a 
combination of clinical, endoscopic, histologic and radiologic internationally accepted 
criteria. Intestinal biopsy specimens of the macroscopically most inflamed ileal and co-
lonic mucosa (when ulcerations were present these biopsy specimens were taken from 
the edge of this ulceration) were obtained at the moment of diagnosis, before the initia-
tion of any medical treatment. Thus, when disease was located in the ileum, only ileal 
biopsies were analyzed; when disease was located in the colon, only colonic biopsies 
were analyzed and when the disease was located in ileum and colon both ileal and co-
lonic biopsies were analyzed. Besides regular histopathological analysis, four samples 
were used to immunophenotype the mucosal lymphocyte population. Patient charac-
teristics were documented and disease phenotype was assessed.
Ileal and colonic biopsy specimens were obtained from eight control subjects un-
dergoing ileocolonoscopy for iron deficiency anemia or polyp surveillance. Biopsy spec-
imens of controls were taken from macroscopically non-affected, non-inflamed ileal 
and colonic areas. Regular histopathological examination confirmed that these areas 
had no signs of inflammation. Besides regular histopathological analysis, four samples 
were used to immunophenotype the mucosal lymphocyte population. Parallel venous 
blood samples were drawn following endoscopic evaluation at primary diagnosis. Serum 
samples were coded and stored at -20°C until analysis.
Immunohistochemistry
Immunohistochemistry was carried out on 3 µm thick sections from formalin-fixed, 
paraffin-embedded archived blocks of biopsied specimen of ileal and colonic mucosa. 
The following monoclonal antibodies were used for immunostaining: MECA-79 (iden-
tifies 6-sulfo sialyl Lewis on core-1 branched O-linked sugars (PNAd) which binds L-
selectin, Sanbio, Uden, The Netherlands), CD31 (monoclonal, identifies human CD31 
to demonstrate endothelial cells, Sanbio, Uden, The Netherlands), CD3 (clone LN10, 
identifies human CD3 to demonstrate T cells, Leica Microsystems B.V., Eindhoven, The 
Netherlands) and CD20 (clone L26, identifies human CD20 to demonstrate B-cells, Leica 
Microsystems B.V., Eindhoven, The Netherlands). Slides were incubated with the prima-
ry antibody in an automatic immunostainer (Bond, Leica biosystems Nussloch GmbH 
2016, Eindhoven, The Netherlands).
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Stained slides were scanned with an Intellisite high-resolution scanner (Philips ultra-
fast scanner 1.6 RA, Philips Digital Pathology, Best, The Netherlands) and analyzed with 
the Intellisite IMS image analyzer. Quantification was done by two independent observ-
ers who were blinded to the clinical outcome and flowcytometric analyses. The total 
surface area of each slide was measured in square millimeter (mm2). Absolute numbers 
of CD31+ vessels and MECA-79+ HEV-like vessels were determined by optical counting of 
vessel numbers on all slides. The location of HEVs vessels relative to lymphoid follicles 
was determined on CD3 and CD20 immunostained sections and absolute numbers of 
intra- and extrafollicular HEVs were quantified. The density of extrafollicular HEVs ves-
sels (HEVs/mm2 excluding the surface of follicles) and the ratio of HEVs vessels amongst 
all vessels (HEVs/CD31 vessels) were calculated. In malignancy, a cut-off point for in-
creased density of HEVs has been described in patients with breast cancer.20 However, 
in chronic inflammation, no such approach has been undertaken. We discriminated 
patients with a high and a low density of HEVs using a cut-off point set at the median 
density of extrafollicular HEVs vessels/mm2 in the inflamed colon of UC patients.
Presence of inflammation was established for all sections based on known archi-
tectural changes and inflammatory features such as crypt distortion, decreased crypt 
density, erosions, ulcers, increased lamina propria cellularity, crypt abscesses and epi-
thelioid granuloma. Lymphoid follicles were defined as a dense nodular lymphocyte 
aggregate containing B and T-cell compartments. Their presence was assessed on CD3 
and CD20 immunostained sections. The number of follicles was counted. In absence of 
a clear-cut definition of TLOs in the gut, we defined TLO as additional follicles in patients 
compared with the number of follicles in controls. Furthermore, it is our interpretation 
that the presence of extrafollicular HEVs represents an early phase of lymphoid neogen-
esis (TLOs).
Immunophenotyping the mucosal lymphocytes
Intestinal biopsy specimen were sampled and analyzed as described earlier7. Briefly, 
besides the standard histopathological analysis of biopsy specimens, four samples of 
the most inflamed regions of colon and ileum were used for flowcytometric immu-
nophenotyping. Biopsy specimen were kept in phosphate-buffered saline solution at 
2-8°C and processed within 8 hours. Specimens were finely minced in Hanks’/1% bovine 
serum albumin using a 70-mm gaze and spatula followed by Ficoll density gradient 
centrifugation.
The homogenate was resuspended, after washing, in 0.5 mL Hanks’/1% bovine serum 
albumin. The cell number was estimated by microscopic counting with a KOVA glasstic 
slide (Hycor Biomedical Ltd., Penicuik, United Kingdom). For flow cytometric analysis 
200 mL of the total cell suspension was used, disregarding absolute cell number. Single 
cell suspensions of the biopsies were analyzed using a FACS Canto (BD Biosciences). 
Mucosal lymphocyte subpopulations were differentiated: B cells (CD19+), T cells (CD3+), 
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regulatory T cells (CD3+CD25highFoxP3+), mucosal T cells (CD3+CD103+), T-helper cells 
(CD3+CD4+) and cytotoxic T cells (CD3+CD8+) and expressed as percentages of the whole 
lymphocyte population (CD45+/low side scatter). The maturation state of T cells was 
assessed by using CD45RA and CD27, defining naive T cells (TN: CD45RA+CD27+), central 
memory T cells (TCM: CD45RA-CD27+), effector memory T cells (TEM: CD45RA-CD27-) and 
T effector memory cells re-expressing CD45RA (TEMRA: CD45RA+CD27-). We also analyzed 
groups of T cells according to their known migration phenotypes. TN and TCM lympho-
cytes are known to enter HEVs through the ligand PNAd, as they are L-selectin+18,19. and 
were analyzed both independently as well as taken together. The same analysis was 
performed for TEM and TEMRA lymphocytes, which are known to be L-selectin-18,19.
Multiplex immunoassay
In a subgroup of the current patient cohort we analyzed serum chemokines using Mul-
tiplex immunoassays, including CXCL-13 and CCL-19, which are known to be required for 
lymphoid organogenesis21. These assays were performed at the MultiPlex Core Facility 
of the Laboratory of Translational Immunology (UMC Utrecht, The Netherlands) using 
an in-house validated platform (ISO9001). Briefly, color-coded magnetic beads (MagPlex 
Microsperes, Luminex, Austin, Texas) were conjugated to analyte-specific antibodies 
and incubated with standard dilutions or sample for 1 hour during continuous shaking 
in the dark. Pre-treatment of samples with HeteroBlock (Omega biologicals, Inc., Boze-
man, Montana, USA) was performed, to prevent interference by binding of heterophilic 
antibodies. Plates were washed (Bio-Plex Pro II Wash Station; Bio-Rad, Hercules, Califor-
nia, USA) and a corresponding cocktail of biotinylated detection antibodies was added 
followed by streptavidin-phycoerythrin (PE) incubation. Fluorescence intensity of PE 
was measured with a Flexmap 3D system (Luminex) and analysed by BioPlex Manager 
Software (version 6.1; Bio-Rad, USA) using 5-parameter curve fitting.
Statistical analysis
Data of ileal biopsy specimens of CD patients was compared to ileal biopsy specimens of 
healthy controls. The data of colonic biopsy specimens of UC and CD patients were com-
pared to the colonic biopsy specimens of healthy controls. Ileum and colon were not 
mutually compared because of anatomical and physiological differences, including the 
influence of the microbiome. Data was collected and analyzed with SPSS statistics (ver-
sion 21.0.0.0; IBM Corp). Differences between groups were tested using non-parametric 
tests. Continuous variables were described as median with interquartile range (IQR, 1st 
quartile-3rd quartile). Mann-Whitney U test was used to identify differences in continu-
ous variables. Categorical variables were described as absolute frequencies. Kruskal-
Wallis analysis was used followed by the Dunn test when applicable. Spearman rank 
correlation was performed to measure the degree of association between variables. 
Statistical significance was defined as a P-value less than 0.05.
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Ethical Considerations
Written informed consent was obtained from each participating patient. The procedures 
were performed in accordance with the Declaration of Helsinki. The regional medical 
ethics committee approved the protocol, according to Dutch Law (NL28761.091.09).
Results
Ten newly diagnosed patients with ulcerative colitis (UC) and 29 newly diagnosed pa-
tients with Crohn’s disease (CD) were included in this study. In addition eight healthy 
controls were studied. Baseline characteristics of patients are outlined in Table 1.
Table 1 Baseline characteristics
CD (n=29) CU (n=10)
Age at diagnosis in years, median (IQR) 28 (20-44) 28 (20-35)
Female, n (%) 21 (72%) 7 (70%)
Symptoms before diagnosis in months
0-3
3-6
>6
10 (35%)
9 (31%)
10 (35%)
7 (70%)
1 (10%)
2 (20%)
Follow-up period in months, median (IQR) 55 (23-62) 44 (22-48)
Family with IBD, n (%) 4 (14%) 4 (40%)
Smoking status
 • Never
 • Current
 • Ceased
 • Unknown
17 (59%)
10 (34%)
2 (7%)
-
8 (89%)
1 (11%)
-
-
HBI score, median (IQR) 9 (6-13) -
CD disease location (Montreal)
 • Ileal, n (%)
 • Colonic, n (%)
 • Ileocolonic, n (%)
 • + Upper GI involved, n (%)
 • + Perianal disease, n (%)
8 (28%)
5 (17%)
16 (55%)*
10 (39%)
5 (17%)
-
CD disease behavior (Montreal)
 • Inflammatory, n (%)
 • Stricturing, n (%)
 • Penetrating, n (%)
21 (72%)
7 (24%)
1 (4%)
-
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Number of blood vessels and follicles was comparable in patients and controls
In each sample, we determined the absolute number of blood vessels (CD31+ vessels and 
MECA-79+, hereafter denoted as HEVs) and follicles by immunohistochemical staining. 
HEV-like vessels were determined by optical counting of MECA-79+ vessel numbers on 
all slides. The location of HEVs relative to lymphoid follicles was determined on CD3 and 
CD20 immunostained sections and absolute numbers of intra- and extrafollicular HEVs 
were quantified. The density of extrafollicular HEVs (MECA-79+/mm2 excluding the sur-
face of follicles) and the ratio of HEVs amongst all vessels (MECA-79+/CD31 vessels) were 
calculated. Overall we observed high heterogeneity in patient results. No statistical sig-
nificant difference was found when comparing the entire patient group and controls 
for the number of vessels or follicles in biopsy specimen (see Table 2). In addition, the 
number of HEVs/CD31+ vessels within these follicles was also comparable. However, in 
UC there was a trend towards more HEVs in inflamed colon (4.80/mm2, (0.45-6.14)) than 
in the colon of healthy controls (0.71/mm2, (0-1.85), P=0.109).
Increased extrafollicular PNAd expression in patients compared to controls
Next, we calculated the percentage and density of HEVs/CD31+ vessels outside the lym-
phoid follicles (extrafollicular) and found that control colon samples did not show any 
SES-CD score, median (IQR) 14 (8-22) -
SES-CD severity
 • Mild (4-10), n (%)
 • Moderate (11-19), n (%)
 • Severe (>19), n (%)
11 (38%)
9 (31%)
9 (31%)
-
UC clinical score (Montreal)
 • Remission, n (%)
 • Mild, n (%)
 • Moderate, n (%)
 • Severe, n (%)
-
-
1 (10%)
4 (40%)
5 (50%)
UC disease location (Montreal)
 • Proctitis, n (%)
 • Left-sided, n (%)
 • Pancolitis, n (%)
- -
-
-
10 (100%)
UC endoscopic severity (Mayo)
 • Normal, n (%)
 • Mild, n (%)
 • Moderate, n (%)
 • Severe, n (%)
-
-
2 (20%)
4 (40%)
4 (40%)
CD = Crohn’s disease, UC = ulcerative colitis, IQR = interquartile range, IBD = inflammatory bowel disease,  
HBI= Harvey-Bradshaw Index, SES-CD = simple endoscopic score for Crohn’s disease
* One patient was excluded from the analyses of colon biopsies because of technical failure of MECA-79 staining.
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Table 2 Blood vessels and follicles in gut mucosa of IBD patients and controls
CD
(inflamed)
UC
(inflamed)
Healthy controls  
(non-inflamed)
P-value
Number of CD31+ vessels/mm2 
colon, median (IQR)
84 (60-107) 125 (63-139) 71 (43-89) NS
Number of CD31+ vessels/mm2 
ileum, median (IQR)
93 (70-114) - 87 (69-102) NS
Number of HEVs/mm2 colon, 
median (IQR)
0.35 (0-5.17) 4.80 (0.45-6.14) 0.71 (0-1.85) NS
Number of HEVs/mm2 ileum, 
median (IQR)
1.58 (0.34-6.69) - 1.23 (0-5.19) NS
% PNAd expressing CD31+ vessels 
colon, median (IQR)
0.85 (0-4.80) 4.63 (0.38-12.24) 0.79 (0-2.59) NS
% PNAd expressing CD31+ vessels 
ileum, median (IQR)
2.02 (0.39-6.82) - 1.02 (0-8.99) NS
Colonic follicles/mm2 tissue, 
median (IQR)
0.27 (0.12-0.51) 0.51 (0-0.82) 0.31 (0.23-0.45) NS
Ileal follicles/mm2 tissue,  
median (IQR)
0.35 (0.15-0.57) - 0.37 (0-0.55) NS
CD = Crohn’s disease, UC = ulcerative colitis, IQR = interquartile range
Figure 1a Density of extra-follicular PNAd expressing HEV-like vessels/mm2 in colon
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extrafollicular HEVs, whereas the inflamed colon of UC patients showed a high percent-
age (median 3.71% (IQR 0-6.23%), P=0.033, Figure 1a) and a high median density (3.05 
/mm2 (IQR 0-6.39), P=0.033) of extrafollicular HEVs. In the inflamed colon of CD, we only 
observed a trend towards a higher number of extrafollicular HEVs/mm2 (median 0.10 
(IQR 0-2.98), P=0.092) compared to controls (median 0 (IQR 0-0), P=0.092).
In the ileum, the percentage of extrafollicular HEVs/CD31+ vessels was higher in inflamed 
ileum of CD patients (median 1.17% (IQR 0-3.77%)) compared to controls (median 0% 
(IQR 0-0.4%)) (P=0.028). These samples showed a median density of 1.40 extrafollicular 
HEVs/mm2 (IQR 0-4.34) whereas in healthy controls only a few HEVs/mm2 (IQR 0-0.50) 
were observed (P=0.033). The presence of extrafollicular HEVs in the ileum and colon of 
inflamed gut mucosa of IBD patients might represent an early phase of TLO formation.
Figure 1b PNAD expressing HEV-like vessels in colonic tissue
B1 B2 B3
B4 B5
B4
B5
Density of extrafollicular PNAd expressing HEV-like vessels in colonic tissue (A), determined in the inflamed colonic 
tissue of CD and UC patients as well as in healthy controls. The density is higher for UC when compared with controls (P 
=0.033) and there is a trend between CD and controls (P =0.092). Immunohistochemical staining (B1-B5). Representative 
photomicrographs, with a magnification of 200x, of an immunostained colonic biopsy sample from a Crohn’s disease 
patient with MECA-79 staining (B1), CD20 staining showing B lymphocytes (B2) and CD3 staining showing T lymphocytes 
(B3). PNAd expressing HEVs are shown in closer detail in B4 (extrafollicular) and B5 (inside a follicle). Arrows in figure B1, 
B4 and B5 indicate PNAd expressing HEVs. Red arrows indicate HEVs inside a lymphoid follicle and black arrows indicate 
extrafollicular HEVs.
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HEV density is not associated with neovascularization
To examine whether the difference in density of PNAd-expressing HEV-like vessels in 
patients could be attributed to neovascularization, we quantified the number of HEVs/
mm2 and correlated this with the total number of CD31+ vessels in patients and controls. 
We also compared inflamed colonic UC with colonic CD biopsy specimens. We did not 
find a correlation and no statistical difference was found between UC and CD patients 
(P=0.198), indicating that the differences in HEVs density were not related or associated 
with neovascularization.
To assess a potential correlation with several confounders, as listed in Table 1, 
we found that HEVs density in inflamed colon was negatively correlated with smok-
ing (Spearman’s rho= -0.543, P=0.002) when calculating the results of all IBD patients. 
However, when subdivided into CD and UC, it was only significantly correlated in CD 
(Spearman’s rho -0.683, P=0.001) and not in UC (Spearman’s rho -0.139, P=0.721). Smok-
ing was not correlated with HEVs density of inflamed ileum in CD patients. We did not 
find any correlations with other baseline characteristics (data not shown).
HEVhigh IBD patients have increased colonic lymphoid follicles and infiltration  
of TN and TCM cells
The immunohistochemical findings were compared with the maturation T-cell infil-
trates, assessed by flowcytometric immunophenotyping of biopsies taken from the 
same area of inflamed tissue and harvested during the same ileocolonoscopy. The ex-
trafollicular density of HEVs in inflamed colon of IBD patients (n=30, 10 UC patients, 20 
CD patients) was positively correlated with the percentage of TN and TCM lymphocytes 
(Spearman’s rho= +0.544, P=0.002) and negatively correlated with the percentage of 
TEM and TEMRA lymphocytes (Spearman’s rho= -0.545, P=0.002). Comparable percentages 
were found in subsets of lymphocytes for UC and CD patients (TN and TCM lymphocytes 
(P=0.406), TEM and TEMRA lymphocytes (P=0.451)).
In malignancy, a cut-off point for increased density of HEVs has been described in 
patients with breast cancer20. However, in chronic inflammation, no such approach has 
been undertaken. We discriminated patients with a high and a low density of HEVs using 
a cut-off point set at the median density of extrafollicular HEVs/mm2 in the inflamed 
colon of UC patients. According to this cut off value, we identified 10 HEVhigh patients and 
20 HEVlow patients (Table 3). Compared to HEVlow patients, HEVhigh patients displayed 
less cytotoxic T cells (P=0.00008), a higher CD4:CD8 ratio (P=0.0008), less mucosal T 
cells (P=0.015), more TCM cells (P=0.0009), more TN and TCM cells (P=0.003), less TEM cells 
(P=0.022), less TEMRA cells (P=0.008) and less TEM and TEMRA cells (P=0.004) in the inflamed 
colonic mucosa (Table 3 and Figure 2).
The number of colonic follicles/mm2 was higher in HEVhigh IBD patients (median 
0.54/mm2, (IQR 0.28-0.84)) compared with HEVlow patients (median 0.25/mm2, (IQR 
0.08-0.45) P=0.031) and controls (0.31/mm2, (IQR 0.23-0.45), P=0.043). The number of 
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Table 3 Characteristics and FACS results of HEVhigh and HEVlow IBD patients
HEVhigh (n=10) HEVlow (n=20) P-value
CD/UC 5/5 15/5 0.169
Age at diagnosis in years, median (IQR) 21 (20-36) 28 (19-33) NS
Female, n (%) 9 (90%) 14 (70%) NS
Symptoms before diagnosis in months
0-3
3-6
>6
4 (40%)
5 (50%)
1 (10%)
12 (60%)
3 (15%)
5 (25%)
NS
Follow-up period in months, median (IQR) 34 (22-56) 50 (28-65) NS
Family with IBD, n (%) 3 (30%) 5 (25%) NS
Smoking status
 • Never
 • Current
 • Ceased
 • Unknown
9 (90%)
-
-
1 (10%)
11 (55%)
8 (40%)
1 (5%)
-
0.029
HBI score, median (IQR) 7 (5-14) (n=5) 10 (7-13) (n=15) NS
CD disease location (Montreal)
 • Ileal, n (%)
 • Colonic, n (%)
 • Ileocolonic, n (%)
 • + Upper GI involved, n (%)
 • + Perianal disease, n (%)
-
2 (40%)
3 (60%)
1 (10%)
2 (20%)
-
3 (20%
12 (80%)
7 (44%)
3 (17%)
NS
CD disease behavior (Montreal)
 • Inflammatory, n (%)
 • Stricturing, n (%)
 • Penetrating, n (%)
5 (100%)
-
-
11 (73%)
3 (20%)
1 (7%)
NS
SES-CD score, median (IQR) 14 (9-19) (n=5) 20 (12-34) (n=15) NS
SES-CD severity
 • Mild (4-10), n (%)
 • Moderate (11-19), n (%)
 • Severe (>19), n (%)
2 (40%)
3 (60%)
0 (0%)
2 (13%)
5 (33%)
8 (53%
NS
UC clinical score (Montreal)
 • Remission, n (%)
 • Mild, n (%)
 • Moderate, n (%)
 • Severe, n (%)
-
1 (20%)
2 (40%)
2 (40%)
-
-
2 (40%)
3 (60%)
NS
UC disease location (Montreal)
 • Proctitis, n (%)
 • Left-sided, n (%)
 • Pancolitis, n (%)
-
-
5 (100%)
-
-
5 (100%)
NS
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colonic follicles/mm2 in the inflamed colon of patients was comparable between CD 
and UC (P=0.348).
In a subgroup of the current patient cohort we analyzed a series of serum cytokines 
and chemokines of which CXCL-13 and CCL-19 (both associated with lymphoid organo-
genesis (22)) were present at higher concentrations in the HEVhigh group of patients. 
Patients in the HEVhigh group (n=4) had higher baseline levels of CXCL-13, with a me-
dian of 67 pg/ml, IQR 52-742 pg/ml) compared to patients in the HEVlow group (n=8) 
with a median level of 36 pg/ml (IQR 27-47 pg/ml) P=0.008 and to healthy controls 
(n=4,median 24 pg/ml (IQR 18-28 pg/ml) P=0.029, Figure 3). Furthermore, there was a 
trend towards higher CCL-19 levels in HEVhigh patients (median 176 pg/ml, IQR 126-199 
pg/ml) compared to HEVlow patients (median 125 pg/ml, IQR 90-141 pg/ml, P=0.073).
Discussion
In the present study, increased percentages of extrafollicular PNAd expressing HEV-like 
vessels were observed in inflamed colon and ileum of newly diagnosed IBD patients 
compared to healthy controls. In controls, these HEVs were restricted to lymphoid fol-
licles. A high heterogeneity was observed in the number of extrafollicular PNAd ex-
pressing vessels in IBD patients. We identified subgroups of patients according to the 
UC endoscopic severity (Mayo)
 • Normal, n (%)
 • Mild, n (%)
 • Moderate, n (%)
 • Severe, n (%)
-
2 (40%)
1 (20%)
2 (40%)
-
-
3 (60%)
2 (40%)
NS
FACS analysis of inflamed colon*
 • CD3, median (IQR)
 • CD19, median (IQR)
 • CD4, median (IQR)
 • CD8, median (IQR)
 • CD4/CD8 ratio, median (IQR)
 • CD103, median (IQR)
 • TN, median (IQR)
 • TCM, median (IQR)
 • TEM, median (IQR)
 • TEMRA, median (IQR)
 • Treg, median (IQR)
50 (45-63)
39 (29-49)
74 (38-83)
15 (11-19)
4.3 (3.0-6.1)
7 (4-12)
23 (20-40)
58 (41-72)
12 (6-18)
2 (1-3)
12 (8-18)
59 (52-72)
23 (18-42)
61 (36-75)
29 (22-37)
2.2 (1.2-3.2)
15 (8-43)
23 (9-54)
33 (20-45)
26 (12-46)
6 (2-12)
14 (12-17)
0.267
0.108
0.169
0.00008
0.0008
0.015
0.779
0.001
0.024
0.010
0.379
CD = Crohn’s disease, UC = ulcerative colitis, HEV = high endothelial venule, IQR = interquartile range,  
IBD = inflammatory bowel disease, HBI= Harvey-Bradshaw Index, SES-CD = simple endoscopic score for Crohn’s 
disease, TN = naïve T lymphocyte, TCM = central memory T lymphocyte, TEM = effector memory T lymphocyte, TEMRA = 
effector memory T lymphocyte re-expressing RA, Treg= regulatory T lymphocyte
* Expressed as percentage of the whole lymphocyte population
133
hevs  associated  with  t-cell  subsets  in  ibd
Figure 2 Correlation between peripheral lymph node addressin (PNAd) expressing high endothelial venules 
(HEVs) and T-cell subpopulations
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Lymphocyte subsets as well as maturation state of T lymphocytes was assessed with flowcytometric immunopheno-
typing of biopsies taken from the same inflamed colonic tissues during the same ileocolonoscopy. Patients are divided 
in HEVhigh (n=10) or HEVlow (n=20) group using the median density of extrafollicular PNAd expressing HEV like vessels 
in inflamed colon of ulcerative colitis (UC) patients as cut off value. Statistical significant results are indicated with an 
asterisk (*).
A Shows more central memory T cells (TCM, CD45RA-CD27+, p=0.0009), less effector memory T cells (TEM, CD45RA-CD27-, 
p=0.022) and less effector memory T cells re-expressing RA (TEMRA, CD45RA+CD27-, p=0.008) in HEVhigh patients when 
compared with HEVlow patients. There was no statistical significant difference for naive T cells  
(TN CD45RA+CD27+).
B Shows less cytotoxic T cells (CD3+CD8+, p=0.00008), a higher CD4:CD8 ratio (p=0.0008) and less mucosal T cells 
(CD3+CD103+, p=0.015) in HEVhigh patients. There was no statistical significant difference for B cells (CD19+), T cells 
(CD3+), T-helper cells (CD3+CD4+) and regulatory T cells (CD3+CD25highFoxP3+).
C Representative flow cytometric dot plots from inflamed colonic biopsy specimens of IBD patients which show 
the distribution of the maturation of (CD3+) T lymphocytes. C1 shows a HEVhigh patient with mostly (75%) TN 
(CD45RA+CD27+) and TCM (CD45RA-CD27+) lymphocytes, whereas C2 shows a HEVlow patient with mostly (91%) TEM 
(CD45RA-CD27-) lymphocytes.
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density of the extrafollicular HEVs in the inflamed colonic mucosa: HEVhigh and HEVlow. 
In HEVhigh patients, a higher percentage of TN and TCM lymphocytes was observed in the 
inflamed colonic mucosa compared to HEVlow patients. Patients in the HEVhigh group also 
displayed a higher number of lymphoid follicles (TLOs) in the inflamed colonic mucosa 
compared to patients in the HEVlow group and controls. Furthermore chemokines asso-
ciated with TLO formation were upregulated in the serum of HEVhigh patients.
In physiologic conditions, HEVs are known to be exclusively present within SLOs, 
whereas in the present study we demonstrated their presence outside follicles in the 
inflamed intestine of IBD patients. It is our interpretation that extrafollicular HEVs rep-
resent an early phase of lymphoid neogenesis, as they were virtually absent in healthy 
controls. In addition to Peyer’s patches, GALT also contains other forms of SLOs, such as 
isolated lymphoid follicles and submucosal lymphocyte aggregations isolated lymphoid 
follicles are mostly seen within the mucosa, while submucosal lymphocyte aggregations 
lie deeper within the muscularis mucosa and submucosa23,24. Both isolated lymphoid 
follicles and submucosal lymphocyte aggregations are accepted as normal components 
of healthy small intestinal mucosa, representing solitary Peyers patches follicles. Peyers 
patches are mostly present in jejunum and ileum while isolated lymphoid follicles have 
also been found in the human colon24. In accordance, we found HEVs within lymphoid 
follicles of the normal gut mucosa of both ileum and colon of healthy controls, whereas 
they did not display such vessels outside these follicles.
Figure 3 Serum CXCL-13 concentrations in IBD patients and healthy controls 
HEVlow
(N=8)
HEVhigh
(N=4)
Healthy controls
(N=4)
1000,00
100,00
10,00
se
ru
m
 C
X
CL
-1
3 
pg
/m
l
HEVhigh
versus
HEVlow
P=0.008
Healthy 
controls
versus
HEVhigh
P=0.029
HEVhigh patients had higher CXC:-13 concentrations compared to HEVlow patients (P=0.008) and compared to controls 
(P=0.029)
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In IBD, HEVs were previously investigated in one study using MECA-79 immunostaining 
of biopsy specimens from UC patients and surgical specimens of CD patients5. Increased 
PNAd expressing HEV-like vessels were found in inflamed colonic mucosa of longstand-
ing UC patients and (to a lesser extent) in CD patients, compared to non-inflamed co-
lonic mucosa of other IBD patients. However, no healthy controls were included, T-cell 
maturation in the gut mucosa was not analyzed and no serial biopsy samples at dif-
ferent time points and phases of disease within the same patients were analyzed. The 
numbers of PNAd expressing HEVs in the patients with non-inflamed colonic mucosa 
have not been investigated during active disease and therefore it might concern a sub-
group of patients without ectopic HEV formation. Our results suggest differences in 
HEVs density and TLOs between IBD patients with active disease..
Direct comparison with the currently presented results is difficult, since we did in-
clude healthy controls, studied mucosal T-cell maturation and both the presence of 
follicles as well as PNAd expression inside and outside these follicles. We demonstrated 
increased extrafollicular HEV formation in a subgroup of patients (HEVhigh) in the early 
phase of disease. The lack of extrafollicular PNAd expression in a subgroup of patients 
(HEVlow) might be explained by a different disease phenotype or the early phase of dis-
ease, assuming that formation of PNAd expressing vessels in inflamed mucosa is a char-
acteristic of chronicity.
Lymphoid follicles in the gut were previously studied in established CD patients, 
where enhanced presence of submucosal de novo lymphoid follicles in the surgical 
resection specimen of CD patients has been demonstrated17. The authors interpreted 
these lymphoid follicles as being TLOs, mostly based on their location in the submuco-
sa, muscularis propria and subserosa, without performing MECA-79 immunostaining17.
Theoretically these follicles might still represent SLOs. Potential differences between 
patients and associated T-cell subsets were not investigated.
The process of TLO development has not yet been clarified, nevertheless chemo-
kines such as CXCL-13, CCL-19 and CCL-21 together with lymphotoxin α1β2 (LTα1β2, TNF 
family member) were shown to be required for lymphoid organogenesis22. LTα1β2 is im-
plicated in generation of follicular dendritic cells and HEVs out of stromal cells, while 
CCL-19, CCL-21 and CXCL-13 control the organization of the T- and B-cell follicular re-
gions12,22,25. Remarkably, we found increased serum CCL-19 and CXCL-13 in the HEVhigh 
patients compared to HEVlow patients (serum CCL-21 was not analyzed). This suggests a 
systemic reflection of the gut localized formation TLOs.
Development of TLOs containing PNAd-expressing HEV-like vessels has also been 
reported in other diseases with chronic inflammation and in patients with solid tumors. 
In patients with rheumatoid arthritis, TLOs were associated with an inferior therapeutic 
response to anti-TNF treatment and reversal of TLOs was a good marker of beneficial 
therapeutic response26.
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In our study, the higher number of colonic follicles found in the HEVhigh group indicated 
that in a subgroup of IBD patients, de novo lymphoid follicles were being formed, repre-
senting TLOs. The patients in HEVhigh group not only had more follicles, they also exhib-
ited more HEVs outside these follicles and this was associated with a higher percentage 
of TN and TCM lymphocytes (known to be L-selectin+18,19) and lower TEM and TEMRA lympho-
cytes (known to be L-selectin-18,19) in their mucosa. Remarkably, the patients in HEVlow 
group were comparable to controls regarding these findings. HEV-like vessels express 
different functional ligands (PNAd, MAdCAM-1) for L-selectin facilitating extravasation 
and entry of TN+TCM lymphocytes into lymphoid organs27. These findings suggest differ-
ences between IBD patients, both UC as CD, regarding TLO formation and recruitment 
of TN+TCM lymphocytes to the inflamed gut mucosa. These results further expand on our 
previous paper in newly diagnosed IBD patients with increased numbers of TN and TCM 
cells in the inflamed gut of a subgroup of patients7. Taken together, our data indicate 
that lymphoid neogenesis with PNAd expressing HEV-like vessels enhances homing of 
TN+TCM lymphocytes to the inflamed gut in a subset of IBD patients.
A limitation of the present study was that mucosal biopsy specimens precluded full ex-
amination of the deeper layers of the intestine wall (submucosa, muscularis propria and 
subserosa), which potentially contain PNAd expressing HEV-like vessels and TLOs in IBD 
patients, particularly in CD. However, the strengths of our study were the prospective 
design, the sampling of untreated patients early in the course of IBD, and the use of a 
standardized description of TLOs and HEVs in inflamed mucosa of IBD patients.
Clinical and therapeutic relevance of these findings remain to be studied; presence 
of lymphoid follicles in initial biopsy specimens may however be predictive for colecto-
my due to drug refractory UC28. Furthermore, novel treatment strategies targeting T-cell 
migration to the inflamed gut mucosa of IBD patients, such as anti-α4β7 (vedolizumab 
(Entyvio®)) and anti-MAdCAM-1 monoclonal antibodies (PF-00547659) are emerging29, 
30. HEVlow patients with higher influx of α4β7+ TEM lymphocytes might theoretically ben-
efit more and thus respond more beneficially to Vedolizumab treatment than HEVhigh 
patients. Moreover, these findings may lead to further development of new treatment 
targets in IBD designed to influence HEVs and TLO formation by targeting the lympho-
toxin pathway31.
Conclusion
Higher numbers of extrafollicular HEV-like vessels were demonstrated in IBD patients 
compared to controls. Increased density of extrafollicular HEVs and TLOs in patients 
was strongly associated with TN and TCM cell mucosal infiltration, while low density of 
HEVs correlated with higher numbers of mucosal TEM cells. This suggests that the hom-
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ing of TN and TCM cells to non-lymphoid gut tissue in IBD patients might be facilitated 
by extrafolicullar HEVs and de novo TLO formation. Different “T-cell migration pheno-
types” based on TLO formation in the early phase of IBD may allow risk-stratification of 
patients and enable individualized treatment.
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This thesis focused on clinical, radiological and immunological aspects of the early 
phase of IBD. First we studied the initial work-up for establishing the primary diagnosis 
including clinical, endoscopic and imaging techniques. Next we hypothesised that as-
sessment of integrated clinical and immunological characteristics in the early phase of 
IBD might identify different immune-based phenotypes with potential value in progno-
sis and therapy choice.
IBD is often regarded as a modern disease because of its increasing incidence, which 
might in part be attributed to advances in endoscopic and radiologic techniques, al-
lowing for more accurate early diagnosis of patients. The clinical diagnostic strategy of 
IBD has changed considerably in the last decades as sophisticated imaging techniques 
such as endoscopy, MRI and Contrast enhanced US (CEUS) have emerged. The research 
described in the first part of the thesis illustrates the complexity of clinical decision-
making at the time of primary diagnosis, which is inherent to the high heterogeneity 
in disease presentation. Knowledge of the endoscopic and histologic findings at upper 
GI endoscopy, as well as imaging by MRE and CEUS in different newly diagnosed adult 
CD phenotypes, is important in the development of a more individualized and efficient 
diagnostic strategy for clinical practice. We therefore chose to study early IBD patients 
before starting treatment in order to answer the research questions.
Despite substantial progress in research, IBD still defies a clear definition, known 
cause and definitive cure. The disease concept of IBD might best be defined as a disease 
of disruption: disrupted immunology and physiology in a specific genetic, microbial and 
environmental context. Characterisation of immunological changes in the early phase 
before the influence of medication might help better understanding of the disrupted 
immunology of IBD. Therefore the second part of the thesis focused on the inflamed 
mucosa of newly diagnosed patients including identification of different T-cell subsets 
and possible mechanisms involved in their recruitment to the gut. In contrast to the 
current paradigm of T-cell migration through lymphoid and non-lymphoid tissues, we 
observed increased numbers of naive (TN) and central memory T (TCM) cells in the in-
flamed mucosa of a subgroup of patients, suggesting a direct entry into the gut. Fur-
thermore, higher numbers of ectopic lymphoid organs were identified in the mucosa of 
patients with predominant TN and TCM cells, providing a plausible explanation for their 
homing to the inflamed gut.
Part I 
Which diagnostic modalities are needed in an individual patient in order to establish a 
certain diagnosis of IBD as well as the severity and extent of the disease?
Chapter 2 is an overview of the changes in the utilisation of diagnostic examina-
tions for the primary diagnosis of IBD in the period between 1970 and 2007. There is 
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an evident trend from a prevalent use of radiological procedures, such as small bow-
el follow-through or enteroclysis and colonography, in the seventies and eighties to 
predominantly endoscopic procedures, ileocolonoscopy, sigmoidoscopy and upper GI 
endoscopy, in the last two decades. These changes might be explained by the promi-
nent technical innovations of flexible video-endoscopy in that period, access to biopsy 
specimens for histopathological examination and increasing interest in an accurate di-
agnostic classification of IBD patients, preferably based on nosology. This was also been 
illustrated in the Montreal classification of IBD (2006), which constitutes a revision of 
the Vienna classification (1998) and allows for the additional designation of upper GI 
tract (+ L4) and perianal (+ P) involvement in CD1,2. However, a definite consensus on 
classification is lacking, e.g. definition of upper GI disease location in adult patients is 
not available. Does it require a combination of endoscopic and histologic findings or are 
isolated histological findings sufficient for disease location? Does upper GI involvement 
refer solely to the oesophagus, stomach and duodenum of does it also include proximal 
jejunum? Despite all this, recent guidelines recommend routine upper GI endoscopy in 
all newly diagnosed CD patients3.
In Chapter 3 we chose to define upper GI involvement (+ L4) as a combination of 
endoscopic and histopathological abnormalities identified by upper GI endoscopy that 
reached up to the duodenum pars horizontalis (pars III). A high prevalence of +L4 disease 
location was observed in newly diagnosed, adult CD patients but the majority of these pa-
tients were symptom-free despite small-sized endoscopic upper GI lesions. Furthermore, 
most histopathological findings, including focally enhanced gastritis, were common for 
both CD as well as UC patients, except for granulomas that were exclusively present in CD 
patients. Given the limited clinical impact of these findings we see no grounds for recom-
mending routine upper GI endoscopy in all newly diagnosed CD patients.
With respect to the predictive value of upper GI location of CD at baseline for a 
severe disease course, the current literature is inconclusive. Differences between pop-
ulation-based studies may be explained by the use of different definitions of severely 
active disease course or lack of complete phenotypic characterization of the patients at 
baseline (no statement as to whether routine upper GI endoscopy was performed at pri-
mary diagnosis in all these patients)4. However, clinical predictors for disabling disease 
described in recent landmark studies4-6 were: initial requirement for steroid use, age be-
low 40 years, stricturing disease behaviour, and perianal disease, while upper GI disease 
location reached no statistical significance. Furthermore, in a recent cross-sectional 
population based study was stated that CD patients with jejunal disease (jejunal L4) 
were more likely to have stricturing disease behaviour and a more severe disease course 
than patients with esophagogastroduodenal location (non-jejunal L4)7.
In an attempt to achieve an accurate classification of different CD phenotypes, re-
cent diagnostic guidelines recommend small bowel imaging in all newly diagnosed CD 
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patients irrespective of ileocolonoscopy findings3. The clinical impact and predictive val-
ue of small bowel imaging at the time of primary CD diagnosis has not yet been studied.
In Chapter 4 we showed that in colonic CD patients no additional small bowel findings 
were depicted by MRE at the time of primary diagnosis. Small bowel imaging conveyed 
most information regarding skip lesions or small bowel complications in CD patients with 
incomplete ileocolonoscopy, severe endoscopic ileitis and stricturing phenotype. There-
fore we believe that an individualized recommendation is more adequate, and routine 
additional small bowel imaging is not necessary in all newly diagnosed CD patients.
Next to the well-known advantages of MRE, such as high diagnostic accuracy for 
small bowel disease location and complications, and lack of radiation, there are also 
some disadvantages. It is a costly procedure requiring expensive technical and (relative-
ly) complicated protocols, which may impair the quantification of inflammation in daily 
practice. In Chapter 5 we demonstrated that Contrast Enhanced Ultrasound (CEUS) has 
a comparable diagnostic accuracy to MRE for terminal ileitis allowing for easy quantifi-
cation of the inflammation. Quantitative measurement of bowel wall enhancement by 
time-intensity curve analysis correlates well with endoscopic disease activity. However, 
given the limitations of abdominal ultrasound in providing information on the whole 
small bowel and enteroenteral fistula, we believe CEUS is less suitable in the primary 
diagnosis of CD when any skip lesions or complications must be excluded. CEUS is an ad-
equate, patient-friendly and less costly alternative to MRE during the follow-up of estab-
lished terminal ileitis in CD patients. Moreover, there is evidence that CEUS allows a clear 
and rapid differentiation of abscesses from inflammatory infiltrates or phlegmons in CD8.
Diagnostic procedures in IBD in 2016
Recent European diagnostic guidelines recommend routine upper GI endoscopy and MRE 
in all newly diagnosed CD patients irrespective of the findings at ileocolonoscopy3. At the 
same time, recent Dutch and British guidelines recommend upper GI endoscopy solely 
in newly diagnosed CD patients with upper GI symptoms but not in the case of IBDU 
diagnosis9,10. The discrepancy between guidelines relies mostly on limited data available 
up till now on upper GI findings or findings at MRE in newly diagnosed IBD patients.
Based on the research presented in this thesis we advise upper GI endoscopy only in 
newly diagnosed patients with upper GI symptoms or when other ailments (coeliac dis-
ease) are considered and, for reasons of specifying classification, in patients diagnosed 
with IBDU. Endoscopic lesions accompanied by histologic granulomatous inflammation 
in the upper GI tract of patients with initial IBDU allow classification of these patients 
as having CD.
With respect to small bowel imaging, we found no evidence in our research for per-
forming routine MRE in all newly diagnosed CD patients irrespective of the findings at 
ileocolonoscopy.
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MRE is needed in new CD patients with an incomplete ileocolonoscopy and in patients 
with severe endoscopic ileitis and stricturing disease phenotype. At the same time we 
recommend no routine small bowel imaging in CD patients with normal aspect of the 
terminal ileum during ileocolonoscopy. Furthermore, we state that CEUS is a feasible 
and a less costly alternative to MRE for follow-up of disease activity in CD patients with 
terminal ileitis (Figure 1).
Part II
Can we identify different immunological phenotypes in the inflamed gut mucosa of 
early IBD?
Both innate and adaptive immune responses are highly dependent upon trafficking of 
immune cells from their sites of origin to target organs. The modern concept of T-cell 
homing is based on the hypothesis that only activated and effector memory T (TEM) cells 
can enter the non-lymphoid tissues, while TN and TCM are thought to recirculate exclu-
sively between secondary lymphoid organs via lymph vessels and the blood stream11. 
Up till now, most research into IBD has concentrated on the homing of activated, effec-
tor memory and regulatory T cells to the inflamed gut. Interestingly, beforehand, TN cells 
are the initiators of the inflammatory cascade as they precede T-cell differentiation and 
expansion, upon activation.
To answer the research question above we performed a prospective study on newly 
diagnosed, untreated IBD patients and healthy controls to assess different T-cell sub-
Figure 1 Individualized diagnostic strategy for endoscopy and imaging in adult IBD patients
Primary diagnosis
All patients ٿ Ileocolonoscopy
Upper GI symptoms; IBDU ٿ upper GI endoscopy
Stricturing CD, severe ileitis, incomplete
endoscopy ٿ MRE
Follow-up
CEUS/MRE
and/or
Ileocolonoscopy
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sets in the inflamed gut mucosa, described in Chapter 6. Different subgroups of pa-
tients were identified according to the maturation profile of T-cell subsets. The most 
“naive” subgroup contained mainly TN cells, the most “mature” group mainly TEM cells 
and the intermediate group displayed mostly TCM cells. In this pilot study, the “naive” 
group was associated with upper GI disease involvement (+L4) and perianal disease at 
the time of first presentation in CD patients. Moreover, higher numbers of regulatory 
(CD4+FoxP3+CD25+) T cells and a lower numbers of mucosal (CD103+) T cells were identi-
fied in IBD patients when compared to healthy controls.
In Chapter 7 a comprehensive review was provided on the migration pathways of 
TN and TCM, putting together recent evidence that TN routinely access peripheral tissues 
and are present in high numbers in the inflamed gut tissue of IBD patients. The hom-
ing process of TN to peripheral non-lymphoid tissues is not completely elucidated, but 
it is likely that TN will tether and roll on vascular endothelium given the high levels of 
L-selectin (CD62L) on their surface12. However, the ligand of CD62L, peripheral LN ad-
dressin (PNAd), is mainly present on high endothelial venules (HEV’s), which are nor-
mally found in peripheral lymph nodes. In chronic inflammation, such as rheumatoid 
arthritis, the formation has been demonstrated of ectopic lymphoid organs, so called 
tertiary lymphoid organs (TLO’s) containing HEV’s, presumably facilitating the homing 
of TN to inflamed tissues13. Data on the presence of TN and TCM in the inflamed gut of 
IBD patients is scarce and restricted to patients with longstanding disease usually using 
immunomodulation14.
In search of an explanation for the increased influx of TN and TCM into the inflamed 
mucosa of a subgroup of patients, we studied the presence of HEV-like vessels and TLO’s 
in the initial biopsies of these patients, before medication use, as reported in Chapter 
9. Extra-follicular HEVs were almost exclusively present in the inflamed colon and ileum 
of patients when compared to healthy controls. Moreover, the patients exhibited high 
variation in the numbers of extra-follicular HEVs, and were classified into two groups: 
a “HEVhigh” and “HEVlow” group. The high numbers of HEV-like vessels in the “HEVhigh” 
group correlated with increased numbers of TN and TCM, while very low numbers of HEV-
like vessels in the “HEVlow” group was associated with higher numbers of TEM cells. This 
data demonstrated a clear association between the new formation of ectopic HEV-like 
vessels in inflamed gut mucosa and the increased local influx of TN and TCM cells.
The role of naïve T cells in gut inflammation has been demonstrated in animal mod-
els where the transfer of naïve T cells (CD4+CD45RB+) into T cell-deficient mice caused 
an IBD-like syndrome15,16. In humans, recruitment of naïve T cells to the gut mucosa 
has solely been studied in patients under immunosuppressive treatment. A relatively 
high number of naïve T cells (CD4+CD45RA+), producing a high amount of TNFα and 
a low amount of IFNγ, has been observed in the intestinal mucosa of both CD and 
UC14. Furthermore, it was recently reported that in IBD patients the number of mucosal 
CD4+CD45RA+ T cells decreased during treatment with corticosteroids or biologicals, 
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whereas memory T cells (CD4+CD45RO+) remained unchanged17. Little is known about 
the homing mechanism of naïve T cells to the peripheral tissues, but a relationship has 
been suggested with lymphoid neogenesis in inflamed tissue18. Increased PNAd-ex-
pressing HEV-like vessels were described in the inflamed colonic mucosa of longstand-
ing IBD compared to the non-inflamed tissue of other IBD patients19 and increased num-
bers of lymph follicles were seen in surgical resection specimens from CD patients20.
Up till now, most research has focused on differences between IBD and healthy 
controls while differences between different clinical IBD phenotypes have received less 
attention. Based on the research described in this thesis we strongly believe that IBD’s 
heterogeneity in clinical presentation and course of disease might be due to different 
immunological pathways. One such a pathway could be that of TLO formation during 
chronic inflammation, leading to different “T-cell migration” phenotypes.
Differences in T-cell migration pathways to the inflamed gut might have great impact on 
the response to new anti-integrin therapies. It is possible that inflammatory responses 
in patients with a “HEVhigh” phenotype are less dependent on the homing of alfa4beta7-
expressing TEM cells from the periphery and might rely more on the local recruitment, 
activation and differentiation of TN and TCM in the inflamed mucosa. These data suggest 
that patients with a “HEVlow” phenotype might benefit more from anti-integrin therapy 
targeting alfa4beta7, than “HEVhigh” patients.
Conclusions and future perspectives
Considering the results of our studies we recommend that a complete primary diagnos-
tic work-up of IBD patients should be individualized according to the clinical phenotype 
at presentation, including symptoms and findings by ileocolonoscopy.
Next to the already known clinical phenotypes, different “ T-cell migration” pheno-
types were identified in newly diagnosed, untreated patients, according to differences in 
TLO formation and maturation status of different T-cell subsets in the mucosa.
Future research should focus on additional experiments regarding mucosal immu-
nological markers in different IBD phenotypes in the early phase of the disease. The he-
terogeneity of IBD and complexity of its pathogenesis preclude proper control of disease 
activity by modulating single components at sporadic time points in the course of the 
disease or by treating all patients in the same way, as we currently do in the manage-
ment of IBD.
We aim to extend our research to further elucidate the heterogeneity of IBD pheno-
types with respect to integrated clinical and immunological features.
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Future research should focus on the following points:
 − Search for new mucosal and serological immunological features in the early phase 
of IBD that will help better characterisation of different immunological phenotypes
 − Study the changes of these immunological features under therapy and in remission 
during long-term follow-up of different IBD phenotypes and identify early predictive 
factors for the course of the disease
 − Perform prospective randomized drug trials in a specific, well-defined cohort of clini-
cal and immunological phenotypes that will open the way for personalized medicine 
for IBD patients
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Dit proefschrift richt zich op klinische, radiologische en immunologische aspecten in 
de vroege fase van IBD. Ten eerste hebben we het initiële onderzoekstraject voor het 
vaststellen van de primaire diagnose, met inbegrip van klinische, endoscopische en 
beeldvormende technieken, onderzocht. Vervolgens werd de hypothese opgesteld dat 
de beoordeling van geïntegreerde klinische en immunologische kenmerken in de vroege 
fase van IBD, verschillende immuun gebaseerde subtypes zou kunnen identificeren met 
potentiële waarde in de prognose en therapiekeuze.
IBD wordt vaak beschouwd als een moderne ziekte vanwege de toenemende in-
cidentie, die deels toegeschreven kan worden aan de vooruitgang in endoscopische 
en radiologische technieken, waardoor nauwkeurigere vroege diagnose van patiënten 
mogelijk is. De klinische diagnostische strategie van IBD is in de afgelopen decennia 
aanzienlijk veranderd omdat geavanceerde beeldvormende technieken zoals endosco-
pie, MRI en contrast versterkte echografie (CEUS) naar voren zijn gekomen. Het on-
derzoek dat in het eerste deel van het proefschrift wordt gepresenteerd, illustreert de 
complexiteit van de klinische besluitvorming ten tijde van de primaire diagnose. Deze 
complexiteit is inherent aan de hoge heterogeniteit van de ziekte bij presentatie. Kennis 
van de endoscopische en histologische bevindingen bij gastroduodenoscopie, evenals 
de kennis van radiologische beeldvorming (MRE en CEUS) in verschillende fenotypen 
van nieuw gediagnosticeerde volwassenen met de ziekte van Crohn, is belangrijk voor 
de ontwikkeling van een geïndividualiseerde en efficiënte diagnostische strategie voor 
de klinische praktijk. Daarom hebben wij ervoor gekozen om nieuw gediagnosticeerde 
patiënten te bestuderen, voorafgaande aan het starten van de behandeling, om zo de 
onderzoeksvragen te kunnen beantwoorden.
Ondanks de aanzienlijke vooruitgang in het onderzoek, ontbreekt het in de IBD toch 
aan een duidelijke definitie, bekende oorzaak en definitieve genezing. De ziekte IBD kan 
het best worden gedefinieerd als een ziekte van storing: verstoorde immunologie en 
fysiologie in een specifieke genetische, microbiële en omgevingscontext. Karakterisatie 
van immunologische veranderingen in de vroege fase, zonder het invloed van immuno-
suppressieve medicatie, kan leiden tot een beter begrip van de verstoorde immunologie 
in IBD. Daarom concentreert het tweede deel van het proefschrift zich op het ontstoken 
slijmvlies van nieuw gediagnosticeerde patiënten, met daarin de identificatie van ver-
schillende T cel subpopulaties en mogelijke mechanismen, die betrokken zijn bij hun 
rekrutering in de darm. In tegenstelling tot het huidige paradigma van T cel migratie 
door lymfoïde en niet- lymfoïde weefsels, observeerden we een verhoogd aantal geheu-
gen naïeve (TN) en centrale T (TCM) cellen in het ontstoken slijmvlies van een subgroep 
van patiënten, suggestief voor een directe toegang tot de darm. Verder werden er ho-
gere aantallen ectopische lymfoïde organen gevonden in de mucosa van patiënten met 
overheersende TN en TCM cellen, die een plausibele verklaring vormt voor hun ‘homing’ 
naar de ontstoken darm.
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Deel I 
Welke diagnostische instrumenten zijn nodig in een individuele patiënt om de diagnose 
van IBD, de ernst en omvang van de ziekte vast te stellen?
In hoofdstuk 2 wordt een overzicht gepresenteerd van de veranderingen in het ge-
bruik van diagnostische onderzoeken voor de primaire diagnose van IBD in de periode 
tussen 1970 en 2007. Er is een duidelijke trend zichtbaar, van een wijdverspreide gebruik 
van radiologische procedures in de jaren zeventig en tachtig, naar overwegend endo-
scopische procedures, in de laatste twee decennia. Deze veranderingen kunnen worden 
verklaard door de prominente technische innovaties van de flexibele video-endoscopie 
in die periode, met toegang tot biopten voor histopathologisch onderzoek en toene-
mende belangstelling voor een nauwkeurige diagnostische classificatie van IBD patiën-
ten, bij voorkeur gebaseerd op nosologie. Dit is ook geïllustreerd in de Montreal indeling 
van IBD (2006), die een herziening van de Vienna classificatie (1998) vormde en zorgde 
voor bijkomende aanwijzing van de bovenste maagdarmkanaal (+ L4) en perianale (+ P) 
betrokkenheid bij ziekte van Crohn1,2. Maar een duidelijke consensus over de indeling 
ontbreekt, zo is een heldere definitie van de bovenste tractus digestivus lokalisatie van 
de ziekte van Crohn bij volwassen patiënten bijvoorbeeld niet beschikbaar. Vereist de 
bovenste tractus digestivus betrokkenheid een combinatie van endoscopische en his-
tologische afwijkingen of zijn geïsoleerde histologische bevindingen voldoende voor de 
locatie van de ziekte van Crohn? Heeft bovenste tractus digestivus betrokkenheid alleen 
betrekking op de slokdarm, maag en de twaalfvingerige darm of moet het ook proximale 
jejunum bevatten? Ondanks dit alles, recente diagnostische richtlijnen bevelen routine 
gastroduodenoscopie aan, voor alle nieuw gediagnosticeerde patiënten met de ziekte 
van Crohn3.
In hoofdstuk 3 hebben wij bovenste tractus digestivus betrokkenheid (+ L4) gedefini-
eerd als een combinatie van endoscopische en histopathologische afwijkingen, geïden-
tificeerd bij gastroduodenoscopie tot pars horizontalis (pars III) van de twaalfvingerige 
darm. Een hoge prevalentie van + L4 locatie van de ziekte werd waargenomen in nieuw 
gediagnosticeerde volwassen patiënten met de ziekte van Crohn, maar de meerderheid 
van deze patiënten waren symptoomvrij, ondanks milde endoscopische laesies. Boven-
dien kwamen de meeste histopathologische bevindingen, inclusief focale gastritis, vaak 
voor, zowel in ziekte van Crohn als in Colitis ulcerosa patiënten, met uitzondering van 
de granulomen die uitsluitend aanwezig waren in patiënten met de ziekte van Crohn. 
Gezien de beperkte klinische impact van deze bevindingen zien we geen reden om routi-
nematig gastroduodenoscopie aan te bevelen in alle nieuw gediagnosticeerde patiënten 
met de ziekte van Crohn.
Met betrekking tot de voorspellende waarde van de bovenste tractus digestivus lo-
catie (+L4) van de ziekte van Crohn, bij aanvang, voor een ernstige ziektebeloop, is de 
huidige literatuur niet overtuigend. Verschillen tussen studieresultaten uit het verle-
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den kunnen worden verklaard door het gebruik van verschillende definities voor ernstig 
ziektebeloop of gebrek aan volledige fenotypische karakterisering van de patiënten bij 
aanvang (geen mededeling of routine gastroduodenoscopie is uitgevoerd ten tijde van 
de primaire diagnose bij al deze patiënten)4. Echter, de klinische voorspellers voor een 
gecompliceerd ziektebeloop – beschreven in de meeste landmark studies4-6 – waren: het 
gebruik van steroïden, leeftijd jonger dan 40 jaar, stenoserend ziekte gedrag en peria-
nale ziekte bij eerste presentatie. Bovendien, in een recente, op populatie gebaseerde 
studie werd gesteld dat het risico op een ernstiger ziektebeloop met stenoserend ziekte-
gedrag, hoger was in Crohn-patiënten met jejunale ziekte (jejunale L4) dan in patiënten 
met esophagogastroduodenale locatie (niet-jejunale L4)7.
In een poging om tot een nauwkeurige classificatie van de verschillende fenotypes 
van ziekte van Crohn te komen, bevelen recente diagnostische richtlijnen aan om dunne 
darm beeldvorming te verrichten, in alle nieuw gediagnosticeerde patiënten ongeacht 
bevindingen bij ileocolonoscopie3. De klinische meerwaarde en de voorspellende waar-
de van de dunne darm beeldvorming ten tijde van de primaire diagnose van ziekte van 
Crohn is nog niet onderzocht.
In hoofdstuk 4 hebben we aangetoond dat in Crohn-patiënten met uitsluitend colon 
lokalisatie geen additionele dunne darm bevindingen werden beschreven op MR Ente-
rografie (MRE) ten tijde van de primaire diagnose. Dunne darm beeldvorming leverde de 
meeste aanvullende informatie over ‘skip lesions’ of dunne darm complicaties (stenose, 
fistels) op in Crohn-patiënten met een incomplete ileocolonoscopie, ernstige endosco-
pische ileitis en stenoserende fenotype. Daarom zijn wij van mening dat een individuele 
aanbeveling gerechtvaardigd is en routinematige dunne darm beeldvorming niet nodig 
in alle nieuw gediagnosticeerde Crohn-patiënten.
Naast de bekende voordelen van MRE zoals hoge diagnostische nauwkeurigheid voor 
dunne darmziekte locatie en complicaties en gebrek aan straling, zijn er ook enkele 
nadelen. Het is een kostbare procedure en vereist relatief complexe protocollen om de 
kwantificering van de ontsteking toe te passen in de praktijk. In hoofdstuk 5 hebben we 
aangetoond dat contrast versterkte echografie (CEUS) een vergelijkbare diagnostische 
nauwkeurigheid heeft met MRE voor ileitis terminalis, en daarnaast een gemakkelijke 
kwantificering van de ontsteking mogelijk maakt. Kwantitatieve meting van darmwand 
aankleuring, door de tijd-intensiteit curve analyse correleert goed met endoscopische 
ziekteactiviteit. Gezien de beperkingen van abdominale echografie in het beoordelen 
van de gehele dunne darm en enteroenterale fistels, vinden wij CEUS minder geschikt in 
de primaire diagnostiek van de ziekte van Crohn, waarbij eventuele skip laesies of com-
plicaties moeten worden uitgesloten. CEUS is een adequaat, patiëntvriendelijk en min-
der kostbaar alternatief voor MRE tijdens de follow-up van een bekende ileitis terminalis 
bij Crohn-patiënten. Bovendien zijn er aanwijzingen dat CEUS een duidelijke en snelle 
differentiatie tussen abcessen met inflammatoire infiltraten of phlegmons in ziekte van 
Crohn mogelijk maakt8.
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Diagnostische procedures in IBD anno 2016
Recente Europese diagnostische richtlijnen bevelen routinematige gastroduodenosco-
pie en MRE in alle nieuw gediagnosticeerde Crohn-patiënten, ongeacht de bevindin-
gen bij ileocolonoscopie3. Tegelijkertijd bevelen de Nederlandse en Britse richtlijnen 
een gastroduodenoscopie uitsluitend in nieuw gediagnosticeerde Crohn-patiënten met 
klachten van het bovenste tractus digestivus, maar niet bij een initiële diagnose van 
niet-classificeerbare IBD9,10. De discrepantie tussen de richtlijnen berust meestal op het 
gebrek aan beschikbare gegevens over de bevindingen bij gastroduodenoscopie of MRE 
in nieuw gediagnosticeerde patiënten, tot nu toe.
Op basis van het in dit proefschrift gepresenteerd onderzoek adviseren wij het uitvoe-
ren van gastroduodenoscopie alleen in nieuw gediagnosticeerde Crohn-patiënten met 
klachten van het bovenste tractus digestivus, eventueel ter uitsluiting van andere aan-
doeningen (coeliakie) en in het belang van een nauwkeurige classificatie bij patiënten 
met niet-classificeerbare IBD. Endoscopische laesies vergezeld van histologische granu-
lomateuze ontsteking in het bovenste maagdarmkanaal van patiënten met niet-classifi-
ceerbare IBD vormt een sterke argument voor het vast stellen van de ziekte van Crohn.
Met betrekking tot de dunne darm beeldvorming, hebben wij geen bewijs kunnen 
verzamelen voor het uitvoeren van routinematige MRE in alle nieuw gediagnosticeerde 
Crohn- patiënten, ongeacht de bevindingen van de ileocolonoscopie. MRE is geïndiceerd bij 
nieuwe Crohn-patiënten met een onvolledige ileocolonoscopie, bij Crohn-patiënten met 
een ernstige endoscopische ileitis en bij stenoserende ziekte fenotype bij presentatie. Te-
gelijkertijd heeft de routinematige dunne darm beeldvorming in Crohn-patiënten met een 
normaal aspect van het terminale ileum tijdens ileocolonoscopie, geen meerwaarde. Ver-
der stellen we dat CEUS een haalbaar en goedkoper alternatief is voor MRE voor de follow-
up van ziekteactiviteit ter hoogte van het ileum in Crohn-patiënten (Figuur 1).
Figuur 1 Individuele diagnostische strategie voor endoscopie en beeldvorming bij volwassen patiënten IBD
Primaire diagnose
Alle patienten ٿ Ileocolonoscopie
Klachten bovenste tr. dig. ; Niet classificerbare
IBD ٿ gastroduodenoscopie
Stenoserende zv Crohn, ernstige ileitis,
incomplete endoscopie ٿ MRE
Follow-up
CEUS/MRE
en/of
Ileocolonoscopie
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Deel II
Is het mogelijk om verschillende immunologische fenotypes te identificeren in het ont-
stoken darm slijmvlies van de vroege IBD?
Zowel de aangeboren als de adaptieve immuunreacties zijn sterk afhankelijk van mi-
gratie van immuun cellen uit hun plaats van oorsprong naar de doelorganen. Het mo-
derne concept van T-cel homing is gebaseerd op de hypothese dat alleen geactiveerde 
en effector memory T (TEM) cellen de niet-lymfoïde weefsels kunnen bereiken, terwijl 
naïeve (TN) en central memory T (TCM) cellen worden verondersteld uitsluitend te circule-
ren tussen secundaire lymfoïde organen via lymfevaten en bloedstroom11. Het meeste 
onderzoek in IBD heeft zich tot nu toe gericht op homing van geactiveerde effector me-
mory en regulatoire T cellen naar de ontstoken darm. Wat naïeve (TN) en central memory 
T (TCM) interessant maakt is dat zij aan het begin staan van de inflammatoire cascade en 
de potentie hebben zich te differentiëren zowel in de richting van proinflammatoire als 
regulatoire T cellen.
Om de hierboven genoemde onderzoeksvraag te kunnen beantwoorden hebben we 
een prospectieve studie uitgevoerd in nieuw gediagnosticeerde, onbehandelde IBD pa-
tiënten en gezonde controles naar de verschillende T cel subpopulaties in het ontstoken 
darm slijmvlies, zoals beschreven in hoofdstuk 6. Verschillende subgroepen van patiën-
ten werden geïdentificeerd op basis van het rijpingsprofiel van de T-cel subpopulaties. 
De meest ‘naïeve’ subgroep bevatte vooral TN cellen, de meest ‘rijpe’ groep voorname-
lijk TEM cellen en de tussenliggende groep vooral TCM cellen. In dit pilot onderzoek werd 
de naïeve groep geassocieerd met bovenste tractus digestivus betrokkenheid (+ L4) en 
perianale ziekte bij de eerste presentatie in Crohn-patiënten. Bovendien werden hogere 
percentages regulatoire (CD4+ CD25+ Foxp3+) T cellen en een lagere percentages mu-
cosale (CD103+) T cellen gevonden in IBD patiënten vergeleken met gezonde controles.
In hoofdstuk 7 wordt een uitgebreid overzicht verstrekt over de migratie paden van 
TN en TCM, inclusief de recente aanwijzingen dat TN routinematig toegang kunnen hebben 
tot perifere weefsels en in hoge aantallen aanwezig kunnen zijn in het ontstoken darm-
weefsel van IBD patiënten. De homing werkwijze van TN richting perifere niet-lymfoïde 
weefsels is niet volledig opgehelderd, maar het is aannemelijk dat TN zich aan bepaalde 
types vasculaire endotheel kan binden gezien de hoge niveaus van L-selectine (CD62L) 
op het oppervlak12. De ligand van CD62L, perifere LN addressin (PNAd) is hoofdzakelijk 
aanwezig op hoge endotheliale venules (HEV’s), die normaliter in perifere lymfklieren 
aanwezig zijn. Nieuwvorming van ectopische lymfoïde organen, zogenaamde tertiaire 
lymfoïde organen (TLO’s) met HEV’s is aangetoond gedurende chronische ontsteking, 
zoals in reumatoïde artritis. De HEV’s binnen deze TLO’s kunnen de homing van TN en 
TCM naar ontstoken weefsels faciliteren13. Gegevens over de aanwezigheid van TN en TCM 
in de ontstoken darm van IBD-patiënten zijn schaars en beperkt tot patiënten met lang-
durige ziekte en gebruik van immunosuppressiva14.
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Op zoek naar een verklaring voor de toegenomen instroom van TN en TCM in het ontsto-
ken slijmvlies van een subgroep van patiënten, hebben we de aanwezigheid van HEV-
achtige vaten en TLO in de initiële biopten van deze patiënten onderzocht, vóór initiatie 
van medicijngebruik, zoals beschreven in hoofdstuk 8. Extra-folliculaire PNAd+ HEV-
achtige vaten waren bijna uitsluitend aanwezig in de ontstoken dikke darm en de dunne 
darm van de patiënten in vergelijking met gezonde controles. Bovendien vertoonden 
de patiënten grote variatie in het aantal extra-folliculaire PNAd+ HEV-achtige vaten en 
werden ingedeeld in twee groepen: een ‘HEVhigh’ en ‘HEVlow’ groep. De hoge aantallen 
HEV-achtige vaten in de ‘HEVhigh’ correleerde goed met verhoogde percentages TN en 
TCM, terwijl de zeer lage aantallen HEV-achtige vaten in de ‘HEVlow’ groep werd geas-
socieerd met hogere percentages TEM cellen in de mucosa. Deze gegevens tonen een 
duidelijk verband tussen de nieuwe formatie van extra-folliculaire HEV-achtige vaten in 
ontstoken darmslijmvlies en verhoogde lokale instroom van TN en TCM-cellen.
De rol van naïeve T cellen in het ontstaan van darm ontsteking werd aangetoond in 
diermodellen wanneer toediening van naïeve T cellen (CD4+ CD45RB+) in T-cel-deficiënte 
muizen een IBD-achtig syndroom15,16 veroorzaakte. Bij mensen is de aanwezigheid van 
naïeve T cellen in de darm mucosa eerder alleen onderzocht bij patiënten onder immu-
nosuppressieve behandeling. Een relatief groot aantal naïeve T cellen (CD4+ CD45RA+), 
geassocieerd meet een grote hoeveelheid TNFalfa en een lage hoeveelheid IFNgamma, 
werd waargenomen in de intestinale mucosa van zowel Crohn als Colitis ulcerosa pati-
enten14. Bovendien werd onlangs gemeld dat in IBD patiënten het aantal mucosale CD4+ 
CD45RA+ T cellen daalde tijdens behandeling met corticosteroïden of TNF blokkers, ter-
wijl effector memory T cellen (CD4+ CD45RO+) onveranderd bleven17. Weinig is bekend 
over het homing mechanisme van de naïeve T cellen in de perifere weefsels, maar een 
relatie met lymfoïde neogenese in ontstoken weefsel is voorgesteld18. Verhoogde ex-
pressie van PNAd HEV-achtige vaten werd beschreven in ontstoken darmmucosa van 
lang bestaand IBD in vergelijking met niet-ontstoken darm mucosa van andere IBD pati-
enten19. Daarnaast zijn verhoogde aantallen lymffollikels waargenomen in chirurgische 
resectie specimen van Crohn- patiënten20.
Tot nu toe richtte het meeste onderzoek zich op verschillen tussen IBD patiënten en 
gezonde controles, terwijl verschillen tussen de verscheidene klinische IBD feno types 
minder aandacht hebben gekregen. Op basis van het in dit proefschrift beschreven on-
derzoek zijn we ervan overtuigd dat de IBD-heterogeniteit in klinische presentatie en 
ziektebeloop te wijten kan zijn aan verschillende immunologische mechanismen. Een 
dergelijk mechanisme kan ook nieuwvorming van TLO’s tijdens chronische ontsteking 
zijn, hetgeen leidt tot verschillende ‘T cel migratie’ fenotypes.
Verschillen in T-celmigratiepaden naar de ontstoken darm kunnen de reactie op de 
nieuwe anti-integrine therapieën sterk beïnvloeden. Het is mogelijk dat ontstekings-
reacties bij patiënten met een ‘HEVhigh’ fenotype minder afhankelijk zijn van de homing 
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van alfa4beta7+ TEM cellen uit de periferie, en een toegenomen rekrutering, activering 
en differentiatie van TN en TCM in het ontstoken slijmvlies vertonen. Deze gegevens sug-
gereren dat patiënten met een ‘HEVlow’ fenotype meer zouden kunnen profiteren van 
anti-integrine alfa4beta7 therapie dan ‘HEVhigh’ patiënten.
Conclusies en toekomstperspectieven
Gezien de resultaten van onze studies vermelden we dat een volledige primaire diagnos-
tische work-up van IBD patiënten geïndividualiseerd zou moeten worden op basis van 
het klinische fenotype bij de presentatie, met inbegrip van symptomen en bevindingen 
bij ileocolonoscopie en histologie.
Naast de reeds bekende klinische fenotypen werden verschillende T cel migratie 
fenotypen geïdentificeerd in nieuw gediagnosticeerde onbehandelde patiënten, geba-
seerd op verschillen in TLO vorming en maturatiestatus van verschillende T cel subpo-
pulaties in de ontstoken mucosa. Toekomstig onderzoek zou zich moeten gaan richten 
op aanvullende experimenten met betrekking tot mucosale immunologische markers in 
verschillende IBD fenotypes in de vroege fase van de ziekte. De heterogeniteit van IBD 
en complexiteit van de pathogenese maakt het haast onmogelijk om de ziekte in alle 
gevallen onder controle te krijgen, door het moduleren van afzonderlijke componenten 
op sporadische tijdstippen, tijdens het verloop van de ziekte of de behandeling van alle 
patiënten, op dezelfde wijze als op dit moment gaande is in de behandeling van IBD.
Ons streven is om ons onderzoek te vervolgen met verdere opheldering van de 
 heterogeniteit van verschillende IBD fenotypes met betrekking tot geïntegreerde klini-
sche en immunologische fenomenen.
Toekomstig onderzoek moet zich richten op de volgende punten:
 − Onderzoek naar nieuwe mucosale en serologische immunologische mechanismen 
in de vroege fase van IBD, waardoor een betere karakterisering van de verschillende 
immunologische fenotypes mogelijk wordt gemaakt.
 − Onderzoek naar de veranderingen van deze immunologische mechanismen onder 
invloed van de behandeling en in de rustige fase van de ziekte tijdens lange termijn 
follow-up waardoor voorspellende factoren voor ziektebeloop geïdentificeerd kun-
nen worden.
 − Uitvoering van prospectieve gerandomiseerde trials met verschillende immunosup-
pressiva en biologische geneesmiddelen in specifieke, welomschreven subgroepen 
van klinische en immunologische subtypes, die de weg zal openen voor gepersona-
liseerde geneeskunde in IBD.
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list of abbreviations
 − IBD Inflammatory bowel disease
 − CD Crohn’s disease
 − UC Ulcerative colitis
 − IBDU IBD unclassified
 − IC indeterminate colitis
 − FEG focally enhanced gastritis
 − MRE Magnetic resonance enterography
 − CEUS contrast-enhanced ultrasound
 − SESCD Simple Endoscopy Score for CD
 − HBI Harvey Bradshaw Index
 − GALT gut associated lymphoid tissue
 − PP Peyer’s patches
 − SLOs secondary lymphoid organs
 − PNAd peripheral lymph node addressin
 − MAdCAM-1 mucosal vascular addressin cell adhesion molecule
 − TCR T cell receptor
 − TRECs TCR excision circles
 − RTE recent thymic emigrants
 − TCM central memory T lymphocytes
 − TEM effector memory T lymphocytes
 − TEMRA effector memory T cells re-expressing CD45RA
 − TN naive T lymphocytes
 − TMN mature naive T lymphocytes
 − FoxP3 forkhead box P3
 − HEVs high endothelial venules
 − TLOs tertiary lymphoid organs
 − IQR interquartile range
 − SD standard deviation
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